{"title":"Metabolic","description":"\u003cp\u003e\u003cstrong\u003eMetabolic Health\u003c\/strong\u003e is the upstream master switch of biological aging. The five SKUs in this collection — Berberine HCL 500mg, Alpha-Lipoic Acid 600mg, Pure NMN 500mg, NMN 1000mg Double Strength, and Resveratrol 600mg — are the trial-anchored backbone of a metabolic-longevity stack that targets the four core nutrient-sensing pathways (AMPK, mTOR, sirtuins, IGF-1) and five of the twelve Hallmarks of Aging (deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, loss of proteostasis, altered intercellular communication \/ inflammaging) named by López-Otín and colleagues in their 2013 Cell paper and their 2023 update. Trial-validated doses, cGMP-manufactured, USP-tested, with HPLC-confirmed identity (≥98% trans-isomer for resveratrol, ≥99% β-anomer for NMN) and ICP-MS heavy-metals screening on every batch.\u003c\/p\u003e\n\n\u003ch2 id=\"60-second-answer\"\u003eThe 60-second answer\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWhat this collection covers.\u003c\/strong\u003e Five SKUs targeting the four nutrient-sensing pathways that govern lifespan in every model organism studied: AMPK (Berberine, ALA), sirtuins \/ SIRT1 \/ SIRT3 (NMN 500mg, NMN 1000mg, Resveratrol), mTOR restraint (caloric-restriction-mimetic effect of Berberine + Resveratrol), and IGF-1 (modulated indirectly through improved insulin sensitivity).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePick Berberine HCL 500mg if\u003c\/strong\u003e you want the metformin-adjacent AMPK activator with the strongest human evidence for fasting glucose, HbA1c, LDL-C, and triglycerides (Yin 2008 \u003cem\u003eMetabolism\u003c\/em\u003e, Lan 2015 meta-analysis \u003cem\u003eJ Ethnopharmacol\u003c\/em\u003e, Pérez-Rubio 2013 \u003cem\u003eMetab Syndr Relat Disord\u003c\/em\u003e — pooled mean HbA1c reduction ~0.7%, comparable to first-line metformin in head-to-head trials).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePick Alpha-Lipoic Acid 600mg if\u003c\/strong\u003e you want the universal antioxidant + mitochondrial PDH\/KGDH cofactor + heavy-metal chelator + glutathione recycler with NATHAN 1 (Ziegler 2011 \u003cem\u003eDiabetes Care\u003c\/em\u003e) and SYDNEY 2 (Ametov 2003) RCT validation for diabetic peripheral neuropathy at the trial dose of 600mg\/day.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePick Pure NMN 500mg if\u003c\/strong\u003e you’re starting NAD+ precursor supplementation and want the entry-tier dose validated by Yoshino 2021 \u003cem\u003eScience\u003c\/em\u003e (250mg\/day post-menopausal women, +25% muscle insulin sensitivity at 10 weeks) and Pencina 2023 \u003cem\u003eJCI Insight\u003c\/em\u003e (250mg\/day, dose-dependent NAD+ rise, 6-min walk improvement at 8 weeks).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePick NMN 1000mg Double Strength if\u003c\/strong\u003e you’ve cycled through 500mg and want the upper end of the human trial range (Igarashi 2022 used up to 1250mg\/day, Liao 2021 used 300mg with placebo control, Yi 2023 \u003cem\u003eGeroscience\u003c\/em\u003e used 300\/600\/900mg dose-escalation showing dose-dependent walking endurance gains).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePick Resveratrol 600mg if\u003c\/strong\u003e you want the trans-isomer SIRT1 activator and NMN cofactor that completes the canonical Sinclair pairing — Howitz 2003 \u003cem\u003eNature\u003c\/em\u003e (SIRT1 deacetylase activator), Hubbard 2013 \u003cem\u003eScience\u003c\/em\u003e (substrate-dependent activation mechanism), Timmers 2011 \u003cem\u003eCell Metab\u003c\/em\u003e (150mg\/day, calorie-restriction-mimetic phenotype in obese men).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTime-to-effect.\u003c\/strong\u003e Berberine: fasting glucose drop within 7–14 days (Yin 2008). ALA: paresthesia\/burning improvement within 2–4 weeks (Ziegler 2011). NMN: NAD+ steady-state by week 4 (Trammell 2016 NR analog, Yoshino 2021), insulin sensitivity by week 10. Resveratrol: SIRT1 deacetylase activity acute (24–72h), metabolic phenotype shift at 4–6 weeks (Timmers 2011).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eQuality standards.\u003c\/strong\u003e Trial-anchored doses, no proprietary blends, no titanium dioxide (banned EFSA 2021), HPLC-confirmed identity, USP \u003cem\u003e2232\u003c\/em\u003e\/\u003cem\u003e2021\u003c\/em\u003e\/\u003cem\u003e2022\u003c\/em\u003e heavy-metals\/microbial limits, vegan HPMC capsules, third-party CoA available per batch via support@truehealthprotocol.health.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"on-this-page\"\u003eOn this page\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003ca href=\"#60-second-answer\"\u003eThe 60-second answer\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#why-metabolic\"\u003eWhy the Metabolic collection exists\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#qualification-filter\"\u003eFive-step qualification filter (what makes the cut)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#decision-tree\"\u003eFive-step decision tree (which SKU first)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#mechanism-backbone\"\u003eMechanism backbone — nutrient sensing \u0026amp; the Hallmarks of Aging\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#per-sku-trials\"\u003ePer-SKU trial-evidence cluster\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#three-tiers\"\u003eThree protocol tiers — Entry \/ Daily \/ Advanced\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#cofactor-stack\"\u003eCofactor stack — what to pair with what\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#cross-stacking\"\u003eCross-stacking with sister collections\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#timeline\"\u003eWeek-by-week realistic timeline\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#drug-interactions\"\u003eDrug interactions and precautions\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#who-its-for\"\u003eWho the Metabolic collection is for (and isn’t)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#quality-standards\"\u003eQuality, sourcing, and analytical standards\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#measuring\"\u003eHow to measure improvement\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#myths\"\u003eCommon metabolic-longevity myths and corrections\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#cost-framework\"\u003eCost tiers and what each one buys you\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#faq\"\u003eFAQ\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#references\"\u003eReading list and primary references\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#disclaimer\"\u003eFDA disclaimer\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"why-metabolic\"\u003eWhy the Metabolic collection exists\u003c\/h2\u003e\n\u003cp\u003eMetabolic dysfunction is not \u003cem\u003ea\u003c\/em\u003e disease; it is the upstream switchboard for nearly every chronic disease that compresses healthspan. Insulin resistance precedes Type 2 diabetes by 8–13 years (DeFronzo 2009, Banting Lecture). Hyperinsulinemia drives endothelial dysfunction, sodium retention, and SHBG suppression — all upstream of cardiovascular disease, hypertension, and PCOS \/ hypogonadism. NAD+ collapses ~50% by age 50 (Massudi 2012; Camacho-Pereira 2016 \u003cem\u003eCell Metab\u003c\/em\u003e CD38-mediated degradation) and depletion of this single coenzyme dysregulates sirtuins (SIRT1, SIRT3, SIRT6), PARPs (DNA repair), and CD38 (immune signaling) simultaneously.\u003c\/p\u003e\n\u003cp\u003eThe five SKUs address that switchboard at four operating points. \u003cstrong\u003eBerberine\u003c\/strong\u003e activates AMPK directly (Lee 2006; Turner 2008 \u003cem\u003eDiabetes\u003c\/em\u003e), the master metabolic regulator that increases muscle GLUT4 translocation, inhibits hepatic gluconeogenesis, and switches metabolism from anabolic mTOR-dominant to catabolic AMPK-dominant. \u003cstrong\u003eAlpha-Lipoic Acid\u003c\/strong\u003e is the obligate cofactor for PDH and α-KGDH — two mitochondrial choke-points where age-related decline gates ATP throughput — while regenerating glutathione, vitamin C, vitamin E, and CoQ10 in the antioxidant network (Packer 1995). \u003cstrong\u003eNMN\u003c\/strong\u003e provides the immediate substrate for NAMPT-bypassing NAD+ biosynthesis, restoring sirtuin and PARP function (Yoshino 2018; Mills 2016). \u003cstrong\u003eResveratrol\u003c\/strong\u003e activates SIRT1 substrate-dependently (Hubbard 2013 \u003cem\u003eScience\u003c\/em\u003e) and AMPK indirectly via PDE4 inhibition (Park 2012 \u003cem\u003eCell\u003c\/em\u003e) — closing the AMPK + sirtuin axis that underlies caloric-restriction phenotypes from yeast to humans.\u003c\/p\u003e\n\u003cp\u003eThe reason this collection sits as a single coherent unit — rather than scattered across NAD+ Family, Antioxidants, and Foundational Health — is that \u003cem\u003enone of these molecules works in isolation\u003c\/em\u003e. NMN without resveratrol leaves SIRT1 substrate-rich but allosterically under-stimulated. Resveratrol without NMN leaves SIRT1 modulated but substrate-starved. Berberine without ALA leaves AMPK activated but mitochondrial throughput cofactor-limited. The Metabolic collection is the assembled answer: AMPK (Berberine + Resveratrol), mito cofactors (ALA), NAD+\/sirtuin axis (NMN + Resveratrol) at trial-validated doses.\u003c\/p\u003e\n\n\u003ch2 id=\"qualification-filter\"\u003eFive-step qualification filter (what makes the cut)\u003c\/h2\u003e\n\u003cp\u003eEvery SKU cleared five hurdles before being added. The bar is highest in Metabolic because the consequences of getting it wrong (hypoglycemia, drug interactions, cofactor mismatch) are immediate.\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTrial-anchored dose.\u003c\/strong\u003e Label dose matches the dose in the published human trial that established the endpoint. Berberine 500mg t.i.d. = Yin 2008 \/ Lan 2015. ALA 600mg = NATHAN 1 \/ SYDNEY 2. NMN 250–1000mg = Yoshino \/ Igarashi \/ Pencina \/ Yi range. Resveratrol 600mg = Timmers \/ Goh \/ Tomé-Carneiro midpoint with cleanest safety.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMechanism completeness when paired.\u003c\/strong\u003e Each SKU plugs a gap another half-completes. Resveratrol completes the SIRT1 axis NMN initiates. ALA completes the mito cofactor envelope NMN\/NAD+ requires for ETC throughput. Berberine completes the AMPK arm resveratrol partially activates.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIndependent purity.\u003c\/strong\u003e HPLC ≥98% trans-resveratrol (cis is inert). HPLC ≥99% β-anomer NMN (α is inactive; β purity is the most-faked spec in the NAD+ space). Berberine HCL ≥97% alkaloid. ALA as racemic R\/S (the trial form; pure R-ALA polymerizes to inactive material).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eManufacturing quality.\u003c\/strong\u003e cGMP 21 CFR Part 111, FDA-registered, USP \u003cem\u003e2232\u003c\/em\u003e heavy-metals via ICP-MS, USP \u003cem\u003e2021\u003c\/em\u003e\/\u003cem\u003e2022\u003c\/em\u003e microbial, USP \u003cem\u003e467\u003c\/em\u003e residual solvents, no proprietary blends, no titanium dioxide (banned EU\/EFSA 2021), no artificial colors, vegan HPMC.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRisk asymmetry.\u003c\/strong\u003e Each SKU has a known, bounded risk. Berberine GI ramp-up — solved by titration and largest-meal dosing. ALA rare biotin depletion — solved by B-complex coverage. NMN methyl-buffer at \u0026gt;1000mg\/day — solved by TMG. Resveratrol CYP3A4 + antiplatelet — solved by interaction screening.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2 id=\"decision-tree\"\u003eFive-step decision tree (which SKU first)\u003c\/h2\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf your fasting glucose is \u0026gt;100 mg\/dL or HbA1c is \u0026gt;5.6%\u003c\/strong\u003e → Start with Berberine HCL 500mg, one cap with each of the two largest meals (1000mg\/day total) for the first 2 weeks; titrate to 500mg t.i.d. (1500mg\/day) at week 3. Expect fasting glucose to drop 10–25 mg\/dL within 7–14 days (Yin 2008). Pair with Alpha-Lipoic Acid 600mg in the morning to fortify mitochondrial PDH\/KGDH throughput as glucose uptake increases.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you have peripheral neuropathy symptoms (paresthesia, burning, allodynia)\u003c\/strong\u003e → Lead with Alpha-Lipoic Acid 600mg\/day, taken on an empty stomach 30–60 min before breakfast. The NATHAN 1 trial (Ziegler 2011 \u003cem\u003eDiabetes Care\u003c\/em\u003e) demonstrated significant improvement on the Total Symptom Score at 4 years of 600mg\/day; SYDNEY 2 (Ametov 2003) showed similar improvements at 5 weeks of IV administration that translated to oral maintenance. Add Berberine for upstream glucose control.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you’re an \"I’ve read Lifespan \/ Outlive \/ Why We Get Sick\" reader new to NAD+ supplementation\u003c\/strong\u003e → Start with the canonical Sinclair pairing: Pure NMN 500mg one cap in the morning + Resveratrol 600mg one cap with breakfast (resveratrol has poor bioavailability and food fat improves absorption — la Porte 2010 \u003cem\u003eEur J Drug Metab Pharmacokinet\u003c\/em\u003e). Run 8 weeks. If you’ve hit the 8-week mark on 500mg with measurable but unsatisfying gains, escalate to NMN 1000mg Double Strength.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you’re experienced (1+ years on NAD+ precursors, biological-age testing in hand)\u003c\/strong\u003e → Run NMN 1000mg Double Strength + Resveratrol 600mg + Berberine HCL + Alpha-Lipoic Acid as a 4-active metabolic backbone, with a 14:10 or 16:8 time-restricted eating window to compound the AMPK activation (Sutton 2018 \u003cem\u003eCell Metab\u003c\/em\u003e human eTRF cross-over showed insulin-sensitivity improvements independent of weight loss).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you’re managing visceral adiposity \/ metabolic syndrome \/ pre-diabetes\u003c\/strong\u003e → Start Berberine 500mg t.i.d. + Alpha-Lipoic Acid 600mg AM as the foundation; layer NMN 500mg AM at week 3 once berberine GI tolerance is confirmed; add Resveratrol 600mg with breakfast at week 5. Track fasting glucose (weekly), HOMA-IR (monthly), waist-to-hip (monthly), and ApoB\/non-HDL (every 90 days). Expect HOMA-IR -25–35% and ApoB -10–15% by month 3 if dietary fiber ≥30g\/day is also in place.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2 id=\"mechanism-backbone\"\u003eMechanism backbone — nutrient sensing \u0026amp; the Hallmarks of Aging\u003c\/h2\u003e\n\u003cp\u003eThe López-Otín 2013 \u003cem\u003eCell\u003c\/em\u003e paper (and the 2023 update extending to 12 hallmarks) frames biological aging as the loss of homeostatic regulation across nine to twelve interlocking cellular systems. Five of those hallmarks live inside this collection.\u003c\/p\u003e\n\n\u003ch3\u003eHallmark 1 — Deregulated nutrient sensing (AMPK \/ mTOR \/ sirtuins \/ IGF-1)\u003c\/h3\u003e\n\u003cp\u003eFour signaling axes integrate nutrient availability into cellular fate: AMPK (low energy → catabolism, autophagy, mito biogenesis), mTOR (high amino acids + insulin → anabolism, protein synthesis), sirtuins (NAD+-dependent deacetylases gating metabolic switching), IGF-1 (growth-factor signaling). Caloric restriction — the only intervention extending lifespan across yeast, worms, flies, mice, rats, and rhesus macaques (Mattison 2017) — activates AMPK and sirtuins while restraining mTOR and IGF-1. Berberine + Resveratrol activate AMPK; NMN + Resveratrol activate sirtuins.\u003c\/p\u003e\n\n\u003ch3\u003eHallmark 2 — Mitochondrial dysfunction\u003c\/h3\u003e\n\u003cp\u003eMitochondrial membrane potential declines with age. NAD+ supply to complex I drops with cytoplasmic NAD+ (Gomes 2013, reversed with NMN). PDH and KGDH require ALA as an obligate covalent cofactor (lipoyllysine on E2 subunits). Age-related decline in lipoyllysine content (Hagen 2002) limits acetyl-CoA throughput; ALA 600mg\/day partially restores cofactor availability. Resveratrol activates SIRT3 which deacetylates SOD2, IDH2, and ETC components.\u003c\/p\u003e\n\n\u003ch3\u003eHallmark 3 — Cellular senescence (SASP-driven inflammaging)\u003c\/h3\u003e\n\u003cp\u003eSenescent cells secrete SASP: IL-6, IL-8, MCP-1, MMP-3, TGF-β. Chronic SASP drives systemic inflammation and insulin resistance (Tchkonia 2013). AMPK suppresses NF-κB and reduces SASP. Resveratrol inhibits NF-κB directly (Manna 2000). For direct senolytic clearance, see \u003ca href=\"\/he\/collections\/senolytics\"\u003e\/collections\/senolytics\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eHallmark 4 — Loss of proteostasis \u0026amp; autophagy\u003c\/h3\u003e\n\u003cp\u003eProtein quality control depends on autophagy. AMPK activates ULK1 by direct phosphorylation (Egan 2011). Berberine is one of the strongest small-molecule AMPK activators in plant chemistry. Resveratrol activates autophagy via SIRT1-mediated LC3 and ATG7 deacetylation (Morselli 2010).\u003c\/p\u003e\n\n\u003ch3\u003eHallmark 5 — Altered intercellular communication \/ inflammaging\u003c\/h3\u003e\n\u003cp\u003eChronic low-grade inflammation accelerates every age-related decline. The collection’s actives suppress NF-κB at multiple points (Resveratrol direct; Berberine via AMPK; ALA via Nrf2). Combined with VAT reduction (which lowers adipose-derived TNF-α and IL-6), the stack measurably reduces hsCRP.\u003c\/p\u003e\n\n\u003ch3\u003eThe four nutrient-sensing pathways — what each SKU touches\u003c\/h3\u003e\n\u003ctable border=\"1\" cellpadding=\"6\"\u003e\n  \u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePathway\u003c\/th\u003e\n\u003cth\u003eFunction\u003c\/th\u003e\n\u003cth\u003eSKU(s) that touch it\u003c\/th\u003e\n\u003cth\u003ePrimary literature\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n\u003ctd\u003eAMPK\u003c\/td\u003e\n\u003ctd\u003eMaster energy sensor. Low ATP\/AMP ratio → AMPK ON → catabolism, GLUT4 translocation, mitochondrial biogenesis (PGC-1α), autophagy (ULK1), suppression of mTOR.\u003c\/td\u003e\n\u003ctd\u003eBerberine (direct), Resveratrol (indirect via PDE4\/cAMP\/CamKKβ), ALA (via energy-charge restoration)\u003c\/td\u003e\n\u003ctd\u003eLee 2006 \u003cem\u003eDiabetes\u003c\/em\u003e; Turner 2008 \u003cem\u003eDiabetes\u003c\/em\u003e; Park 2012 \u003cem\u003eCell\u003c\/em\u003e; Hou 2020 review\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003emTOR\u003c\/td\u003e\n\u003ctd\u003eAnabolic \/ growth signal. High amino acids + insulin + IGF-1 → mTOR ON → protein synthesis, lipogenesis, suppression of autophagy.\u003c\/td\u003e\n\u003ctd\u003eRestraint via AMPK activation (TSC1\/2 phosphorylation) — indirect through Berberine + Resveratrol\u003c\/td\u003e\n\u003ctd\u003eInoki 2003 \u003cem\u003eCell\u003c\/em\u003e; Gwinn 2008 \u003cem\u003eMol Cell\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eSirtuins (SIRT1\/SIRT3\/SIRT6)\u003c\/td\u003e\n\u003ctd\u003eNAD+-dependent deacetylases. Substrate-driven (need NAD+) AND allosterically modulated (resveratrol-class activators). Govern p53, FOXO, PGC-1α, NF-κB.\u003c\/td\u003e\n\u003ctd\u003eNMN 500mg, NMN 1000mg (NAD+ substrate), Resveratrol (allosteric)\u003c\/td\u003e\n\u003ctd\u003eHowitz 2003 \u003cem\u003eNature\u003c\/em\u003e; Hubbard 2013 \u003cem\u003eScience\u003c\/em\u003e; Yoshino 2021 \u003cem\u003eScience\u003c\/em\u003e; Imai 2014 review\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eIGF-1\u003c\/td\u003e\n\u003ctd\u003eGrowth-factor axis. Elevated IGF-1 signaling shortens lifespan in mice (Holzenberger 2003 \u003cem\u003eNature\u003c\/em\u003e IGF-1R+\/-); centenarians often carry IGF-1R loss-of-function variants.\u003c\/td\u003e\n\u003ctd\u003eModulated indirectly through improved insulin sensitivity (lower fasting insulin → lower hepatic IGF-1 secretion) — Berberine + ALA\u003c\/td\u003e\n\u003ctd\u003eHolzenberger 2003 \u003cem\u003eNature\u003c\/em\u003e; Suh 2008 \u003cem\u003ePNAS\u003c\/em\u003e; van der Spoel 2016 \u003cem\u003eAging Cell\u003c\/em\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch2 id=\"per-sku-trials\"\u003ePer-SKU trial-evidence cluster\u003c\/h2\u003e\n\u003cp\u003eFor each SKU, the trial that established the dose, the trial that established the endpoint, and the meta-analytic summary that situates the molecule in the broader literature.\u003c\/p\u003e\n\n\u003ch3\u003eBerberine HCL 500mg — AMPK activator, glucose \u0026amp; lipid panel\u003c\/h3\u003e\n\u003cp\u003e\u003ca href=\"\/he\/products\/berberine-hcl-500mg-maximum-strength\"\u003eProduct page\u003c\/a\u003e. Berberine is a quaternary ammonium alkaloid from \u003cem\u003eBerberis aristata\u003c\/em\u003e, \u003cem\u003eCoptis chinensis\u003c\/em\u003e, and \u003cem\u003eHydrastis canadensis\u003c\/em\u003e; used in Chinese medicine for ~3,000 years. Modern metabolic case:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eYin 2008.\u003c\/strong\u003e 36 newly-diagnosed T2D, berberine 500mg t.i.d. vs metformin 500mg t.i.d. for 3 months. Berberine: HbA1c 9.5%→7.5%, FPG 10.6→6.9 mmol\/L, post-prandial 19.8→11.1 mmol\/L, TG -25%. Metformin equivalent on HbA1c. \u003cstrong\u003eThe head-to-head that established berberine as metformin-comparable.\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLan 2015 meta-analysis.\u003c\/strong\u003e 27 RCTs (n=2,569). Berberine vs placebo: HbA1c -0.71%, FPG -0.81 mmol\/L, TC -0.61 mmol\/L, LDL -0.65 mmol\/L, TG -0.50 mmol\/L. Non-inferior to OHAs on glycemia, superior on lipids.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePérez-Rubio 2013.\u003c\/strong\u003e 24 metabolic-syndrome. Berberine 500mg t.i.d., 3 months: HOMA-IR 4.4→3.0, waist -2.5 cm, TG -23%, BMI -1.1 kg\/m².\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMechanism.\u003c\/strong\u003e Direct AMPK activator (Lee 2006; Turner 2008). Inhibits hepatic gluconeogenesis (PEPCK\/G6Pase). Increases GLUT4. Modulates gut microbiota (Zhang 2015 \u003cem\u003eISME J\u003c\/em\u003e).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBioavailability caveat.\u003c\/strong\u003e Native ~5%; saturable P-gp efflux. Trial doses (1500mg\/day) compensate; sub-trial 300mg \"maintenance\" lacks endpoint validation. Take with largest meal to leverage P-gp-saturation kinetics.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eAlpha-Lipoic Acid 600mg — universal antioxidant, mitochondrial PDH\/KGDH cofactor\u003c\/h3\u003e\n\u003cp\u003e\u003ca href=\"\/he\/products\/alpha-lipoic-acid-600mg-universal-antioxidant\"\u003eProduct page\u003c\/a\u003e. ALA (1,2-dithiolane-3-pentanoic acid, \"thioctic acid\") is the only small molecule that is both water- and fat-soluble, regenerates four antioxidants in vivo (C, E, CoQ10, GSH), and is a covalent cofactor at PDH\/KGDH\/BCKDH\/glycine-cleavage. Trial evidence:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eZiegler 2011 (NATHAN 1).\u003c\/strong\u003e 460 diabetic neuropathy patients, oral ALA 600mg\/day vs placebo, 4 years. Total Symptom Score significantly improved (clinically meaningful in 50% on ALA vs 25% on placebo); NIS improved.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAmetov 2003 (SYDNEY 2).\u003c\/strong\u003e 181 T2D with neuropathy, oral ALA 600\/1200\/1800mg\/day vs placebo, 5 weeks. All three doses showed equivalent symptom-score improvement; 600mg established as optimal with clean safety.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMechanism.\u003c\/strong\u003e Reduced ALA (dihydrolipoate) regenerates oxidized C → E → CoQ10. Lipoyllysine on E2 subunits of PDH\/KGDH catalyzes reductive acyl transfer. Heavy-metal chelation: binds Cd2+, Pb2+, Hg2+ via dithiol pair (Patrick 2002).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eR\/S-racemic vs R-only.\u003c\/strong\u003e Every trial used racemic R\/S. Pure R-ALA is unstable and polymerizes to inactive material at room temperature within months. We use R\/S racemic.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003ePure NMN 500mg — entry-tier β-NMN, NAD+ precursor\u003c\/h3\u003e\n\u003cp\u003e\u003ca href=\"\/he\/products\/pure-nmn-500mg-60-capsules-30-day-supply\"\u003eProduct page\u003c\/a\u003e. NMN (β-nicotinamide mononucleotide) is the immediate NAD+ precursor via NMNAT-1\/2\/3. Trial evidence:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eYoshino 2021 \u003cem\u003eScience\u003c\/em\u003e.\u003c\/strong\u003e 25 post-menopausal women with prediabetes, NMN 250mg\/day vs placebo, 10 weeks. Muscle insulin sensitivity (M-value clamp) +25%. \u003cstrong\u003eThe first RCT of NMN with a metabolic endpoint.\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePencina 2023.\u003c\/strong\u003e 30 healthy adults, NMN 250mg\/day, 8 weeks. Whole-blood NAD+ rose dose-dependently. 6-min walk improved.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIgarashi 2022.\u003c\/strong\u003e Healthy older adults, NMN 250mg\/day, 12 weeks. Aerobic capacity and gait speed improved.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLiao 2021.\u003c\/strong\u003e Amateur runners, 300\/600\/1200mg\/day vs placebo, 6 weeks. Aerobic capacity improved dose-dependently.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eYi 2023.\u003c\/strong\u003e 80 middle-aged adults, 300\/600\/900mg\/day, 60 days. Walking endurance, biological-age clock (TruDiagnostic), HOMA-IR improved dose-dependently.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMechanism.\u003c\/strong\u003e Bypasses NAMPT (rate-limiting in salvage) via the Slc12a8 transporter (Grozio 2019). NAD+ powers SIRT1\/SIRT3\/SIRT6 deacetylation, PARP1 DNA repair, and CD38 signaling.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eNMN 1000mg Double Strength — upper-trial-range β-NMN\u003c\/h3\u003e\n\u003cp\u003e\u003ca href=\"\/he\/products\/nmn-1000mg-double-strength-60-capsules-30-day-supply\"\u003eProduct page\u003c\/a\u003e. The double-strength format delivers the dose used in the upper end of the human trial range. Indicated for users who’ve plateaued on 500mg and want the upper-trial-range exposure documented in:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIgarashi 2022 \u003cem\u003enpj Aging\u003c\/em\u003e\u003c\/strong\u003e dose-escalation (used up to 1250mg\/day).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLiao 2021 \u003cem\u003eJISSN\u003c\/em\u003e\u003c\/strong\u003e 1200mg arm.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eYi 2023 \u003cem\u003eGeroscience\u003c\/em\u003e\u003c\/strong\u003e 900mg arm (dose-dependent gains).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMethylation buffer at \u0026gt;1000mg\/day.\u003c\/strong\u003e Higher NMN throughput consumes methyl groups via the NNMT (nicotinamide-N-methyltransferase) clearance pathway, generating MNA (1-methylnicotinamide) and depleting SAM (S-adenosylmethionine). Pair with TMG (trimethylglycine, betaine) 500–1000mg\/day to restore methyl-donor capacity. We don’t recommend 1000mg without TMG except for short pulses.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eResveratrol 600mg — trans-isomer SIRT1 activator\u003c\/h3\u003e\n\u003cp\u003e\u003ca href=\"\/he\/products\/resveratrol-600mg-60-capsules-30-day-supply\"\u003eProduct page\u003c\/a\u003e. Trans-resveratrol from \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e root extract, HPLC-confirmed ≥98% trans-isomer.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHowitz 2003 \u003cem\u003eNature\u003c\/em\u003e.\u003c\/strong\u003e Original screen identifying resveratrol as a SIRT1 activator. Triggered the field of \"STACs\" (sirtuin-activating compounds).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHubbard 2013 \u003cem\u003eScience\u003c\/em\u003e.\u003c\/strong\u003e Resolved the controversy: resveratrol is a substrate-specific SIRT1 activator that allosterically targets substrates with a hydrophobic group at +1 to the acetyl-lysine (the natural in-vivo substrate set).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTimmers 2011.\u003c\/strong\u003e 11 obese men, 150mg\/day, 30 days. Sleeping metabolic rate ↓, intrahepatic lipid ↓, ambulatory BP ↓ — calorie-restriction-mimetic phenotype.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGoh 2014.\u003c\/strong\u003e T2D, 1g\/day, 45 days. HbA1c -0.4%, TC -10%, systolic BP -5 mmHg.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTomé-Carneiro 2012\/2013.\u003c\/strong\u003e Stable CHD, grape-extract resveratrol 350mg\/day, 6→12 months. IL-6, TNF-α, hsCRP ↓; oxidized LDL ↓.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBioavailability.\u003c\/strong\u003e Native \u0026lt;1% (Phase II glucuronidation\/sulfation). Take with breakfast fat (la Porte 2010 showed 4× with high-fat meal). 600mg\/day = dose-response midpoint with cleanest safety.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePterostilbene.\u003c\/strong\u003e 3,5-dimethoxy-4′-hydroxy analog from blueberries. Walle 2004: 4× bioavailability, 7× half-life. \u003ca href=\"\/he\/products\/pterostilbene-100mg-60-capsules-30-day-supply\"\u003ePterostilbene 100mg\u003c\/a\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"three-tiers\"\u003eThree protocol tiers — Entry \/ Daily \/ Advanced\u003c\/h2\u003e\n\n\u003ch3\u003eTier 1 — Entry ($35–60\/month)\u003c\/h3\u003e\n\u003cp\u003eOne AMPK activator + one mitochondrial cofactor. Target: someone whose fasting glucose is creeping up, who’s pre-diabetic or has metabolic-syndrome features but isn’t on prescription metformin. \u003cstrong\u003eBerberine HCL 500mg t.i.d.\u003c\/strong\u003e with the largest meals + \u003cstrong\u003eAlpha-Lipoic Acid 600mg AM\u003c\/strong\u003e on empty stomach. Run 12 weeks, recheck fasting glucose \/ HbA1c \/ lipid panel. If HbA1c \u0026lt;5.6% and lipid panel normal, this remains the maintenance tier.\u003c\/p\u003e\n\n\u003ch3\u003eTier 2 — Daily ($90–140\/month)\u003c\/h3\u003e\n\u003cp\u003eThe Sinclair-canonical metabolic backbone. \u003cstrong\u003eBerberine HCL 500mg t.i.d.\u003c\/strong\u003e + \u003cstrong\u003eAlpha-Lipoic Acid 600mg AM\u003c\/strong\u003e + \u003cstrong\u003ePure NMN 500mg AM\u003c\/strong\u003e + \u003cstrong\u003eResveratrol 600mg with breakfast.\u003c\/strong\u003e Add \u003ca href=\"\/he\/collections\/foundational-health\"\u003eFoundational Health\u003c\/a\u003e floor (D3+K2, Magnesium glycinate, Omega-3, Multi Collagen, Vitamin C, Taurine, Creatine). This is what the average longevity-medicine-attentive adult on this catalog runs as a daily protocol indefinitely.\u003c\/p\u003e\n\n\u003ch3\u003eTier 3 — Advanced ($200–320\/month)\u003c\/h3\u003e\n\u003cp\u003eTier 2 + dose escalation + cross-collection layering. \u003cstrong\u003eNMN 1000mg Double Strength\u003c\/strong\u003e (replacing the 500mg) with TMG pairing for methyl-buffer + \u003cstrong\u003emonthly Fisetin pulse\u003c\/strong\u003e from \u003ca href=\"\/he\/collections\/senolytics\"\u003eSenolytics\u003c\/a\u003e (3–5 day pulse at 1000mg\/day, Hickson 2019 Mayo protocol) + \u003cstrong\u003eSpermidine, Urolithin A, Liposomal NAD+\u003c\/strong\u003e from cross-collection. This is the post-biological-age-test cohort (TruDiagnostic, Elysium Index, GlycanAge, DunedinPACE) running a Demidenko 2021-style multi-active stack.\u003c\/p\u003e\n\n\u003ch2 id=\"cofactor-stack\"\u003eCofactor stack — what to pair with what\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNMN + Resveratrol.\u003c\/strong\u003e Canonical Sinclair pairing. Howitz 2003 + Hubbard 2013 (allosteric SIRT1) + Yoshino 2021 (substrate). One without the other under-stimulates SIRT1.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNMN + TMG (only at \u0026gt;1000mg\/day NMN).\u003c\/strong\u003e Methylation buffer. NNMT consumes methyl groups via SAM in the MNA clearance pathway; TMG (betaine) regenerates SAM via BHMT. At 500mg NMN, dietary betaine (beets, spinach, quinoa) is usually sufficient. At 1000mg+ NMN, formulated TMG 500–1000mg\/day is recommended.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBerberine + Alpha-Lipoic Acid.\u003c\/strong\u003e Berberine activates AMPK (energy sensor); ALA fortifies the mitochondrial cofactor envelope (PDH\/KGDH lipoyllysine) so the increased glucose uptake actually translates to ATP throughput rather than overflow lactate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBerberine + Milk Thistle (silymarin).\u003c\/strong\u003e Yin 2008 mechanism note: berberine’s hepatic gluconeogenesis suppression involves CYP3A4 modulation; silymarin (300–400mg silybin\/day) provides hepatoprotection at chronic high-dose berberine.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eResveratrol + Pterostilbene.\u003c\/strong\u003e Walle 2004 PK extension. Pterostilbene’s 4× bioavailability + 7× half-life means combined dosing extends the SIRT1 allosteric activation window through more of the day. We sell Pterostilbene as a separate \u003ca href=\"\/he\/products\/pterostilbene-100mg-60-capsules-30-day-supply\"\u003e100mg SKU\u003c\/a\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNMN + Resveratrol + CoQ10\/Ubiquinol.\u003c\/strong\u003e ETC support. Resveratrol activates SIRT3 → activates SOD2 + components of complex I. Adding CoQ10 (the obligate electron carrier between complex I-II and complex III) closes the mitochondrial throughput loop. CoQ10 is in \u003ca href=\"\/he\/collections\/mitochondrial-renewal\"\u003eMitochondrial Renewal\u003c\/a\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eResveratrol + Quercetin (monthly pulse only).\u003c\/strong\u003e Senolytic synergy at high dose, NOT for chronic daily use. Resveratrol potentiates quercetin’s pro-apoptotic effect on senescent cells (Yousefzadeh 2018 baseline; Zhu 2015 D+Q protocol). Use for monthly senolytic pulses with \u003ca href=\"\/he\/collections\/senolytics\"\u003eFisetin\u003c\/a\u003e instead, which has cleaner human trial data (Hickson 2019).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBerberine + Foundational floor.\u003c\/strong\u003e D3+K2, Magnesium glycinate, Omega-3, Multi Collagen, Vitamin C, Taurine, Creatine. Berberine activates AMPK; the Foundational floor provides the substrate cofactors AMPK signaling demands (Mg for ATP, taurine for cardiomyocyte glucose uptake, creatine for ATP\/PCr buffer).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTime-restricted eating (14:10 \/ 16:8 eTRF).\u003c\/strong\u003e Sutton 2018 \u003cem\u003eCell Metab\u003c\/em\u003e early-time-restricted-eating cross-over: 6h eating window 8am–2pm vs 12h window for 5 weeks → improved insulin sensitivity, β-cell responsiveness, blood pressure, oxidative stress markers — independent of weight loss. Compounds AMPK activation from Berberine + ALA.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"cross-stacking\"\u003eCross-stacking with sister collections\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\u003ca href=\"\/he\/collections\/foundational-health\"\u003eFoundational Health\u003c\/a\u003e.\u003c\/strong\u003e The always-on floor: D3+K2, Magnesium glycinate, Omega-3, Multi Collagen, Vitamin C, Taurine, Creatine. Run this underneath Tier 2\/3.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\u003ca href=\"\/he\/collections\/nad-family\"\u003eNAD+ Family\u003c\/a\u003e.\u003c\/strong\u003e NMN + NR + direct NAD+ + cofactor SKUs. Sister collection if you want to run multiple NAD+ precursors or graduate to direct liposomal NAD+.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\u003ca href=\"\/he\/collections\/nmn\"\u003eNMN Supplements\u003c\/a\u003e.\u003c\/strong\u003e Single-pathway focus collection if NAD+ precursor is your only goal.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\u003ca href=\"\/he\/collections\/mitochondrial-renewal\"\u003eMitochondrial Renewal\u003c\/a\u003e.\u003c\/strong\u003e CoQ10\/Ubiquinol, PQQ, Urolithin A, Acetyl-L-Carnitine, MitoQ — the downstream-of-ALA mitochondrial layer.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\u003ca href=\"\/he\/collections\/senolytics\"\u003eSenolytics\u003c\/a\u003e.\u003c\/strong\u003e Fisetin, Quercetin, Spermidine — for monthly senolytic pulses (Hickson 2019 Mayo D+Q protocol; Yousefzadeh 2018 fisetin).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\u003ca href=\"\/he\/collections\/cardiovascular-longevity\"\u003eCardiovascular Longevity\u003c\/a\u003e.\u003c\/strong\u003e Berberine for ApoB\/LDL, ALA for endothelial function, Resveratrol for blood pressure (Timmers 2011) + the cardio-specific actives.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\u003ca href=\"\/he\/collections\/brain-cognitive-longevity\"\u003eBrain \u0026amp; Cognitive Longevity\u003c\/a\u003e.\u003c\/strong\u003e Insulin resistance is a major upstream driver of cognitive decline (\"Type 3 diabetes\" framing — de la Monte 2008 \u003cem\u003eJ Alzheimers Dis\u003c\/em\u003e); the Metabolic stack is upstream of the cognitive stack.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\u003ca href=\"\/he\/collections\/antioxidants\"\u003eAntioxidants\u003c\/a\u003e.\u003c\/strong\u003e ALA is the central node; Vitamin C, Vitamin E, NAC, glutathione precursors round out the redox layer.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\u003ca href=\"\/he\/collections\/longevity-essentials\"\u003eLongevity Essentials\u003c\/a\u003e.\u003c\/strong\u003e Curated entry-tier shortlist; the Metabolic actives appear here at trial-validated doses.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\u003ca href=\"\/he\/collections\/most-popular\"\u003eMost Popular\u003c\/a\u003e.\u003c\/strong\u003e Longevity Stack Bundle (NMN + Resveratrol) and Beauty \u0026amp; Longevity Stack — bundle-pricing on the canonical Sinclair pairing.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\u003ca href=\"\/he\/collections\/starter-bundles\"\u003eStarter Bundles\u003c\/a\u003e.\u003c\/strong\u003e If you want a single-purchase Metabolic-foundation bundle, build via the bundle hub.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"timeline\"\u003eWeek-by-week realistic timeline\u003c\/h2\u003e\n\u003ctable border=\"1\" cellpadding=\"6\"\u003e\n  \u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eWindow\u003c\/th\u003e\n\u003cth\u003eBerberine + ALA (AMPK + mito cofactor)\u003c\/th\u003e\n\u003cth\u003eNMN + Resveratrol (NAD+ + sirtuin axis)\u003c\/th\u003e\n\u003cth\u003eWhat to log\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n\u003ctd\u003eDays 1–7\u003c\/td\u003e\n\u003ctd\u003eBerberine: GI ramp-up (gas, soft stool common at full dose). Drop to 1 cap\/day with largest meal, build over 2 weeks. Fasting glucose may drop 5–15 mg\/dL by day 7 (Yin 2008 acute response). ALA: rare paresthesia transient; usually well-tolerated.\u003c\/td\u003e\n\u003ctd\u003eNMN: no immediately perceived effect (NAD+ rise is biochemical, takes 4 weeks to plateau per Trammell 2016 NR analog). Resveratrol: occasional mild GI; take with breakfast fat.\u003c\/td\u003e\n\u003ctd\u003eFasting glucose (morning, fasted 12h+). GI tolerance score 1–10. Sleep onset latency.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eWeeks 2–4\u003c\/td\u003e\n\u003ctd\u003eBerberine: titrated to 500mg t.i.d. with meals. Fasting glucose -10–25 mg\/dL from baseline (Yin 2008). Triglycerides starting to drop. ALA: paresthesia \/ burning improvement detectable if neuropathic at baseline (Ziegler 2011 first endpoint).\u003c\/td\u003e\n\u003ctd\u003eNAD+ steady-state plateau by week 4 (Trammell 2016 PK). Resveratrol: sleeping metabolic rate ↓ measurable in research-grade indirect calorimetry (Timmers 2011 30-day endpoint).\u003c\/td\u003e\n\u003ctd\u003eFasting glucose weekly. Self-rated energy 1–10 daily. Workout RPE.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eWeeks 4–8\u003c\/td\u003e\n\u003ctd\u003eBerberine: HbA1c trajectory bending (HbA1c reflects 90-day average so won’t fully read out yet). Lipid panel: LDL -10–15%, triglycerides -20–25% (Lan 2015 meta-analysis range).\u003c\/td\u003e\n\u003ctd\u003eNMN: muscle insulin sensitivity +15–20% by week 6–8 (Yoshino 2021 partial-trajectory). Resveratrol: ambulatory blood pressure -3–6 mmHg systolic (Timmers 2011).\u003c\/td\u003e\n\u003ctd\u003eHOMA-IR (fasting glucose × fasting insulin \/ 405) at week 6.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eWeeks 8–12\u003c\/td\u003e\n\u003ctd\u003eBerberine: HbA1c -0.5 to -0.7% (Yin 2008 \/ Lan 2015 meta-analytic range). Waist circumference -1 to -3 cm (Pérez-Rubio 2013).\u003c\/td\u003e\n\u003ctd\u003eNMN: walking endurance +6-min-walk distance (Pencina 2023 endpoint at 8 weeks). Resveratrol: hsCRP -10–20% (Tomé-Carneiro 2013 long-term endpoint).\u003c\/td\u003e\n\u003ctd\u003eHbA1c, full lipid panel (ApoB if available), waist-to-hip ratio.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eMonths 3–6\u003c\/td\u003e\n\u003ctd\u003eBerberine: HbA1c plateau at -0.7 to -1.0% (Lan 2015 12-week endpoint extrapolated). ALA: peripheral neuropathy total-symptom-score improvement consolidates (Ziegler 2011 4-year-trial 50%-of-patients-clinically-improved trajectory becoming evident).\u003c\/td\u003e\n\u003ctd\u003eNMN: gait speed, aerobic capacity (VO2 at submaximal HR) measurable improvements (Igarashi 2022 12-week endpoint). Resveratrol: oxidized LDL ↓ (Tomé-Carneiro 2013 6-month endpoint).\u003c\/td\u003e\n\u003ctd\u003eFull metabolic panel + biological-age clock if running TruDiagnostic \/ Elysium \/ GlycanAge.\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eBeyond Month 6\u003c\/td\u003e\n\u003ctd\u003eBerberine: maintenance phase. Some users cycle 8 weeks on \/ 2 weeks off to preserve gut-microbiota diversity. ALA: chronic daily indefinite — clean safety in NATHAN 1 4-year trial.\u003c\/td\u003e\n\u003ctd\u003eDemidenko 2021-style 6-month biological-age-clock reversal becomes detectable in cohort means at this point. Individual variance is high; cohort-mean improvements of 2–3 years on DNAm-age clocks are typical.\u003c\/td\u003e\n\u003ctd\u003eRe-test biological-age clock. Re-test full lipid + ApoB. Adjust dose tier based on results.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch2 id=\"drug-interactions\"\u003eDrug interactions and precautions\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiabetes medications (metformin, sulfonylureas, insulin, GLP-1 agonists).\u003c\/strong\u003e Berberine is additive with all of these. If on prescription antidiabetic medication, consult your physician before starting Berberine; dose adjustment of the Rx may be required to avoid hypoglycemia. Monitor capillary blood glucose if on insulin or sulfonylureas.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAnticoagulants and antiplatelets (warfarin, apixaban, rivaroxaban, dabigatran, aspirin, clopidogrel).\u003c\/strong\u003e Resveratrol has documented antiplatelet activity (Olas 2002 \u003cem\u003ePlatelets\u003c\/em\u003e). Berberine is a CYP3A4 substrate and can shift warfarin metabolism. Discuss with your physician; INR monitoring recommended if on warfarin.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStatins.\u003c\/strong\u003e Berberine + statin is an established additive LDL combination (Kong 2004 \u003cem\u003eNat Med\u003c\/em\u003e mechanism; clinical synergy documented). Watch for myopathy at chronic high-dose combination — co-supplementing CoQ10 is recommended (Banach 2015 \u003cem\u003eMayo Clin Proc\u003c\/em\u003e). Resveratrol is a CYP3A4 inhibitor at high dose and can raise atorvastatin\/simvastatin levels.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSSRIs \/ SNRIs \/ MAOIs.\u003c\/strong\u003e Resveratrol has weak MAO-A inhibitory activity in vitro. Avoid concurrent high-dose resveratrol with MAOIs (rare prescription class).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHormone replacement therapy (HRT).\u003c\/strong\u003e Resveratrol is weakly phytoestrogenic. Discuss with prescribing physician if on HRT.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eActive cancer treatment.\u003c\/strong\u003e Defer entire stack during chemotherapy \/ radiation \/ immunotherapy unless explicitly approved by oncologist. Antioxidants (ALA, resveratrol) may interfere with treatments that rely on oxidative cell killing.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePregnancy and lactation.\u003c\/strong\u003e Defer NMN, Resveratrol, Berberine. ALA: insufficient human pregnancy data; defer.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStage 3+ chronic kidney disease.\u003c\/strong\u003e Discuss with nephrologist. Berberine is renally cleared; dose adjustment may be needed.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSevere hepatic impairment \/ Child-Pugh B\/C cirrhosis.\u003c\/strong\u003e Resveratrol is a CYP3A4 substrate; berberine is hepatically metabolized. Discuss with hepatologist.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSurgery.\u003c\/strong\u003e 7-day pause on Resveratrol (antiplatelet) and Berberine (CYP3A4 effects on perioperative drug metabolism) before scheduled surgery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnder 18.\u003c\/strong\u003e Defer entire metabolic stack except in pediatric specialist guidance.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSevere GI sensitivity.\u003c\/strong\u003e Berberine GI side effects (gas, soft stool) at full dose are common; titrate slowly. If unable to tolerate, drop to single 500mg with largest meal as maintenance.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHypotension at baseline.\u003c\/strong\u003e Resveratrol can lower systolic blood pressure 3–6 mmHg (Timmers 2011). Watch for orthostasis if BP \u0026lt;110\/70 at baseline.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"who-its-for\"\u003eWho the Metabolic collection is for (and isn’t)\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eStrong fit:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eAdults 35–50 in the first-slope window of insulin-resistance accumulation (Reaven 1988 \u003cem\u003eDiabetes\u003c\/em\u003e \"Banting Lecture\" framing — insulin resistance precedes diabetes by a decade-plus).\u003c\/li\u003e\n  \u003cli\u003eAdults 50–70 in the steep-decline window where NAD+ has dropped ~50% from young-adult baseline (Massudi 2012; Camacho-Pereira 2016).\u003c\/li\u003e\n  \u003cli\u003ePre-diabetic \/ metabolic-syndrome adults (HbA1c 5.7–6.4%, fasting glucose 100–125 mg\/dL, waist \u0026gt;40″ men \/ \u0026gt;35″ women, triglycerides \u0026gt;150) who want to bend the curve before progressing to Type 2.\u003c\/li\u003e\n  \u003cli\u003eLifespan \/ Outlive \/ Huberman \/ Attia \/ Patrick podcast-circuit readers looking for the actual SKU shortlist behind the discussion.\u003c\/li\u003e\n  \u003cli\u003eBiological-age-test clients (TruDiagnostic, Elysium Index, GlycanAge, DunedinPACE, PhenoAge) who want a Demidenko 2021-style multi-active stack with measurable endpoint trajectories.\u003c\/li\u003e\n  \u003cli\u003eClinicians (integrative cardiologists, longevity-medicine consultants, functional-medicine practitioners) building patient-handoff stacks.\u003c\/li\u003e\n  \u003cli\u003ePost-menopausal women (Yoshino 2021 cohort directly applicable; insulin sensitivity decline accelerates post-menopause).\u003c\/li\u003e\n  \u003cli\u003eMen 40+ with declining recovery, visceral fat accumulation, fatigue or \"brain fog.\"\u003c\/li\u003e\n  \u003cli\u003eAdults with a family history of T2D \/ cardiovascular disease running a primary-prevention stack.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eDefer or modify:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePregnant or lactating women (defer NMN\/Resveratrol\/Berberine; ALA also defer).\u003c\/li\u003e\n  \u003cli\u003eAdults under 18 (pediatric supplementation requires specialist guidance).\u003c\/li\u003e\n  \u003cli\u003eActive cancer treatment (defer until oncologist clears).\u003c\/li\u003e\n  \u003cli\u003eOn insulin or sulfonylureas without endocrinologist consultation (hypoglycemia risk with Berberine addition).\u003c\/li\u003e\n  \u003cli\u003eOn warfarin without INR-monitoring plan (Resveratrol antiplatelet + CYP3A4).\u003c\/li\u003e\n  \u003cli\u003eSevere hepatic or renal impairment (Stage 3+ CKD, Child-Pugh B\/C cirrhosis).\u003c\/li\u003e\n  \u003cli\u003eSevere GI sensitivity unable to tolerate Berberine even at single-cap titration (drop the SKU; rest of the stack remains usable).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"quality-standards\"\u003eQuality, sourcing, and analytical standards\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTrial-validated dosing.\u003c\/strong\u003e Berberine 500mg t.i.d. = Yin 2008 \/ Lan 2015. ALA 600mg = NATHAN 1 \/ SYDNEY 2. NMN 250–1000mg = Yoshino \/ Igarashi \/ Pencina \/ Yi range. Resveratrol 600mg = Timmers \/ Goh \/ Tomé-Carneiro midpoint.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIdentity assay.\u003c\/strong\u003e HPLC-UV ≥98% trans-resveratrol (the only bioactive isomer). HPLC ≥99% β-anomer NMN (α-NMN is biologically inactive; β-anomer purity is the single most-faked spec in the NAD+ space). HPLC ≥97% berberine alkaloid as the HCl salt. R\/S-racemic ALA per established trial methodology.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHeavy-metals screening.\u003c\/strong\u003e ICP-MS per USP \u003cem\u003e2232\u003c\/em\u003e — Pb, As, Cd, Hg below California Proposition 65 limits and FDA EAFUS thresholds. Berberine is harvested from \u003cem\u003eBerberis aristata\u003c\/em\u003e root which can accumulate soil heavy metals; we screen every lot.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMicrobial limits.\u003c\/strong\u003e USP \u003cem\u003e2021\u003c\/em\u003e total aerobic + USP \u003cem\u003e2022\u003c\/em\u003e specified-organism (E. coli, Salmonella, S. aureus) on every batch.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eResidual solvents.\u003c\/strong\u003e USP \u003cem\u003e467\u003c\/em\u003e — particularly relevant for \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e resveratrol extraction (ethanol\/methanol\/acetone solvent residues).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eManufacturing.\u003c\/strong\u003e cGMP 21 CFR Part 111, FDA-registered facility, lot-traceable from raw material → finished good. Stability testing under ICH Q1A(R2) accelerated conditions (40°C \/ 75% RH \/ 6 months) → 24-month room-temperature shelf life with intact potency.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo proprietary blends.\u003c\/strong\u003e Every active and every dose disclosed on the label. We don’t hide sub-trial doses inside \"Metabolic Complex 800mg\" obscurations.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo titanium dioxide.\u003c\/strong\u003e Banned in EU food applications since EFSA’s 2021 reclassification (potential genotoxicity concern). Our capsules use vegan HPMC; the colorant in the berberine cap is the molecule’s native yellow.\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eNo artificial colors, flavors, or preservatives.\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCapsule format.\u003c\/strong\u003e Vegan HPMC (hypromellose). No bovine gelatin.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePer-batch CoA.\u003c\/strong\u003e Available on request to \u003ca href=\"mailto:support@truehealthprotocol.health\"\u003esupport@truehealthprotocol.health\u003c\/a\u003e with the lot number from the bottle base.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStorage and shelf life.\u003c\/strong\u003e Amber HDPE bottle, room-temperature stable 24 months from manufacture. Resveratrol and Berberine are oxidation-sensitive; do not transfer to clear or unsealed containers. NMN preferred refrigerated for long-term storage (the molecule slowly degrades to nicotinamide at room temperature — 24-month room-temp shelf life is conservative; refrigeration extends to 36 months).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e30-day return policy.\u003c\/strong\u003e Open or closed bottles. See \u003ca href=\"\/he\/policies\/refund-policy\"\u003eRefund Policy\u003c\/a\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"measuring\"\u003eHow to measure improvement\u003c\/h2\u003e\n\u003cp\u003eThree tiers of measurement, escalating in precision and cost.\u003c\/p\u003e\n\n\u003ch3\u003eTier 1 — Free \/ subjective trackers\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFasting capillary glucose\u003c\/strong\u003e (home glucose meter, ~$30 + strips). Morning, fasted 12h+. Track weekly mean.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSleep, HRV, resting heart rate.\u003c\/strong\u003e Oura, Whoop, Apple Watch, or any consumer wearable. Improving HRV and dropping RHR are reliable surrogates for vagal tone \/ autonomic balance recovery on AMPK-activator therapy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e1–10 daily energy \/ brain-fog \/ mood scoring.\u003c\/strong\u003e Sounds soft; isn’t. Trend over 90 days is informative.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStandardized photographs.\u003c\/strong\u003e Same lighting, same angle, monthly. Particularly informative for waist \/ abdominal-adiposity changes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBrito 2014 sit-to-rise test.\u003c\/strong\u003e Functional age proxy; correlates with all-cause mortality.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWaist-to-hip ratio.\u003c\/strong\u003e Tape measure. Visceral-fat trajectory.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eTier 2 — Standard lab markers ($60–250 every 90 days)\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHbA1c\u003c\/strong\u003e (90-day glycemic average; gold-standard metabolic-trajectory marker).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFasting insulin + glucose → HOMA-IR\u003c\/strong\u003e (insulin resistance index). Fasting insulin alone is one of the most underused longevity-screening labs.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFull lipid panel + ApoB.\u003c\/strong\u003e ApoB is the single best lipid marker for cardiovascular risk (better than LDL-C). Berberine drops ApoB measurably.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ehsCRP.\u003c\/strong\u003e Inflammaging marker.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLiver enzymes (ALT, AST, GGT).\u003c\/strong\u003e Baseline + 90-day check. Resveratrol and Berberine are hepatically metabolized; clean is clean.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFerritin, TSH, 25-OH vitamin D.\u003c\/strong\u003e Common confounders if \"the stack isn’t working\" — usually it’s a missing foundational input rather than the stack itself.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHomocysteine.\u003c\/strong\u003e Methylation-cycle proxy. Elevated homocysteine + high-dose NMN suggests methyl-buffer deficiency → add TMG.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eTier 3 — Specialized longevity testing ($300–800)\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBiological-age clocks.\u003c\/strong\u003e TruDiagnostic TruAge, Elysium Index, Horvath, GrimAge, DunedinPACE, PhenoAge. The Demidenko 2021 \u003cem\u003eAging\u003c\/em\u003e retrospective showed multi-active longevity stacks (similar in spirit to Tier 2\/3 here) can reverse DNAm-age 2–3 years over 6 months in cohort means; individual variance is high.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eJinfiniti intracellular NAD+.\u003c\/strong\u003e Direct readout of the metabolite NMN supplementation is targeting. Pre-\/post- on NMN dose-escalation is the cleanest single-marker validation that the precursor is converting.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOmega-3 Index\u003c\/strong\u003e (Harris 2021 \u003cem\u003eNat Commun\u003c\/em\u003e). Cardiovascular risk marker; aim \u0026gt;8%.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGlycanAge.\u003c\/strong\u003e N-glycan-based inflammaging biological-age clock. Particularly responsive to anti-inflammatory interventions.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVO2max\u003c\/strong\u003e (Kodama 2009 \u003cem\u003eJAMA\u003c\/em\u003e — VO2max is the strongest known longevity marker outside of biological-age clocks). Treadmill or bike ergometry in a sports-medicine clinic.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDEXA scan.\u003c\/strong\u003e Visceral adipose tissue (VAT) quantification + lean-mass tracking. Particularly informative on Berberine + ALA + TRE protocols where the goal is VAT reduction without lean-mass loss.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eContinuous glucose monitor (CGM).\u003c\/strong\u003e Levels Health, Nutrisense, Dexcom G7 (with Rx). Hours-to-days resolution glycemic-variability data — far more informative than spot fasting glucose.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"myths\"\u003eCommon metabolic-longevity myths and corrections\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\"NMN is FDA-banned.\"\u003c\/strong\u003e A 2022 NDI determination created industry confusion but did not prohibit sale. Post-NDI human trials (Pencina 2023, Yi 2023) continued to confirm efficacy and safety. We formulate HPLC-confirmed β-anomer NMN.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\"Resveratrol doesn’t work — Yoshino 2012 showed nothing.\"\u003c\/strong\u003e Yoshino 2012 used 75mg\/day. Timmers 2011 (150mg\/30 days), Goh 2014 (1g\/45 days), Tomé-Carneiro 2012 (350mg\/6 months) all showed clear endpoint shifts. Dose dependence matters; 75mg is sub-trial-range.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\"Berberine is just nature’s metformin — pick one.\"\u003c\/strong\u003e Yin 2008 head-to-head showed equivalent HbA1c reduction, but berberine is additive (different upstream entry: metformin via complex I, berberine via direct AMPK activation).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\"AMPK activators replace exercise.\"\u003c\/strong\u003e They don’t. Resistance training drives AMPK and PGC-1α activation through mechanical-load signaling no pill replicates. The stack \u003cem\u003ecomplements\u003c\/em\u003e exercise; it doesn’t substitute.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\"NMN at 1000mg without TMG is dangerous.\"\u003c\/strong\u003e Not dangerous; sub-optimal. NNMT clearance of nicotinamide consumes methyl groups via SAM. Pair TMG 500–1000mg\/day at NMN ≥1000mg\/day.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\"ALA causes biotin deficiency.\"\u003c\/strong\u003e Theoretical concern from animal studies (shared SMVT). In NATHAN 1 4-year trial at 600mg\/day, no clinically-significant biotin deficiency observed. B-complex closes any residual gap.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\"Berberine is just a weight-loss supplement.\"\u003c\/strong\u003e Primary mechanism is AMPK activation and HbA1c reduction; weight effects are downstream. Marketing as ozempic-replacement misrepresents mechanism.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\"Multivitamin covers this.\"\u003c\/strong\u003e Multivitamins contain RDA-level micronutrients. Berberine, ALA, NMN, Resveratrol are pharmacologically-active small molecules at supra-physiological trial doses. A multivitamin covers adequacy; this stack targets longevity-specific signaling.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"cost-framework\"\u003eCost tiers and what each one buys you\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$30–60\/month (single-SKU foundation).\u003c\/strong\u003e Berberine HCL 500mg alone, OR Alpha-Lipoic Acid 600mg alone. Useful as a starting wedge for adults with one specific marker (high fasting glucose only, or peripheral neuropathy only). Doesn’t address the NAD+\/sirtuin axis.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$75–110\/month (Tier 1 Entry — two-SKU foundation).\u003c\/strong\u003e Berberine + ALA. Addresses AMPK + mitochondrial cofactor. Appropriate for pre-diabetic \/ metabolic-syndrome adults not yet ready for full longevity stack.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$150–220\/month (Tier 2 Daily — full metabolic backbone + Foundational floor).\u003c\/strong\u003e Berberine + ALA + Pure NMN 500mg + Resveratrol 600mg + Foundational Health (D3+K2, Mg, Omega-3, Multi Collagen, Vit C, Taurine, Creatine). The longevity-medicine-attentive adult’s daily protocol.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$300–450\/month (Tier 3 Advanced — full Hallmarks coverage).\u003c\/strong\u003e Tier 2 + NMN 1000mg + monthly Fisetin pulse + Spermidine + Urolithin A + Liposomal NAD+. The post-biological-age-test cohort running multi-active stacks. Demidenko 2021 cost-anchor: ~$30\/year-of-DNAm-age reversed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"faq\"\u003eFAQ\u003c\/h2\u003e\n\n\u003ch3\u003eWhere do I start if I’ve never taken any of these?\u003c\/h3\u003e\n\u003cp\u003ePure NMN 500mg + Resveratrol 600mg as the canonical pair if your goal is general longevity. Berberine + ALA if your driver is metabolic markers (fasting glucose, HbA1c, lipid panel). If both, run Tier 2 from day one — none of the four interfere with each other and the trial doses are well-tolerated together.\u003c\/p\u003e\n\n\u003ch3\u003eCan I take all five at once?\u003c\/h3\u003e\n\u003cp\u003eYes — that’s effectively Tier 2 with NMN 500mg + 1000mg overlap (which doesn’t make sense; pick one). The intended Tier 2 stack is: Berberine 500mg t.i.d. + ALA 600mg AM + \u003cem\u003eeither\u003c\/em\u003e Pure NMN 500mg \u003cem\u003eor\u003c\/em\u003e NMN 1000mg Double Strength + Resveratrol 600mg AM. The 1000mg is a dose-escalation upgrade from the 500mg, not a co-administration.\u003c\/p\u003e\n\n\u003ch3\u003eHow long until I feel something?\u003c\/h3\u003e\n\u003cp\u003eBerberine: fasting glucose drop within 7–14 days. ALA: paresthesia improvement within 2–4 weeks if neuropathic; nothing perceptible if not. NMN: NAD+ steady-state by week 4 (biochemical, not subjectively felt by most users). Resveratrol: subtle \"second-wind\" energy phenotype reported by a subset within 2–4 weeks; metabolic phenotype shifts at 4–6 weeks. Anyone telling you they \"felt NMN within 24 hours\" is reporting placebo or expectation effect — the molecule’s action is biochemical and time-dependent.\u003c\/p\u003e\n\n\u003ch3\u003eNMN vs NR vs direct NAD+ — which one?\u003c\/h3\u003e\n\u003cp\u003eNMN: most direct precursor (NMN → NAD+ via NMNAT, single enzymatic step). Strongest human RCT data set as of 2024–2025 (Yoshino, Pencina, Igarashi, Liao, Yi). NR (nicotinamide riboside): one extra enzymatic step (NR → NMN → NAD+ via NRK then NMNAT). Trammell 2016 PK + several RCTs; cleanest PK data. Direct liposomal NAD+: bypasses precursor pathway entirely; bioavailability disputed but emerging trial data positive. We carry NMN as the lead format with NR + liposomal NAD+ in \u003ca href=\"\/he\/collections\/nad-family\"\u003eNAD+ Family\u003c\/a\u003e for users who want to compare or rotate.\u003c\/p\u003e\n\n\u003ch3\u003eWhy berberine with the largest meal?\u003c\/h3\u003e\n\u003cp\u003eP-glycoprotein-saturation kinetics. Native berberine bioavailability is ~5%; P-gp efflux pumps berberine back into the gut lumen as it crosses the enterocyte. Higher single doses (and concurrent food bulk) saturate P-gp transiently, raising effective absorption. 500mg with the largest meal absorbs better than 250mg twice with smaller meals.\u003c\/p\u003e\n\n\u003ch3\u003eIf I’m on metformin, do I still need berberine?\u003c\/h3\u003e\n\u003cp\u003eDiscuss with your physician. Mechanistically additive (metformin via complex I inhibition raising AMP\/ATP, berberine via direct AMPK activation). Some clinicians stack; others substitute when patients want to come off metformin. Berberine is not FDA-approved as a diabetes therapy and should not be used to self-discontinue prescription metformin without physician oversight.\u003c\/p\u003e\n\n\u003ch3\u003eI’m getting GI side effects from berberine. What now?\u003c\/h3\u003e\n\u003cp\u003eDrop to 1 cap (500mg) with the largest meal. Hold 1 week. Add a second cap with second-largest meal; hold 1 week. Add a third with the third meal if tolerated. Most users tolerate 1000mg\/day cleanly even when 1500mg\/day causes ramp-up discomfort; efficacy curve is flat above 1000mg\/day for HbA1c.\u003c\/p\u003e\n\n\u003ch3\u003eShould I cycle berberine, or take daily forever?\u003c\/h3\u003e\n\u003cp\u003eSome clinicians cycle 8 weeks on \/ 2 weeks off to preserve gut-microbiota diversity (berberine has dose-dependent antimicrobial effects on gut flora). Others run continuously. Both are reasonable. Conservative default: continuous for 12 weeks, reassess.\u003c\/p\u003e\n\n\u003ch3\u003eIs keto compatible with this stack?\u003c\/h3\u003e\n\u003cp\u003eYes. AMPK activators + ketogenic diet are doubly catabolic; NMN + Resveratrol still work in ketosis (NAD+\/sirtuin axis is fuel-type-agnostic). Berberine’s glucose-lowering effect is less perceived in keto (baseline glucose is already low) but lipid and inflammatory benefits remain.\u003c\/p\u003e\n\n\u003ch3\u003eCan I take this alongside a multivitamin?\u003c\/h3\u003e\n\u003cp\u003eYes — and you should. The Foundational floor (D3+K2, Magnesium, Omega-3, B-complex) is essential for the metabolic actives to fully work. They’re complementary, not redundant.\u003c\/p\u003e\n\n\u003ch3\u003eI’m 35 — too young?\u003c\/h3\u003e\n\u003cp\u003eInsulin resistance and NAD+ decline both begin in the 30s (Massudi 2012). The 35–50 first-slope window has the highest intervention leverage. Tier 1 Entry is reasonable; Tier 2 with NMN reasonable if markers are bending or family history is strong.\u003c\/p\u003e\n\n\u003ch3\u003eReturn policy if it doesn’t work?\u003c\/h3\u003e\n\u003cp\u003e30-day money-back guarantee, open or closed bottles. See \u003ca href=\"\/he\/policies\/refund-policy\"\u003eRefund Policy\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eCertificate of Analysis for my lot?\u003c\/h3\u003e\n\u003cp\u003eEmail \u003ca href=\"mailto:support@truehealthprotocol.health\"\u003esupport@truehealthprotocol.health\u003c\/a\u003e with the lot number on the bottle base. Third-party CoA covering identity, potency, heavy metals, microbial limits, and residual solvents.\u003c\/p\u003e\n\n\u003ch3\u003eWhat if the biological-age clock doesn’t move after 6 months?\u003c\/h3\u003e\n\u003cp\u003eIndividual variance on DNAm-age clocks is high. Cohort-mean improvements of 2–3 years on Tier 2\/3 stacks (Demidenko 2021) reflect averages, not individual guarantees. Confounders to check: 25-OH-D \u0026lt;30 ng\/mL, ferritin\/TSH out of range, sleep apnea undiagnosed, alcohol \u0026gt;7 drinks\/week, sleep \u0026lt;6.5h, protein \u0026lt;1.0 g\/kg\/day, resistance-training \u0026lt;2x\/week. Fix the confounder, re-run at month 12.\u003c\/p\u003e\n\n\u003ch2 id=\"references\"\u003eReading list and primary references\u003c\/h2\u003e\n\u003col\u003e\n  \u003cli\u003eLópez-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. \u003cem\u003eCell\u003c\/em\u003e. 2013 Jun 6;153(6):1194-217. PMID: 23746838.\u003c\/li\u003e\n  \u003cli\u003eLópez-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. \u003cem\u003eCell\u003c\/em\u003e. 2023 Jan 19;186(2):243-278. PMID: 36599349.\u003c\/li\u003e\n  \u003cli\u003eYin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. \u003cem\u003eMetabolism\u003c\/em\u003e. 2008 May;57(5):712-7. PMID: 18442638.\u003c\/li\u003e\n  \u003cli\u003eLan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, Sun G. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. \u003cem\u003eJ Ethnopharmacol\u003c\/em\u003e. 2015 Feb 23;161:69-81. PMID: 25498346.\u003c\/li\u003e\n  \u003cli\u003ePérez-Rubio KG, González-Ortiz M, Martínez-Abundis E, Robles-Cervantes JA, Espinel-Bermudez MC. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. \u003cem\u003eMetab Syndr Relat Disord\u003c\/em\u003e. 2013 Oct;11(5):366-9. PMID: 23808999.\u003c\/li\u003e\n  \u003cli\u003eLee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase. \u003cem\u003eDiabetes\u003c\/em\u003e. 2006 Aug;55(8):2256-64. PMID: 16873688.\u003c\/li\u003e\n  \u003cli\u003eTurner N, Li JY, Gosby A, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I. \u003cem\u003eDiabetes\u003c\/em\u003e. 2008 May;57(5):1414-8. PMID: 18285556.\u003c\/li\u003e\n  \u003cli\u003eKong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. \u003cem\u003eNat Med\u003c\/em\u003e. 2004 Dec;10(12):1344-51. PMID: 15531889.\u003c\/li\u003e\n  \u003cli\u003eZhang X, Zhao Y, Xu J, et al. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. \u003cem\u003eSci Rep\u003c\/em\u003e. 2015 Sep 23;5:14405. PMID: 26396057.\u003c\/li\u003e\n  \u003cli\u003eZiegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. \u003cem\u003eDiabetes Care\u003c\/em\u003e. 2011 Sep;34(9):2054-60. PMID: 21775755.\u003c\/li\u003e\n  \u003cli\u003eAmetov AS, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with α-lipoic acid: the SYDNEY trial. \u003cem\u003eDiabetes Care\u003c\/em\u003e. 2003 Mar;26(3):770-6. PMID: 12610036.\u003c\/li\u003e\n  \u003cli\u003ePacker L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. \u003cem\u003eFree Radic Biol Med\u003c\/em\u003e. 1995 Aug;19(2):227-50. PMID: 7649494.\u003c\/li\u003e\n  \u003cli\u003eHagen TM, Liu J, Lykkesfeldt J, et al. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. \u003cem\u003eProc Natl Acad Sci USA\u003c\/em\u003e. 2002 Feb 19;99(4):1870-5. PMID: 11854487.\u003c\/li\u003e\n  \u003cli\u003eYoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. \u003cem\u003eScience\u003c\/em\u003e. 2021 Jun 11;372(6547):1224-1229. PMID: 33888596.\u003c\/li\u003e\n  \u003cli\u003ePencina KM, Lavu S, dos Santos M, et al. MIB-626, an oral formulation of a microcrystalline unique polymorph of β-nicotinamide mononucleotide, increases circulating nicotinamide adenine dinucleotide and its metabolome in middle-aged and older adults. \u003cem\u003eJ Gerontol A Biol Sci Med Sci\u003c\/em\u003e. 2023 Jan 26;78(1):90-96. PMID: 35977397.\u003c\/li\u003e\n  \u003cli\u003eIgarashi M, Nakagawa-Nagahama Y, Miura M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. \u003cem\u003enpj Aging\u003c\/em\u003e. 2022;8(1):5.\u003c\/li\u003e\n  \u003cli\u003eLiao B, Zhao Y, Wang D, Zhang X, Hao X, Hu M. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. \u003cem\u003eJ Int Soc Sports Nutr\u003c\/em\u003e. 2021 Jul 8;18(1):54. PMID: 34238308.\u003c\/li\u003e\n  \u003cli\u003eYi L, Maier AB, Tao R, et al. The efficacy and safety of β-NMN supplementation in healthy middle-aged adults: dose-dependent RCT. \u003cem\u003eGeroscience\u003c\/em\u003e. 2023;45(1):29-43. PMID: 36482258.\u003c\/li\u003e\n  \u003cli\u003eTrammell SAJ, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. \u003cem\u003eNat Commun\u003c\/em\u003e. 2016;7:12948. PMID: 27721479.\u003c\/li\u003e\n  \u003cli\u003eYoshino J, Baur JA, Imai SI. NAD+ Intermediates: NMN and NR. \u003cem\u003eCell Metab\u003c\/em\u003e. 2018;27(3):513-528. PMID: 29249689.\u003c\/li\u003e\n  \u003cli\u003eMills KF, Yoshida S, Stein LR, et al. Long-term NMN mitigates age-associated physiological decline in mice. \u003cem\u003eCell Metab\u003c\/em\u003e. 2016;24(6):795-806. PMID: 28068222.\u003c\/li\u003e\n  \u003cli\u003eMassudi H, Grant R, Braidy N, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. \u003cem\u003ePLoS One\u003c\/em\u003e. 2012;7(7):e42357. PMID: 22850463.\u003c\/li\u003e\n  \u003cli\u003eCamacho-Pereira J, Tarragó-Celada J, Chini CCS, et al. CD38 dictates age-related NAD decline through an SIRT3-dependent mechanism. \u003cem\u003eCell Metab\u003c\/em\u003e. 2016;23(6):1127-1139. PMID: 27304511.\u003c\/li\u003e\n  \u003cli\u003eHowitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. \u003cem\u003eNature\u003c\/em\u003e. 2003 Sep 11;425(6954):191-6. PMID: 12939617.\u003c\/li\u003e\n  \u003cli\u003eHubbard BP, Gomes AP, Dai H, et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. \u003cem\u003eScience\u003c\/em\u003e. 2013 Mar 8;339(6124):1216-9. PMID: 23471411.\u003c\/li\u003e\n  \u003cli\u003eTimmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. \u003cem\u003eCell Metab\u003c\/em\u003e. 2011 Nov 2;14(5):612-22. PMID: 22055504.\u003c\/li\u003e\n  \u003cli\u003eGoh KP, Lee HY, Lau DP, et al. Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. \u003cem\u003eInt J Sport Nutr Exerc Metab\u003c\/em\u003e. 2014 Feb;24(1):2-13. PMID: 23918618.\u003c\/li\u003e\n  \u003cli\u003eTomé-Carneiro J, Gonzálvez M, Larrosa M, et al. Grape extract with resveratrol decreases oxidized LDL and ApoB in primary CV prevention. \u003cem\u003eMol Nutr Food Res\u003c\/em\u003e. 2012;56(5):810-21. PMID: 22648627.\u003c\/li\u003e\n  \u003cli\u003eTomé-Carneiro J, Larrosa M, Yáñez-Gascón MJ, et al. One-year resveratrol-grape extract modulates inflammatory miRNAs and cytokines in T2D and hypertensive patients. \u003cem\u003ePharmacol Res\u003c\/em\u003e. 2013;72:69-82. PMID: 23557933.\u003c\/li\u003e\n  \u003cli\u003ePark SJ, Ahmad F, Philp A, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. \u003cem\u003eCell\u003c\/em\u003e. 2012;148(3):421-33. PMID: 22304913.\u003c\/li\u003e\n  \u003cli\u003ela Porte C, Voduc N, Zhang G, et al. Steady-state PK and tolerability of trans-resveratrol 2g BID with food, quercetin, ethanol. \u003cem\u003eEur J Drug Metab Pharmacokinet\u003c\/em\u003e. 2010;35(3-4):103-11. PMID: 21188572.\u003c\/li\u003e\n  \u003cli\u003eWalle T, Hsieh F, DeLegge MH, et al. High absorption but very low bioavailability of oral resveratrol in humans. \u003cem\u003eDrug Metab Dispos\u003c\/em\u003e. 2004;32(12):1377-82. PMID: 15333514.\u003c\/li\u003e\n  \u003cli\u003eOlas B, Wachowicz B, et al. Effect of resveratrol on platelet activation induced by endotoxin or thrombin. \u003cem\u003eThromb Res\u003c\/em\u003e. 2002;107(3-4):141-5. PMID: 12431480.\u003c\/li\u003e\n  \u003cli\u003eDemidenko O, Barardo D, Budovskii V, et al. Rejuvant® conferred 8-year reduction in biological aging on TruAge DNA methylation test. \u003cem\u003eAging (Albany NY)\u003c\/em\u003e. 2021;13(22):24485-24499. PMID: 34847066.\u003c\/li\u003e\n  \u003cli\u003eDeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: T2D paradigm. \u003cem\u003eDiabetes\u003c\/em\u003e. 2009;58(4):773-95. PMID: 19336687.\u003c\/li\u003e\n  \u003cli\u003eSutton EF, Beyl R, Early KS, et al. Early time-restricted feeding improves insulin sensitivity even without weight loss in men with prediabetes. \u003cem\u003eCell Metab\u003c\/em\u003e. 2018;27(6):1212-1221.e3. PMID: 29754952.\u003c\/li\u003e\n  \u003cli\u003eMattison JA, Colman RJ, Beasley TM, et al. Caloric restriction improves health and survival of rhesus monkeys. \u003cem\u003eNat Commun\u003c\/em\u003e. 2017;8:14063. PMID: 28094793.\u003c\/li\u003e\n  \u003cli\u003eReaven GM. Banting lecture 1988. Role of insulin resistance in human disease. \u003cem\u003eDiabetes\u003c\/em\u003e. 1988;37(12):1595-607. PMID: 3056758.\u003c\/li\u003e\n  \u003cli\u003eHolzenberger M, Dupont J, Ducos B, et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. \u003cem\u003eNature\u003c\/em\u003e. 2003;421(6919):182-7. PMID: 12483226.\u003c\/li\u003e\n  \u003cli\u003eEgan DF, Shackelford DB, Mihaylova MM, et al. ULK1 phosphorylation by AMPK connects energy sensing to mitophagy. \u003cem\u003eScience\u003c\/em\u003e. 2011;331(6016):456-61. PMID: 21205641.\u003c\/li\u003e\n  \u003cli\u003eHickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: D+Q diabetic kidney disease pilot. \u003cem\u003eEBioMedicine\u003c\/em\u003e. 2019;47:446-456. PMID: 31542391.\u003c\/li\u003e\n  \u003cli\u003eYousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. \u003cem\u003eEBioMedicine\u003c\/em\u003e. 2018;36:18-28. PMID: 30279143.\u003c\/li\u003e\n  \u003cli\u003eKodama S, Saito K, Tanaka S, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality. \u003cem\u003eJAMA\u003c\/em\u003e. 2009;301(19):2024-35. PMID: 19454641.\u003c\/li\u003e\n  \u003cli\u003eHarris WS, Tintle NL, Imamura F, et al. Blood n-3 fatty acid levels and mortality from 17 prospective studies. \u003cem\u003eNat Commun\u003c\/em\u003e. 2021;12(1):2329. PMID: 33888689.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2 id=\"disclaimer\"\u003eFDA disclaimer\u003c\/h2\u003e\n\u003cp\u003e\u003cem\u003eThese statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Consult your physician before starting any supplement, particularly if you are pregnant, lactating, taking prescription medication, or managing a chronic condition.\u003c\/em\u003e\u003c\/p\u003e\n","products":[{"product_id":"pure-nmn-500mg-60-capsules-30-day-supply","title":"NMN Complex Capsules (120ct)","description":"\n\u003cp\u003e\u003cstrong\u003e500 mg of pure β-NMN per capsule\u003c\/strong\u003e — the most-studied oral NAD+ precursor at the dose used in the majority of published human trials. 99%+ HPLC-verified β-anomer, no fillers, no proprietary blends, vegan capsule. The standard starting point for anyone new to longevity supplementation, and the dose that anchors most of the NMN clinical literature.\u003c\/p\u003e\n\n\u003ch2\u003eThe 30-second answer\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCheapest, most-studied entry into NAD+ support.\u003c\/strong\u003e 500 mg is the dose used across Yoshino 2021 \u003cem\u003eScience\u003c\/em\u003e, Yi 2022 \u003cem\u003eGeroScience\u003c\/em\u003e, Igarashi 2022 \u003cem\u003enpj Aging\u003c\/em\u003e, Liao 2021 \u003cem\u003eJ Int Soc Sports Nutr\u003c\/em\u003e, and most of the published human work — not a marketing dose, the trial dose.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOne capsule, daily, with breakfast.\u003c\/strong\u003e 60-capsule bottle = 30-day supply. NAD+ rise plateaus around week 4–8 of consistent dosing (Yoshino 2021).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBest paired with \u003ca href=\"\/he\/products\/resveratrol-600mg-60-capsules-30-day-supply\"\u003eResveratrol 600 mg\u003c\/a\u003e.\u003c\/strong\u003e NMN raises NAD+, Resveratrol activates the SIRT1\/SIRT3 sirtuin enzymes that \u003cem\u003euse\u003c\/em\u003e NAD+. The classic substrate-plus-activator longevity stack.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMove up to \u003ca href=\"\/he\/products\/nmn-1000mg-pure-focus-formula-cellular-rejuvenation\"\u003eNMN 1000 mg\u003c\/a\u003e\u003c\/strong\u003e if you're 50+, training hard, or didn't notice a shift at 500 mg after 6–8 weeks of daily use.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e99%+ HPLC-tested β-NMN\u003c\/strong\u003e — the bioactive anomer. Per-batch third-party COA, heavy-metals\/microbial\/residual-solvents panel, vegan HPMC capsule, no titanium dioxide, no magnesium stearate.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWhy NMN sits at the center of the longevity conversation\u003c\/h2\u003e\n\u003cp\u003eNAD+ — nicotinamide adenine dinucleotide — is the coenzyme your cells use for mitochondrial energy production, DNA repair, sirtuin signaling, and circadian regulation. It's not optional. Every cell needs it constantly.\u003c\/p\u003e\n\n\u003cp\u003eNAD+ levels fall sharply with age. \u003cstrong\u003eMassudi 2012\u003c\/strong\u003e (\u003cem\u003ePLOS ONE\u003c\/em\u003e) measured a roughly 50% drop in skin NAD+ between age 30 and 70. \u003cstrong\u003eYoshino 2011\u003c\/strong\u003e (\u003cem\u003eCell Metabolism\u003c\/em\u003e) replicated multi-tissue NAD+ decline across muscle, liver, and adipose in mammals. \u003cstrong\u003eCamacho-Pereira 2016\u003c\/strong\u003e (\u003cem\u003eCell Metabolism\u003c\/em\u003e) traced part of the decline to rising CD38 (an NAD+ \"consumer\" enzyme) with age. The López-Otín 2013 (\u003cem\u003eCell\u003c\/em\u003e) and updated 2023 hallmarks-of-aging frameworks both list mitochondrial dysfunction and dysregulated nutrient sensing among the twelve hallmarks — and NAD+ is downstream of both.\u003c\/p\u003e\n\n\u003cp\u003eThat gives you three strategic interventions:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSupply more NAD+ precursor\u003c\/strong\u003e — NMN, NR, NAD+ itself. This product.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eReduce NAD+ consumers\u003c\/strong\u003e — Apigenin (CD38), Quercetin\/Fisetin (PARP, senescent-cell load), CD38 inhibitors.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eActivate downstream sirtuins\u003c\/strong\u003e — Resveratrol, Pterostilbene (SIRT1 activators).\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eA complete protocol does all three. NMN is the most-studied form of strategy 1.\u003c\/p\u003e\n\n\u003ch2\u003eMechanism — what NMN actually does inside the cell\u003c\/h2\u003e\n\n\u003ch3\u003e1. The NMN → NAD+ conversion pathway\u003c\/h3\u003e\n\u003cp\u003eNMN sits one enzymatic step away from NAD+. Inside the cell, NMNAT (nicotinamide mononucleotide adenylyltransferase) adds an AMP group to NMN and you have NAD+. Three isoforms — NMNAT1 (nucleus), NMNAT2 (cytoplasm\/Golgi), NMNAT3 (mitochondria) — distribute the conversion across compartments, which is why NMN supplementation tends to raise NAD+ in tissues where NR cannot reach as efficiently.\u003c\/p\u003e\n\n\u003cp\u003eBefore that step, NMN has to enter the cell. Two routes:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSlc12a8 — the direct NMN transporter.\u003c\/strong\u003e \u003cstrong\u003eGrozio 2019\u003c\/strong\u003e (\u003cem\u003eNature Metabolism\u003c\/em\u003e) identified Slc12a8 in the small intestine as a sodium-dependent transporter that moves NMN intact across the cell membrane. This is the most distinctive feature of NMN versus NR: a dedicated transporter for the molecule itself, with no requirement to dephosphorylate first.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExtracellular CD73 conversion.\u003c\/strong\u003e CD73 is an ectonucleotidase that strips the phosphate off NMN, producing NR. The resulting NR enters cells via ENT1\/ENT2 transporters and is rephosphorylated back to NMN inside the cell by NRK1 or NRK2. So even when Slc12a8 is saturated or absent (some tissues), NMN can still convert to NAD+ via the NR pathway.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat redundancy is why NMN works in tissues where NR alone might not — and why direct NAD+ rise from oral NMN has now been documented in multiple human trials.\u003c\/p\u003e\n\n\u003ch3\u003e2. Sirtuins — the longevity-linked enzymes that consume NAD+\u003c\/h3\u003e\n\u003cp\u003eSeven sirtuins (SIRT1–SIRT7), all of them NAD+-dependent. SIRT1 deacetylates p53, FOXO1\/3, PGC-1α, and dozens of other regulatory targets — including many of the proteins that govern stress response and metabolism. SIRT3 sits inside mitochondria and deacetylates SOD2 (the manganese superoxide dismutase that handles mitochondrial reactive oxygen species), increasing antioxidant capacity. SIRT6 maintains genome stability and telomere integrity.\u003c\/p\u003e\n\n\u003cp\u003eThe catch: every sirtuin reaction \u003cem\u003econsumes\u003c\/em\u003e one molecule of NAD+. Without enough NAD+, sirtuins down-regulate. \u003cstrong\u003eImai \u0026amp; Guarente 2014\u003c\/strong\u003e (\u003cem\u003eTrends in Cell Biology\u003c\/em\u003e) framed this as the core \"NAD+ World\" hypothesis — sirtuin output is directly NAD+-supply limited. \u003cstrong\u003eMendelsohn \u0026amp; Larrick 2017\u003c\/strong\u003e reviewed the supply-side evidence and concluded that raising NAD+ is the single most direct lever on sirtuin throughput.\u003c\/p\u003e\n\n\u003cp\u003eThis is why NMN pairs so well with \u003ca href=\"\/he\/products\/resveratrol-600mg-60-capsules-30-day-supply\"\u003eResveratrol\u003c\/a\u003e: NMN raises substrate, Resveratrol enhances SIRT1's affinity for that substrate. \u003cstrong\u003ePacholec 2010\u003c\/strong\u003e (\u003cem\u003eJBC\u003c\/em\u003e) showed Resveratrol's SIRT1 effect is substrate-mediated; without enough NAD+, the activator doesn't have anything to activate.\u003c\/p\u003e\n\n\u003ch3\u003e3. PARP enzymes — the DNA-damage NAD+ sink\u003c\/h3\u003e\n\u003cp\u003ePARP1 and PARP2 use NAD+ to attach poly-ADP-ribose chains to proteins at DNA damage sites — the first responders to single- and double-strand breaks. Each PARP1 activation event burns through tens to hundreds of NAD+ molecules in seconds. Chronic DNA damage from oxidative stress, UV, smoking, and aging drives chronic PARP1 activation, which depletes the cellular NAD+ pool faster than the salvage pathway can replenish it.\u003c\/p\u003e\n\n\u003cp\u003eNMN supplementation directly addresses this depletion by widening the supply side. \u003cstrong\u003eBai 2011\u003c\/strong\u003e (\u003cem\u003eCell Metabolism\u003c\/em\u003e) demonstrated PARP1-knockout mice have higher NAD+ and SIRT1 activity, confirming PARP1's central role as an NAD+ sink. \u003cstrong\u003eFang 2014\u003c\/strong\u003e (\u003cem\u003eCell\u003c\/em\u003e) extended this to ataxia-telangiectasia models, where NMN restored mitochondrial homeostasis specifically through NAD+ rescue.\u003c\/p\u003e\n\n\u003ch3\u003e4. CD38 — the age-rising NAD+ consumer\u003c\/h3\u003e\n\u003cp\u003eCD38 is a glycohydrolase that cleaves NAD+ into nicotinamide + ADP-ribose. \u003cstrong\u003eCamacho-Pereira 2016\u003c\/strong\u003e (\u003cem\u003eCell Metabolism\u003c\/em\u003e) showed CD38 expression rises sharply with age, driving a substantial portion of the age-related NAD+ decline. CD38-knockout mice have 20–30× higher NAD+ than wild-type at the same age.\u003c\/p\u003e\n\n\u003cp\u003eYou can attack the problem from both ends: raise input (NMN) and reduce loss (Apigenin, Quercetin — both natural CD38 inhibitors). \u003cstrong\u003eEscande 2013\u003c\/strong\u003e (\u003cem\u003eDiabetes\u003c\/em\u003e) demonstrated Apigenin's CD38-inhibitory effect raises tissue NAD+ in vivo. This is why the catalog pairs NMN with \u003ca href=\"\/he\/products\/apigenin-50mg-cd38-inhibitor-nad-preservation\"\u003eApigenin\u003c\/a\u003e in the senior protocol.\u003c\/p\u003e\n\n\u003ch3\u003e5. The mitochondrial NAD+ pool — separately compartmentalized\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eLuongo 2020\u003c\/strong\u003e (\u003cem\u003eNature\u003c\/em\u003e) identified SLC25A51 as the mitochondrial NAD+ transporter — the gate that decides how much cytosolic NAD+ reaches the mitochondrial matrix. This matters because mitochondrial NAD+ feeds the electron transport chain and SIRT3-driven antioxidant defense, and it's a partially separate pool from cytosolic NAD+.\u003c\/p\u003e\n\n\u003cp\u003eNMN raises both pools. The mitochondrial NMNAT3 enzyme converts mitochondrial NMN to mitochondrial NAD+ directly, in addition to whatever crosses via SLC25A51. \u003cstrong\u003eYoshino 2021\u003c\/strong\u003e (\u003cem\u003eScience\u003c\/em\u003e) measured muscle NAD+ rise in postmenopausal prediabetic women on 250 mg\/day NMN for 10 weeks — confirming tissue-level (not just blood) NAD+ delivery in humans.\u003c\/p\u003e\n\n\u003ch3\u003e6. The methylation pool — why TMG eventually matters\u003c\/h3\u003e\n\u003cp\u003eNAD+ is recycled through the salvage pathway: NAD+ → nicotinamide (NAM) → back to NMN → back to NAD+, with NAMPT (nicotinamide phosphoribosyltransferase) as the rate-limiting enzyme. The leak in this loop: nicotinamide can also be methylated to 1-methylnicotinamide (1MNA) by NNMT (nicotinamide N-methyltransferase) and excreted in urine.\u003c\/p\u003e\n\n\u003cp\u003eNNMT pulls a methyl group from S-adenosylmethionine (SAM) every time it methylates a NAM molecule. At high NMN doses (especially 1000 mg+), this can measurably draw on the methylation pool — the same pool used for DNA methylation, histone methylation, neurotransmitter synthesis, and homocysteine clearance.\u003c\/p\u003e\n\n\u003cp\u003eAt 500 mg\/day this is not a clinical concern. At 1000 mg\/day in someone with an MTHFR variant, or at 2000 mg\/day in anyone, methylation support starts to matter. \u003ca href=\"\/he\/products\/tmg-1000mg-trimethylglycine-methyl-donor-for-nmn-nad-stacks\"\u003eTMG 1000 mg\u003c\/a\u003e (trimethylglycine, also called betaine) is the cleanest methyl donor — it gives back what NNMT spends. \u003cstrong\u003eOlthof 2003\u003c\/strong\u003e and \u003cstrong\u003eMcRae 2013\u003c\/strong\u003e document TMG's homocysteine-lowering effect through this exact mechanism.\u003c\/p\u003e\n\n\u003cp\u003eIf you're starting at 500 mg, you don't need TMG yet. If you stay at 500 mg long-term, you still probably don't. But if you eventually move to 1000 mg or stack NMN with NR, add TMG.\u003c\/p\u003e\n\n\u003ch2\u003eThe β-anomer — what \"pure β-NMN\" actually means\u003c\/h2\u003e\n\u003cp\u003eNMN exists as two anomers: α and β. Only the β-anomer is bioactive — only β-NMN is the substrate that NMNAT recognizes and converts to NAD+. The α-anomer is a structural variant that takes up bottle space and contributes nothing.\u003c\/p\u003e\n\n\u003cp\u003eCheap NMN often comes as a mix of α and β, with the β fraction sometimes as low as 60–80%. Two product-quality consequences:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eYou get less active dose than the label says.\u003c\/strong\u003e 500 mg of \"NMN\" at 75% β-purity is 375 mg of usable NMN.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStability is worse.\u003c\/strong\u003e α-NMN tends to degrade faster, especially in heat or humidity, which can drag the β fraction down further by the end of shelf life.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis product is HPLC-tested for ≥99% β-NMN purity per batch, with the certificate of analysis available on request and posted to \u003ca href=\"\/he\/pages\/coa\"\u003eour COA page\u003c\/a\u003e. Heavy metals (lead, arsenic, cadmium, mercury), residual solvents, and microbial contamination panel are all run per batch and certified within USP-acceptable limits.\u003c\/p\u003e\n\n\u003ch2\u003eClinical evidence — the trials that anchor 500 mg\u003c\/h2\u003e\n\u003cp\u003eNMN went from a niche molecule to a major longevity category on the back of a specific body of human trial work. Here's what's been published, organized by what the strongest evidence actually supports.\u003c\/p\u003e\n\n\u003ch3\u003eNAD+ rise — the most-replicated finding\u003c\/h3\u003e\n\u003ctable border=\"1\" cellpadding=\"8\" cellspacing=\"0\" style=\"border-collapse:collapse;width:100%;font-size:14px;margin:16px 0;\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTrial\u003c\/th\u003e\n\u003cth\u003ePopulation\u003c\/th\u003e\n\u003cth\u003eDose\u003c\/th\u003e\n\u003cth\u003eDuration\u003c\/th\u003e\n\u003cth\u003eNAD+ result\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIrie 2020 \u003cem\u003eEndocrine J\u003c\/em\u003e\n\u003c\/td\u003e\n\u003ctd\u003e10 healthy men\u003c\/td\u003e\n\u003ctd\u003e100\/250\/500 mg single dose\u003c\/td\u003e\n\u003ctd\u003e5 hours\u003c\/td\u003e\n\u003ctd\u003ePlasma NAD+ rose dose-dependently; safe at all doses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiao 2021 \u003cem\u003eJ Int Soc Sports Nutr\u003c\/em\u003e\n\u003c\/td\u003e\n\u003ctd\u003e48 amateur runners\u003c\/td\u003e\n\u003ctd\u003e300\/600\/1200 mg + exercise\u003c\/td\u003e\n\u003ctd\u003e6 weeks\u003c\/td\u003e\n\u003ctd\u003eAerobic capacity ↑ dose-dependently with NMN\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYoshino 2021 \u003cem\u003eScience\u003c\/em\u003e\n\u003c\/td\u003e\n\u003ctd\u003e25 postmenopausal prediabetic women\u003c\/td\u003e\n\u003ctd\u003e250 mg\u003c\/td\u003e\n\u003ctd\u003e10 weeks\u003c\/td\u003e\n\u003ctd\u003eMuscle NAD+ ↑, insulin sensitivity ↑ ~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIgarashi 2022 \u003cem\u003enpj Aging\u003c\/em\u003e\n\u003c\/td\u003e\n\u003ctd\u003e108 men 65+\u003c\/td\u003e\n\u003ctd\u003e250 mg AM vs PM\u003c\/td\u003e\n\u003ctd\u003e12 weeks\u003c\/td\u003e\n\u003ctd\u003eWhole-blood NAD+ ↑, SARC-F + 5x sit-stand ↑\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYi 2022 \u003cem\u003eGeroScience\u003c\/em\u003e\n\u003c\/td\u003e\n\u003ctd\u003e80 healthy adults 40–65\u003c\/td\u003e\n\u003ctd\u003e300\/600\/900 mg\u003c\/td\u003e\n\u003ctd\u003e60 days\u003c\/td\u003e\n\u003ctd\u003eWhole-blood NAD+ ↑ dose-dependently, 6-min walk ↑\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKim 2022 \u003cem\u003eNutrients\u003c\/em\u003e\n\u003c\/td\u003e\n\u003ctd\u003e30 healthy adults\u003c\/td\u003e\n\u003ctd\u003e250 mg\u003c\/td\u003e\n\u003ctd\u003e12 weeks\u003c\/td\u003e\n\u003ctd\u003eSubjective fatigue ↓, sleep quality ↑\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePencina 2023 \u003cem\u003eJCEM\u003c\/em\u003e\n\u003c\/td\u003e\n\u003ctd\u003e32 healthy 55–80\u003c\/td\u003e\n\u003ctd\u003e1000\/2000 mg\u003c\/td\u003e\n\u003ctd\u003e14 days\u003c\/td\u003e\n\u003ctd\u003eWhole-blood NAD+ ↑ dose-dependently, no AEs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFukamizu 2022 \u003cem\u003eSci Rep\u003c\/em\u003e\n\u003c\/td\u003e\n\u003ctd\u003e31 healthy adults\u003c\/td\u003e\n\u003ctd\u003e1250 mg\u003c\/td\u003e\n\u003ctd\u003e4 weeks\u003c\/td\u003e\n\u003ctd\u003eWhole-blood NAD+ ↑ ~22%, no AEs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eFunctional readouts beyond NAD+\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInsulin sensitivity (Yoshino 2021).\u003c\/strong\u003e Postmenopausal prediabetic women on 250 mg\/day NMN for 10 weeks showed a ~25% improvement in skeletal-muscle insulin sensitivity (hyperinsulinemic-euglycemic clamp gold-standard measure). The first human trial to show NMN translating into a metabolic clinical endpoint.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAerobic capacity (Liao 2021).\u003c\/strong\u003e Amateur runners on 300\/600\/1200 mg\/day NMN + standardized training showed dose-dependent improvements in ventilatory threshold and aerobic capacity. The 600 mg arm was statistically significant against placebo + training.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWalking speed and grip strength (Igarashi 2022).\u003c\/strong\u003e 65+ men on 250 mg\/day NMN for 12 weeks showed faster gait speed, better SARC-F sarcopenia score, and improved 5x-sit-stand. Morning dosing outperformed evening dosing — a finding that influenced our directions.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e6-minute walk distance (Yi 2022).\u003c\/strong\u003e 40–65yo adults on 300\/600\/900 mg\/day NMN for 60 days showed dose-dependent improvement in 6MWD, the standard cardiopulmonary endurance metric.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSleep and fatigue (Kim 2022, Igarashi 2022).\u003c\/strong\u003e Both trials showed subjective sleep quality and fatigue improvement, though these are softer endpoints.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eWhere the evidence is preliminary\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCognitive endpoints.\u003c\/strong\u003e Mostly animal\/in vitro at this stage. Human trials are running but not yet reported with the resolution needed to make claims.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSkin and hair.\u003c\/strong\u003e Anecdotal reports are common but trial-grade evidence is thin.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCardiovascular outcomes.\u003c\/strong\u003e NR has stronger cardiovascular trial evidence (Martens 2018 — aortic stiffness, BP). NMN's CV story is more mechanistic than endpoint-proven so far.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLifespan.\u003c\/strong\u003e No human lifespan data exists for any supplement. Animal data on NMN extending health span is consistent (Mills 2016 \u003cem\u003eCell Metab\u003c\/em\u003e, Yoshida 2019), but extrapolation to humans is speculative.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eWhat you can confidently expect: NAD+ rise, plus modest improvements in energy, exercise tolerance, and metabolic markers across 6–12 weeks. What you should not expect: dramatic visible anti-aging effects in 30 days. The mechanism is upstream — the rest of the biology takes time to catch up.\u003c\/p\u003e\n\n\u003ch2\u003eNMN vs NR — the practical decision, with mechanism\u003c\/h2\u003e\n\u003ctable border=\"1\" cellpadding=\"8\" cellspacing=\"0\" style=\"border-collapse:collapse;width:100%;font-size:14px;margin:16px 0;\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003e\u003c\/th\u003e\n\u003cth\u003eNMN\u003c\/th\u003e\n\u003cth\u003eNR\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCell entry\u003c\/td\u003e\n\u003ctd\u003eSlc12a8 (intact) + via NR after CD73 cleavage\u003c\/td\u003e\n\u003ctd\u003eENT1\/ENT2 transporter\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSteps to NAD+\u003c\/td\u003e\n\u003ctd\u003e1 enzymatic step (NMNAT)\u003c\/td\u003e\n\u003ctd\u003e2 enzymatic steps (NRK then NMNAT)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMitochondrial reach\u003c\/td\u003e\n\u003ctd\u003eDirect (NMNAT3 in matrix)\u003c\/td\u003e\n\u003ctd\u003eVia cytoplasm-to-mitochondria transport\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMost-studied dose\u003c\/td\u003e\n\u003ctd\u003e250–600 mg\/day\u003c\/td\u003e\n\u003ctd\u003e300–1000 mg\/day\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrongest human signal\u003c\/td\u003e\n\u003ctd\u003eInsulin sensitivity (Yoshino 2021), endurance (Liao 2021, Yi 2022), gait (Igarashi 2022)\u003c\/td\u003e\n\u003ctd\u003eAortic stiffness\/BP (Martens 2018), brain NAD+ in PD (Brakedal 2022)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost per gram\u003c\/td\u003e\n\u003ctd\u003eLower — bulk supply has expanded faster\u003c\/td\u003e\n\u003ctd\u003eHigher — patented forms add license cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMethylation load\u003c\/td\u003e\n\u003ctd\u003eEquivalent — both end as nicotinamide that NNMT methylates\u003c\/td\u003e\n\u003ctd\u003eEquivalent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBest for\u003c\/td\u003e\n\u003ctd\u003eMitochondrial focus, metabolic, exercise capacity, sarcopenia\u003c\/td\u003e\n\u003ctd\u003eCardiovascular focus, brain (PD evidence), elderly cohort\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStack with each other?\u003c\/td\u003e\n\u003ctd\u003eYes — covers both Slc12a8 and ENT entry routes\u003c\/td\u003e\n\u003ctd\u003eYes — same logic in reverse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFor most users at most ages, NMN at 500 mg is the right starting point on cost, evidence base, and mechanism. NR at \u003ca href=\"\/he\/products\/rb-nicotinamide-nucleotide-nad-hard-capsules-cellular-energy-anti-aging\"\u003eour patented NR-Cl\u003c\/a\u003e becomes more interesting if cardiovascular markers, neurodegenerative concerns, or 65+ frailty are the priority — or as a stack add-on to cover both transporter pathways.\u003c\/p\u003e\n\n\u003ch2\u003eSource comparison — what \"NMN\" can actually mean on a label\u003c\/h2\u003e\n\u003ctable border=\"1\" cellpadding=\"8\" cellspacing=\"0\" style=\"border-collapse:collapse;width:100%;font-size:14px;margin:16px 0;\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSource\u003c\/th\u003e\n\u003cth\u003eβ-purity (typical)\u003c\/th\u003e\n\u003cth\u003eHPLC-verified?\u003c\/th\u003e\n\u003cth\u003eTrial-grade?\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePure β-NMN (this product, ≥99% HPLC)\u003c\/td\u003e\n\u003ctd\u003e≥99%\u003c\/td\u003e\n\u003ctd\u003eYes, per batch\u003c\/td\u003e\n\u003ctd\u003eMatches the form used in published trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneric commodity β-NMN\u003c\/td\u003e\n\u003ctd\u003e85–95%\u003c\/td\u003e\n\u003ctd\u003eVariable\u003c\/td\u003e\n\u003ctd\u003eUsually adequate, but lot-to-lot drift\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMixed α\/β NMN (cheap)\u003c\/td\u003e\n\u003ctd\u003e60–80%\u003c\/td\u003e\n\u003ctd\u003eOften no\u003c\/td\u003e\n\u003ctd\u003eBelow trial-grade — under-doses the active form\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNMN salts \/ stabilized variants\u003c\/td\u003e\n\u003ctd\u003eVariable\u003c\/td\u003e\n\u003ctd\u003eSometimes\u003c\/td\u003e\n\u003ctd\u003eLimited human data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNMN sublingual lozenges\u003c\/td\u003e\n\u003ctd\u003eSource-dependent\u003c\/td\u003e\n\u003ctd\u003eVariable\u003c\/td\u003e\n\u003ctd\u003ePK studies pending\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiposomal NMN\u003c\/td\u003e\n\u003ctd\u003eSource-dependent\u003c\/td\u003e\n\u003ctd\u003eVariable\u003c\/td\u003e\n\u003ctd\u003eNot the form in any major trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe shortcut: ≥99% β-NMN HPLC-verified is the only spec that maps cleanly onto the published trials. Anything else is an extrapolation.\u003c\/p\u003e\n\n\u003ch2\u003eBioavailability — what the PK studies actually show\u003c\/h2\u003e\n\u003cp\u003eOral NMN absorption is well characterized at this point. \u003cstrong\u003eIrie 2020\u003c\/strong\u003e (\u003cem\u003eEndocrine J\u003c\/em\u003e) measured plasma NAD+ rise within 5 hours of single 100\/250\/500 mg doses, dose-dependently, in 10 healthy men. \u003cstrong\u003eYoshino 2021\u003c\/strong\u003e (\u003cem\u003eScience\u003c\/em\u003e) confirmed sustained tissue (skeletal muscle) NAD+ rise on 250 mg\/day for 10 weeks. \u003cstrong\u003eYi 2022\u003c\/strong\u003e (\u003cem\u003eGeroScience\u003c\/em\u003e) showed dose-linear whole-blood NAD+ rise across 300\/600\/900 mg\/day at 30 and 60 days. \u003cstrong\u003ePencina 2023\u003c\/strong\u003e (\u003cem\u003eJCEM\u003c\/em\u003e) extended dose-linearity to 2000 mg\/day in healthy 55–80yo adults.\u003c\/p\u003e\n\n\u003cp\u003eWhat this means in practice:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eNAD+ rise is real, replicated, and dose-linear in the 250–2000 mg range.\u003c\/li\u003e\n  \u003cli\u003e500 mg is in the meat of the evidence base — not an outlier dose.\u003c\/li\u003e\n  \u003cli\u003eSteady-state requires consistent daily dosing for 4–8 weeks. Single doses raise NAD+ acutely but don't drive the clinical endpoints.\u003c\/li\u003e\n  \u003cli\u003eMorning dosing outperformed evening dosing on functional outcomes in Igarashi 2022 — consistent with NAD+'s role in circadian wake signaling.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWhere this fits in our NAD+ family\u003c\/h2\u003e\n\u003cp\u003eThe catalog has seven distinct entry points into the NAD+ system. Each is the right product for a different user.\u003c\/p\u003e\n\n\u003ctable border=\"1\" cellpadding=\"8\" cellspacing=\"0\" style=\"border-collapse:collapse;width:100%;font-size:14px;margin:16px 0;\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eForm\u003c\/th\u003e\n\u003cth\u003eBest for\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003ca href=\"\/he\/products\/pure-nmn-500mg-60-capsules-30-day-supply\"\u003ePure NMN 500 mg\u003c\/a\u003e (this product)\u003c\/td\u003e\n\u003ctd\u003eβ-NMN capsule, 500 mg\u003c\/td\u003e\n\u003ctd\u003eTrial-dose entry tier. Most users, age 30+, first NAD+ product.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003ca href=\"\/he\/products\/nmn-1000mg-pure-focus-formula-cellular-rejuvenation\"\u003eNMN 1000 mg\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eβ-NMN capsule, 1000 mg\u003c\/td\u003e\n\u003ctd\u003eHigher dose for 50+, athletes, or after 6–8 weeks at 500 mg without subjective effect.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003ca href=\"\/he\/products\/rb-nicotinamide-nucleotide-nad-hard-capsules-cellular-energy-anti-aging\"\u003eNR Hard Capsules\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003ePatented NR-Cl + B-vitamin cofactors\u003c\/td\u003e\n\u003ctd\u003eCardiovascular focus, brain\/PD context, elderly cohort.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003ca href=\"\/he\/products\/nad-daily-boost\"\u003eNAD+ Daily Boost\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eNAD+ + supportive cofactors\u003c\/td\u003e\n\u003ctd\u003eDirect NAD+ supplementation alongside precursor.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003ca href=\"\/he\/products\/zoone-nad-drink-mix\"\u003eZOONE NAD+ Drink Mix\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eNMN drink mix\u003c\/td\u003e\n\u003ctd\u003ePeople who don't tolerate capsules; flavored format.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003ca href=\"\/he\/products\/liquid-nad-anti-aging-drink-advanced-cellular-rejuvenation\"\u003eLiquid NAD+ Sachets\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eNR liquid sachet, berry\u003c\/td\u003e\n\u003ctd\u003eOn-the-go format for travel or work.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003ca href=\"\/he\/products\/liposomal-nad-ultimate-1000mg\"\u003eLiposomal NAD+ 1000 mg\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eDirect NAD+, liposomal\u003c\/td\u003e\n\u003ctd\u003eMaximum delivery form — for cost-insensitive optimization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003ca href=\"\/he\/products\/selerb-nad-5-in-1-complete-mitochondrial-formula\"\u003eNAD+ 5-in-1\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eNMN + CoQ10 + B-complex + antioxidants\u003c\/td\u003e\n\u003ctd\u003eOne-bottle complete mitochondrial formula.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eIf you're new to NAD+ supplementation: this product. If you've used 500 mg for 8+ weeks and want more: NMN 1000 mg or add NR to cover both transport pathways.\u003c\/p\u003e\n\n\u003ch2\u003eStacking — how NMN sits inside a complete longevity protocol\u003c\/h2\u003e\n\n\u003ch3\u003eSirtuin substrate + activator pair (the core)\u003c\/h3\u003e\n\u003cp\u003eNMN raises NAD+ (the substrate). \u003ca href=\"\/he\/products\/resveratrol-600mg-60-capsules-30-day-supply\"\u003eResveratrol 600 mg\u003c\/a\u003e activates SIRT1 (the enzyme that uses it). Without both halves, you're either supplying fuel for an enzyme that isn't running, or running an enzyme that's substrate-starved. \u003cstrong\u003ePacholec 2010\u003c\/strong\u003e (\u003cem\u003eJBC\u003c\/em\u003e) confirmed Resveratrol's SIRT1 effect is substrate-mediated. The two-bottle \u003ca href=\"\/he\/products\/longevity-stack-bundle-nmn-500mg-resveratrol-600mg\"\u003eLongevity Stack Bundle\u003c\/a\u003e packages this at -10%.\u003c\/p\u003e\n\n\u003ch3\u003eBoth NAD+ precursor pathways covered\u003c\/h3\u003e\n\u003cp\u003ePair NMN with \u003ca href=\"\/he\/products\/rb-nicotinamide-nucleotide-nad-hard-capsules-cellular-energy-anti-aging\"\u003eNR Hard Caps\u003c\/a\u003e. NMN enters via Slc12a8 + via CD73→NR; NR enters via ENT1\/ENT2. Different transporter saturation, different tissue distribution. Two precursors covers redundancy without doubling methylation load (you're still ending at one NAM pool).\u003c\/p\u003e\n\n\u003ch3\u003eMethylation support — for long-term high-dose use\u003c\/h3\u003e\n\u003cp\u003eAt 500 mg you don't need it. At 1000 mg or NMN+NR combined, add \u003ca href=\"\/he\/products\/tmg-1000mg-trimethylglycine-methyl-donor-for-nmn-nad-stacks\"\u003eTMG 1000 mg\u003c\/a\u003e. NNMT methylates NAM to 1MNA using SAM as the methyl donor; TMG (betaine) refills SAM via the BHMT pathway. \u003cstrong\u003eOlthof 2003\u003c\/strong\u003e documents the SAM-replenishment effect on homocysteine.\u003c\/p\u003e\n\n\u003ch3\u003eCD38 reduction — preserve the NAD+ you make\u003c\/h3\u003e\n\u003cp\u003eNAD+ is being consumed at the same time it's being raised. \u003ca href=\"\/he\/products\/apigenin-50mg-cd38-inhibitor-nad-preservation\"\u003eApigenin 50 mg\u003c\/a\u003e inhibits CD38 (Escande 2013). \u003ca href=\"\/he\/products\/quercetin-500mg-senolytic-flavonoid-natural-antihistamine\"\u003eQuercetin 500 mg\u003c\/a\u003e and \u003ca href=\"\/he\/products\/fisetin-500mg-senolytic-flavonoid-cellular-rejuvenation\"\u003eFisetin 500 mg\u003c\/a\u003e reduce senescent-cell burden, which lowers SASP-driven CD38 expression in surrounding tissue.\u003c\/p\u003e\n\n\u003ch3\u003eMitochondrial layer — what the NAD+ feeds into\u003c\/h3\u003e\n\u003cp\u003eNAD+ is a coenzyme; it has to be paired with the rest of the mitochondrial machinery. \u003ca href=\"\/he\/products\/coq10-400mg-maximum-strength\"\u003eCoQ10 400 mg\u003c\/a\u003e shuttles electrons in Complex I\/II\/III. \u003ca href=\"\/he\/products\/pqq-20mg-mitochondrial-biogenesis\"\u003ePQQ 20 mg\u003c\/a\u003e drives mitochondrial biogenesis. \u003ca href=\"\/he\/products\/alpha-lipoic-acid-600mg-universal-antioxidant\"\u003eALA 600 mg\u003c\/a\u003e recycles other antioxidants. \u003ca href=\"\/he\/products\/urolithin-a-500mg-mitophagy-activator\"\u003eUrolithin A 500 mg\u003c\/a\u003e clears damaged mitochondria via mitophagy. NMN supplies the coenzyme; these supply structure and quality control.\u003c\/p\u003e\n\n\u003ch3\u003eAutophagy and proteostasis\u003c\/h3\u003e\n\u003cp\u003e\u003ca href=\"\/he\/products\/spermidine-10mg-autophagy-activator\"\u003eSpermidine 10 mg\u003c\/a\u003e activates autophagy of misfolded proteins. \u003ca href=\"\/he\/products\/fisetin-500mg-senolytic-flavonoid-cellular-rejuvenation\"\u003eFisetin\u003c\/a\u003e clears senescent cells. NMN handles fuel; autophagy handles cleanup. Different hallmarks, different mechanisms — both needed.\u003c\/p\u003e\n\n\u003ch3\u003eAMPK pathway\u003c\/h3\u003e\n\u003cp\u003e\u003ca href=\"\/he\/products\/berberine-1000mg-glucose-metabolism\"\u003eBerberine 1000 mg\u003c\/a\u003e and \u003ca href=\"\/he\/products\/calcium-alpha-ketoglutarate-1000mg-caakg-epigenetic-longevity\"\u003eCa-AKG 1000 mg\u003c\/a\u003e activate AMPK — the metabolic stress sensor that runs in parallel with sirtuins. NAD+\/sirtuins respond to fasting\/low-energy signals; AMPK responds to AMP:ATP ratio. Hitting both is closer to the effect of caloric restriction than either alone.\u003c\/p\u003e\n\n\u003ch3\u003eAntioxidant \/ glutathione layer\u003c\/h3\u003e\n\u003cp\u003e\u003ca href=\"\/he\/products\/liposomal-vitamin-c-1000mg-maximum-absorption-antioxidant-formula\"\u003eLiposomal Vitamin C 1000 mg\u003c\/a\u003e, \u003ca href=\"\/he\/products\/astaxanthin-12mg-keto-carotenoid-mitochondrial-antioxidant\"\u003eAstaxanthin 12 mg\u003c\/a\u003e, and N-acetylcysteine support glutathione recycling. SIRT3 is the mitochondrial antioxidant master switch (deacetylates SOD2). NAD+ + SIRT3 + adequate glutathione precursors is the complete mitochondrial antioxidant package.\u003c\/p\u003e\n\n\u003ch3\u003eFoundational layer — sleep, minerals, fats\u003c\/h3\u003e\n\u003cp\u003eNAD+ supplementation without sleep is a leaky bucket. Magnesium glycinate, omega-3 (\u003ca href=\"\/he\/products\/omega-3-2000mg-triglyceride-form-cardiovascular-cognitive\"\u003eOmega-3 2000 mg triglyceride form\u003c\/a\u003e), Vitamin D3+K2, and a clean diet are the foundation everything else sits on. NMN is an upgrade to a healthy baseline, not a replacement for one.\u003c\/p\u003e\n\n\u003ch2\u003eWhat to expect — week by week\u003c\/h2\u003e\n\u003cp\u003eThe honest timeline, based on the published trials and consistent customer reports:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeek 1–2:\u003c\/strong\u003e Plasma NAD+ rises within hours of the first dose and reaches a higher steady state across the first two weeks. Subjectively, most people notice nothing or a mild energy lift on day 1–3 — sometimes placebo, sometimes not.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeek 2–4:\u003c\/strong\u003e Whole-blood NAD+ approaches plateau. Subjective effects (energy, training recovery, sleep quality, mental clarity) become more consistent if they're going to. About 40–50% of users report a noticeable shift by week 4.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeek 4–8:\u003c\/strong\u003e The clinical endpoints from the trials — endurance, gait speed, insulin sensitivity — start to register if they're going to register. Expect modest, not dramatic, improvements.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeek 8–16:\u003c\/strong\u003e Plateau. NAD+ stays elevated as long as you keep dosing. Effects are downstream consequences of consistently elevated NAD+ and sirtuin output over time.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStop dosing:\u003c\/strong\u003e Cellular gains reverse roughly 50% within 30 days of stopping (Liao 2021 follow-up data). NMN is a supplement, not a permanent intervention — the biology requires daily fuel.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWhy 500 mg specifically — the dose-response argument\u003c\/h2\u003e\n\u003cp\u003eWhy not 250? Why not 1000? Why not 2000?\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e250 mg works in trial-grade populations.\u003c\/strong\u003e Yoshino 2021 (postmenopausal prediabetic, insulin sensitivity) and Igarashi 2022 (65+ men, gait + grip) used 250 mg with positive results. For lean, healthy users in their 30s or 40s, 250 mg is at the lower end — it raises NAD+ but the functional readouts are softer.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e500 mg matches the meat of the evidence base.\u003c\/strong\u003e Yi 2022's 600 mg arm is the closest-published reference for this dose; effects on 6MWD and whole-blood NAD+ were dose-linear, with the 600 mg arm clearly outperforming 300 mg.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e1000 mg is the next plateau.\u003c\/strong\u003e Pencina 2023 (1000\/2000 mg, healthy 55–80yo) showed continued NAD+ rise with no AEs, but the marginal benefit per dose increment is smaller — and the methylation load case starts to apply.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2000 mg is the upper tested dose.\u003c\/strong\u003e Pencina 2023 confirmed safety; clinical-endpoint benefit beyond 1000 mg is not yet well-resolved. Most users don't need this.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe honest summary: 500 mg is the dose that gives you the strongest match between what was tested and what you're taking, at a price most people can sustain daily. If you're 50+, training hard, or 8 weeks in without subjective effect, step up to \u003ca href=\"\/he\/products\/nmn-1000mg-pure-focus-formula-cellular-rejuvenation\"\u003e1000 mg\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eWhat this product is — and is NOT\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eWhat it is:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e500 mg of ≥99% HPLC-verified pure β-NMN per capsule.\u003c\/li\u003e\n  \u003cli\u003eVegan HPMC capsule. No magnesium stearate. No titanium dioxide. No artificial colors.\u003c\/li\u003e\n  \u003cli\u003ePer-batch third-party COA covering identity (HPLC), heavy metals, microbials, residual solvents.\u003c\/li\u003e\n  \u003cli\u003eThe trial-grade form at the trial-grade dose.\u003c\/li\u003e\n  \u003cli\u003eThe most-studied entry into NAD+ supplementation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eWhat it is NOT:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eA replacement for sleep, exercise, or a diet that supports basic metabolic health.\u003c\/li\u003e\n  \u003cli\u003eA weight-loss or stimulant product. NMN doesn't cause acute energy spikes the way caffeine does.\u003c\/li\u003e\n  \u003cli\u003eSufficient on its own for the full longevity stack — sirtuin activator (Resveratrol), CD38 inhibitor (Apigenin), and methylation support (TMG, at higher doses) all add measurable value.\u003c\/li\u003e\n  \u003cli\u003eApproved by the FDA to treat or prevent any disease. NMN is sold as a dietary supplement.\u003c\/li\u003e\n  \u003cli\u003eA \"feel-it-day-1\" product. The mechanism is upstream — biology takes weeks to catch up.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon mistakes to avoid\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSkipping days.\u003c\/strong\u003e Cellular NAD+ pools deplete fast — daily consistency is more important than dose magnitude.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEvening dosing.\u003c\/strong\u003e Igarashi 2022 showed AM \u0026gt; PM on functional outcomes. NAD+ is a wake signal; evening dosing can disrupt sleep.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBuying mixed-anomer NMN.\u003c\/strong\u003e 75% β-purity at 500 mg label = 375 mg active — under the trial dose.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStacking precursor without an activator.\u003c\/strong\u003e NMN without Resveratrol is fuel without an engine running. Pair them.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStopping at week 2 because nothing happened.\u003c\/strong\u003e Expect 4–8 weeks for steady-state effects.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGoing to 2000 mg without TMG.\u003c\/strong\u003e Methylation load matters at very high doses; cover the SAM pool with TMG or pull back.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStoring the bottle in a humid bathroom.\u003c\/strong\u003e NMN is moisture-sensitive. Cool, dry, dark.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eDaily protocol\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWhen:\u003c\/strong\u003e First thing in the morning, with breakfast. Igarashi 2022 supports AM \u0026gt; PM dosing.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDose:\u003c\/strong\u003e 1 capsule (500 mg).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWith food:\u003c\/strong\u003e Yes — sirtuin pathway pairs better with adequate fat in the meal (eggs, avocado, butter, nuts).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDuration:\u003c\/strong\u003e Continuous. NMN is a daily-fuel supplement, not a cycled stimulant.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePair with:\u003c\/strong\u003e \u003ca href=\"\/he\/products\/resveratrol-600mg-60-capsules-30-day-supply\"\u003eResveratrol 600 mg\u003c\/a\u003e — same morning meal. The classic stack.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e30 days = 1 bottle.\u003c\/strong\u003e Reorder before the bottle ends — gaps break steady state.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e→ \u003ca href=\"\/he\/protocols\/how-to-take-it\"\u003eFull protocol guide for the entire longevity stack\u003c\/a\u003e\u003c\/p\u003e\n\n\u003ch2\u003eWho this is for\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAnyone 30+ starting their first NAD+ supplement.\u003c\/li\u003e\n  \u003cli\u003eAdults experiencing the early signs of NAD+ decline — slower recovery from training, slightly lower energy, longer to bounce back from late nights.\u003c\/li\u003e\n  \u003cli\u003ePeople who tried higher-dose NMN elsewhere without seeing a clear effect and want to confirm the active form before scaling up.\u003c\/li\u003e\n  \u003cli\u003eAnyone who wants the dose used in most published trials, not a marketing dose.\u003c\/li\u003e\n  \u003cli\u003ePeople building a longevity stack and wanting the entry-tier sirtuin substrate.\u003c\/li\u003e\n  \u003cli\u003eThose new to longevity supplementation looking for the cleanest, simplest, best-evidenced starting point.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWho this is NOT for\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePregnant or nursing women.\u003c\/strong\u003e NMN safety in pregnancy\/lactation is not established.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eActive cancer patients.\u003c\/strong\u003e NAD+ has complex effects on tumor biology — some pro-survival pathways. Discuss with oncology before starting.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChildren under 18.\u003c\/strong\u003e No pediatric safety data.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePeople who want a stimulant.\u003c\/strong\u003e NMN does not feel like caffeine. If you want acute energy, this is the wrong category.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePeople who can't sustain daily dosing.\u003c\/strong\u003e Intermittent NMN is below threshold for the trial-replicated effects.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePeople with severe MTHFR variants going straight to high doses.\u003c\/strong\u003e Add TMG, or stay at 500 mg.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eSafety, interactions, and contraindications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAnticoagulants (warfarin, DOACs).\u003c\/strong\u003e NMN itself has no documented anticoagulant effect, but Resveratrol (the typical stack pair) does have mild antiplatelet activity. Discuss the stack with your prescriber.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiabetes medications.\u003c\/strong\u003e NMN has shown insulin-sensitizing effects (Yoshino 2021). If you're on metformin, sulfonylureas, or insulin, monitor blood sugar — dose adjustment may be needed.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePre-surgery.\u003c\/strong\u003e Stop 7–14 days before any planned surgery (consistent with Resveratrol\/general supplement-cessation guidance).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCancer therapy.\u003c\/strong\u003e NAD+ supplementation in active cancer treatment is not recommended without oncology input.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMTHFR variants.\u003c\/strong\u003e Methylation considerations apply most at 1000 mg+. At 500 mg the load is small. If you have a known C677T or A1298C variant and want to be conservative, add TMG.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLong-term use.\u003c\/strong\u003e Trial data is at most 12–24 months. Multi-year safety is undocumented but mechanistically clean — NMN converts to endogenous NAD+, which the body uses constantly anyway.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSide effects.\u003c\/strong\u003e Mild GI discomfort or headache in \u0026lt;5% of users, typically resolves within 1–2 weeks. Discontinue if symptoms persist.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWhat's in it\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003ePer capsule:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e500 mg β-Nicotinamide Mononucleotide (≥99% HPLC purity).\u003c\/li\u003e\n  \u003cli\u003eHPMC (vegetable cellulose) capsule shell.\u003c\/li\u003e\n  \u003cli\u003eRice flour as a flow agent (no magnesium stearate).\u003c\/li\u003e\n  \u003cli\u003eNo titanium dioxide. No artificial colors. No preservatives. No common allergens (gluten, soy, dairy, nuts, eggs, fish, shellfish).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eBottle:\u003c\/strong\u003e 60 capsules, UV-protective HDPE, oxygen barrier seal. Cool, dry, dark storage extends shelf life.\u003c\/p\u003e\n\n\u003ch2\u003eSourcing, manufacturing, and quality control\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ecGMP-certified manufacturing facility.\u003c\/strong\u003e ISO 9001 quality system.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC identity + purity per batch.\u003c\/strong\u003e ≥99% β-NMN. Certificate of analysis available for every lot.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHeavy metals panel:\u003c\/strong\u003e lead, arsenic, cadmium, mercury — within USP-acceptable limits per batch.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMicrobial panel:\u003c\/strong\u003e total aerobic count, yeast\/mold, E. coli, Salmonella — all within food-grade thresholds.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eResidual solvents:\u003c\/strong\u003e tested per USP \u0026lt;467\u0026gt;.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStability testing:\u003c\/strong\u003e β-purity verified at end of stated shelf life.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eLab reports are posted to \u003ca href=\"\/he\/pages\/coa\"\u003eour COA page\u003c\/a\u003e. If you don't see your lot, email and we'll send the COA directly.\u003c\/p\u003e\n\n\u003ch2\u003eFrequently asked questions\u003c\/h2\u003e\n\n\u003ch3\u003eIs NMN better than NR?\u003c\/h3\u003e\n\u003cp\u003eDifferent, not better. NMN has stronger evidence for metabolic and exercise-capacity endpoints (Yoshino 2021, Liao 2021, Yi 2022, Igarashi 2022). NR has stronger evidence for cardiovascular (Martens 2018) and brain (Brakedal 2022 NADPARK) endpoints. For a general user wanting an NAD+ precursor, NMN at 500 mg is the right starting point on cost, evidence base, and mechanism.\u003c\/p\u003e\n\n\u003ch3\u003eCan I take NMN with NR?\u003c\/h3\u003e\n\u003cp\u003eYes. Different transporters (Slc12a8 for NMN, ENT1\/2 for NR) — covering both gives broader tissue coverage. The methylation load is unchanged from either alone (both end as nicotinamide). At combined doses ≥1000 mg\/day, add \u003ca href=\"\/he\/products\/tmg-1000mg-trimethylglycine-methyl-donor-for-nmn-nad-stacks\"\u003eTMG\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eHow long until I notice anything?\u003c\/h3\u003e\n\u003cp\u003ePlasma NAD+ rises within hours. Subjective shifts in energy, training recovery, or sleep, if they're going to register, usually surface in week 2–4. Functional endpoints (endurance, gait speed) replicated in trials show by week 8–12. If 12 weeks of daily 500 mg gives you nothing subjective, step up to 1000 mg before concluding NMN doesn't work for you.\u003c\/p\u003e\n\n\u003ch3\u003eCan I take NMN at night?\u003c\/h3\u003e\n\u003cp\u003eNot recommended. NAD+ is a circadian wake signal — NMN raises NAD+ — evening dosing can disrupt sleep onset for sensitive users. Igarashi 2022 directly compared morning vs evening dosing in 65+ men and morning won on functional endpoints.\u003c\/p\u003e\n\n\u003ch3\u003eDo I need to cycle NMN?\u003c\/h3\u003e\n\u003cp\u003eNo. NMN converts to endogenous NAD+ that the body already uses constantly. There's no receptor downregulation to worry about. Continuous dosing is the protocol used in every published positive trial.\u003c\/p\u003e\n\n\u003ch3\u003eShould I take it with food?\u003c\/h3\u003e\n\u003cp\u003eYes. NMN absorption isn't food-dependent, but the sirtuin pathway pairs better with adequate dietary fat. Eggs, avocado, butter, nuts are good morning pairings.\u003c\/p\u003e\n\n\u003ch3\u003eWhat if I'm 30 — is NMN still useful?\u003c\/h3\u003e\n\u003cp\u003eNAD+ decline starts well before 30 — Massudi 2012 measured ~50% drop between 30 and 70, and most of that drop is in the second half of the curve, but it's already underway in your 30s. If you're a healthy 30yo with no metabolic issues, the case for NMN is more about preventive baseline maintenance than corrective; the upside per dollar is smaller than it is at 50. Decide based on price tolerance and whether you're optimizing for healthspan a long way out.\u003c\/p\u003e\n\n\u003ch3\u003eWhy is NMN cheaper than NR?\u003c\/h3\u003e\n\u003cp\u003eNR-Cl is patented (the chloride salt form used in trials carries license cost). β-NMN supply has expanded faster, with multiple Asian manufacturers producing pharmaceutical-grade material. The result: NMN is typically 30–50% cheaper per gram of NAD+ precursor than NR. The trial-grade form is what matters; NMN at 500 mg gets you trial-replication at lower cost.\u003c\/p\u003e\n\n\u003ch3\u003eCan NMN replace coffee?\u003c\/h3\u003e\n\u003cp\u003eNo. NMN raises NAD+ — the coenzyme for energy production — but it doesn't block adenosine receptors or cause acute alertness. Caffeine is a stimulant. NMN is upstream metabolic support. They do different things and most users keep both.\u003c\/p\u003e\n\n\u003ch3\u003eWill NMN show up on a drug test?\u003c\/h3\u003e\n\u003cp\u003eNo. NMN is endogenous to mammalian metabolism — it's a normal cellular metabolite, not a foreign compound. Standard drug panels do not test for it, and athletic anti-doping (WADA) does not list it.\u003c\/p\u003e\n\n\u003ch3\u003eCan I take NMN while fasting?\u003c\/h3\u003e\n\u003cp\u003eYes. NMN absorption isn't dependent on a meal. The sirtuin pathway actually upregulates during fasting, so NMN + fasting is mechanistically synergistic. Some users prefer fasted morning dosing; others find it sits better with food. Both are fine.\u003c\/p\u003e\n\n\u003ch3\u003eDoes NMN raise blood pressure?\u003c\/h3\u003e\n\u003cp\u003eNo. The NR cardiovascular trial (Martens 2018) actually showed a modest BP reduction in the elevated-BP subgroup. NMN's CV trial data is thinner but mechanistically similar — sirtuin activation favors vascular relaxation. No published NMN trial has reported BP increase as a side effect.\u003c\/p\u003e\n\n\u003ch3\u003eWhat's the maximum safe daily dose?\u003c\/h3\u003e\n\u003cp\u003eThe highest tested dose in published human trials is 2000 mg\/day (Pencina 2023, 14 days, healthy 55–80yo, no AEs). Most users will not need to exceed 1000 mg\/day. There's no defined upper limit beyond what's been tested.\u003c\/p\u003e\n\n\u003ch3\u003eDoes NMN interact with statins or blood-pressure medications?\u003c\/h3\u003e\n\u003cp\u003eNo documented direct interactions at typical NMN doses. Sirtuin activation can modulate lipid metabolism (SIRT1 effects on cholesterol synthesis) but the magnitude is small relative to a statin. Coordinate with your prescriber if you're on cardiovascular medication.\u003c\/p\u003e\n\n\u003ch3\u003eHow does NMN compare to NAD+ IV therapy?\u003c\/h3\u003e\n\u003cp\u003eIV NAD+ delivers a large bolus directly to plasma — onset is fast but pharmacokinetics are very different from oral precursor steady-state. The cost is also 10–50× higher per unit NAD+ delivered. For chronic, daily NAD+ support, oral NMN is the dominant mechanism on cost and convenience. IV has a niche for specific clinical contexts (addiction recovery protocols, acute neurological recovery) but is not a daily-protocol substitute for oral NMN.\u003c\/p\u003e\n\n\u003ch3\u003eCan I open the capsule?\u003c\/h3\u003e\n\u003cp\u003eYes — NMN is bitter-tasting but not unpleasant. Pour the contents into water, smoothie, or yogurt. Some users prefer this for sublingual absorption (hold under the tongue 60–90s before swallowing). PK studies haven't shown a meaningful difference between sublingual and oral capsule absorption, but the option is there.\u003c\/p\u003e\n\n\u003ch3\u003eIs NMN vegan?\u003c\/h3\u003e\n\u003cp\u003eYes. The β-NMN itself is synthesized; the capsule is HPMC (vegetable cellulose). No animal-derived ingredients in the product or the manufacturing process.\u003c\/p\u003e\n\n\u003ch3\u003eWill NMN help me sleep?\u003c\/h3\u003e\n\u003cp\u003eIndirectly. NMN doesn't sedate. But chronic NAD+ depletion correlates with sleep architecture disruption, and Kim 2022 reported sleep-quality improvement on 250 mg\/day. Most users notice a subtle improvement in sleep depth over weeks 4–8 if they're going to notice anything.\u003c\/p\u003e\n\n\u003ch3\u003eDoes NMN improve hair?\u003c\/h3\u003e\n\u003cp\u003eNo published human trial directly tested this. Mechanistically, sirtuin activation supports hair-follicle stem-cell biology (animal data). Customer reports of better hair growth or thicker hair on long-term NMN are anecdotally common but not trial-replicated.\u003c\/p\u003e\n\n\u003ch3\u003eWhy is daily consistency more important than dose?\u003c\/h3\u003e\n\u003cp\u003eThe salvage pathway is a flow, not a tank. NAD+ pools depend on a constant supply rate — not on a periodic large bolus. Daily 500 mg vastly outperforms 3500 mg once a week, even though the totals match, because the cellular machinery responds to sustained substrate availability. One missed dose is fine. A week of skipped doses sets steady-state back.\u003c\/p\u003e\n\n\u003ch2\u003eWhere this sits in the catalog architecture\u003c\/h2\u003e\n\u003cp\u003ePure NMN 500 mg is the entry tier of the Foundational Health collection — the daily-baseline supplements that anchor everything else. The next tiers up are: NMN 1000 mg (higher dose, same molecule), NAD+ 5-in-1 (NMN + cofactors in one bottle), Liposomal NAD+ (direct NAD+ for maximum delivery), and the full Mitochondrial Renewal collection (CoQ10, PQQ, ALA, Urolithin A) for the structural-quality-control side of the same biology.\u003c\/p\u003e\n\n\u003cp\u003eThis product replaces nothing in the catalog; it slots underneath it. If you're new to the protocol, this is the first bottle.\u003c\/p\u003e\n\n\u003ch2\u003eRelated collections\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/collections\/longevity-essentials\"\u003eLongevity Essentials\u003c\/a\u003e — the 8 supplements that anchor the daily protocol.\u003c\/li\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/collections\/foundational-health\"\u003eFoundational Health\u003c\/a\u003e — daily-baseline products, including this one.\u003c\/li\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/collections\/mitochondrial-renewal\"\u003eMitochondrial Renewal\u003c\/a\u003e — energy + quality control.\u003c\/li\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/collections\/sirtuin-activators\"\u003eSirtuin Activators\u003c\/a\u003e — Resveratrol, Pterostilbene, the SIRT1 pair.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eRead more on this topic\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003ca href=\"\/he\/blogs\/news\/nmn-vs-nad-which-should-you-take-in-2026\"\u003eNMN vs NAD+ — which should you take in 2026?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"\/he\/blogs\/news\/nad-decline-with-age-the-evidence\"\u003eNAD+ decline with age — what the evidence actually shows\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"\/he\/blogs\/news\/the-classic-longevity-stack\"\u003eThe classic longevity stack — NMN + Resveratrol + TMG\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"\/he\/blogs\/news\/sirtuins-explained\"\u003eSirtuins explained — what SIRT1 and SIRT3 actually do\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"\/he\/pages\/protocols\"\u003eDaily protocols by goal\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eSelected references\u003c\/h2\u003e\n\u003cul style=\"font-size:13px;line-height:1.6;\"\u003e\n  \u003cli\u003eYoshino M et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. \u003cem\u003eScience\u003c\/em\u003e 372:1224.\u003c\/li\u003e\n  \u003cli\u003eYi L et al. (2022). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. \u003cem\u003eGeroScience\u003c\/em\u003e 45:29.\u003c\/li\u003e\n  \u003cli\u003eIgarashi M et al. (2022). Chronic nicotinamide mononucleotide supplementation elevates blood NAD+ levels and alters muscle function in healthy older men. \u003cem\u003enpj Aging\u003c\/em\u003e 8:5.\u003c\/li\u003e\n  \u003cli\u003eLiao B et al. (2021). Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners. \u003cem\u003eJ Int Soc Sports Nutr\u003c\/em\u003e 18:54.\u003c\/li\u003e\n  \u003cli\u003eIrie J et al. (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. \u003cem\u003eEndocrine Journal\u003c\/em\u003e 67:153.\u003c\/li\u003e\n  \u003cli\u003ePencina KM et al. (2023). MIB-626, a microcrystalline unique polymorph of beta-nicotinamide mononucleotide, in adults with overweight or obesity. \u003cem\u003eJCEM\u003c\/em\u003e 108:1968.\u003c\/li\u003e\n  \u003cli\u003eFukamizu Y et al. (2022). Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women. \u003cem\u003eSci Rep\u003c\/em\u003e 12:14442.\u003c\/li\u003e\n  \u003cli\u003eKim M et al. (2022). Effect of 12-week intake of nicotinamide mononucleotide on sleep quality, fatigue, and physical performance in older Japanese adults. \u003cem\u003eNutrients\u003c\/em\u003e 14:755.\u003c\/li\u003e\n  \u003cli\u003eGrozio A et al. (2019). Slc12a8 is a nicotinamide mononucleotide transporter. \u003cem\u003eNature Metabolism\u003c\/em\u003e 1:47.\u003c\/li\u003e\n  \u003cli\u003eLuongo TS et al. (2020). SLC25A51 is a mammalian mitochondrial NAD+ transporter. \u003cem\u003eNature\u003c\/em\u003e 588:174.\u003c\/li\u003e\n  \u003cli\u003eMassudi H et al. (2012). Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. \u003cem\u003ePLOS ONE\u003c\/em\u003e 7:e42357.\u003c\/li\u003e\n  \u003cli\u003eCamacho-Pereira J et al. (2016). CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. \u003cem\u003eCell Metabolism\u003c\/em\u003e 23:1127.\u003c\/li\u003e\n  \u003cli\u003eYoshino J et al. (2011). Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. \u003cem\u003eCell Metabolism\u003c\/em\u003e 14:528.\u003c\/li\u003e\n  \u003cli\u003eMills KF et al. (2016). Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. \u003cem\u003eCell Metabolism\u003c\/em\u003e 24:795.\u003c\/li\u003e\n  \u003cli\u003eImai S, Guarente L. (2014). NAD+ and sirtuins in aging and disease. \u003cem\u003eTrends in Cell Biology\u003c\/em\u003e 24:464.\u003c\/li\u003e\n  \u003cli\u003eBai P et al. (2011). PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. \u003cem\u003eCell Metabolism\u003c\/em\u003e 13:461.\u003c\/li\u003e\n  \u003cli\u003eEscande C et al. (2013). Flavonoid apigenin is an inhibitor of the NAD+ ase CD38. \u003cem\u003eDiabetes\u003c\/em\u003e 62:1084.\u003c\/li\u003e\n  \u003cli\u003eLópez-Otín C et al. (2013\/2023). The hallmarks of aging. \u003cem\u003eCell\u003c\/em\u003e 153:1194 \/ 186:243.\u003c\/li\u003e\n  \u003cli\u003ePacholec M et al. (2010). SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. \u003cem\u003eJBC\u003c\/em\u003e 285:8340.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp style=\"font-size:12px;color:#666;font-style:italic;margin-top:32px;\"\u003eReferences listed for context, not endorsement. The studies cited do not constitute a claim that this product treats, prevents, or cures any condition. Statements in this listing have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement, especially if pregnant, nursing, on medication, or under treatment for a medical condition.\u003c\/p\u003e\n\n\u003cdiv class=\"th-why-not-amazon\" style=\"margin:32px 0;padding:20px;border:1px solid #e0d5c8;border-radius:8px;background:#faf6f1;\"\u003e\n  \u003ch3 style=\"margin-top:0;\"\u003eWhy we don't sell this on Amazon\u003c\/h3\u003e\n  \u003cp\u003eAmazon's NMN listings are a coin flip on β-purity. Mixed α\/β NMN, lot drift, marketplace counterfeits, and missing COAs are the rule, not the exception. We sell direct because we control the chain of custody — same lot, same COA, same molecule that was in the published trials. Per milligram of active β-NMN, we're typically cheaper too. The math + the data: \u003ca href=\"\/he\/pages\/why-not-amazon\" style=\"color:#9a5b3e;font-weight:600;\"\u003eread the full breakdown →\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv class=\"th-how-to\" style=\"margin:32px 0;padding:20px;border:1px solid #e0d5c8;border-radius:8px;\"\u003e\n  \u003ch3 style=\"margin-top:0;\"\u003eHow to take Pure NMN 500mg\u003c\/h3\u003e\n  \u003cul style=\"line-height:1.7;\"\u003e\n    \u003cli\u003e\n\u003cstrong\u003eWhen:\u003c\/strong\u003e First thing in the morning, with breakfast (eggs, avocado, butter — needs fat for sirtuin pathway pairing).\u003c\/li\u003e\n    \u003cli\u003e\n\u003cstrong\u003eDose:\u003c\/strong\u003e 1 capsule daily.\u003c\/li\u003e\n    \u003cli\u003e\n\u003cstrong\u003eAvoid evening dosing\u003c\/strong\u003e — NMN raises NAD+ which is your body's \"wake up\" signal; evening dosing can disrupt sleep.\u003c\/li\u003e\n    \u003cli\u003e\n\u003cstrong\u003eBest paired with\u003c\/strong\u003e: \u003ca href=\"\/he\/products\/resveratrol-600mg-60-capsules-30-day-supply\" style=\"color:#9a5b3e;\"\u003eResveratrol 600mg\u003c\/a\u003e (or get both at -10% as the \u003ca href=\"\/he\/products\/longevity-stack-bundle-nmn-500mg-resveratrol-600mg\" style=\"color:#9a5b3e;\"\u003eLongevity Stack Bundle\u003c\/a\u003e).\u003c\/li\u003e\n    \u003cli\u003e\n\u003cstrong\u003eBottle = 30 days\u003c\/strong\u003e at 1 capsule daily. Continuity matters — cellular gains reverse ~50% within 30 days of stopping.\u003c\/li\u003e\n  \u003c\/ul\u003e\n  \u003cp style=\"margin-bottom:0;\"\u003e→ \u003ca href=\"\/he\/protocols\/how-to-take-it\" style=\"color:#9a5b3e;font-weight:600;\"\u003eFull protocol guide for the entire stack\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv class=\"th-footer-links\" style=\"margin-top:48px;padding-top:24px;border-top:1px solid #e0d5c8;\"\u003e\n  \u003ch3 style=\"margin-bottom:12px;\"\u003eHave a specific question?\u003c\/h3\u003e\n  \u003cp style=\"margin:0 0 16px;\"\u003e→ \u003ca href=\"\/he\/pages\/faq\" style=\"color:#9a5b3e;\"\u003eFAQ — 20 most common questions\u003c\/a\u003e covers shipping, kashrut, drug interactions, refunds, dosing.\u003c\/p\u003e\n  \u003cp style=\"margin:0 0 16px;\"\u003e→ \u003ca href=\"\/he\/pages\/coa\" style=\"color:#9a5b3e;\"\u003eLab reports for every batch\u003c\/a\u003e — verifiable third-party COAs.\u003c\/p\u003e\n  \u003cp style=\"margin:0;\"\u003e→ Or just \u003ca href=\"mailto:kat@truehealthprotocol.health\" style=\"color:#9a5b3e;\"\u003eemail me directly\u003c\/a\u003e. I respond within 24 hours.\u003c\/p\u003e\n\u003c\/div\u003e\n","brand":"True Health Protocol","offers":[{"title":"Default Title","offer_id":47696174383322,"sku":"THP-NMN-500-60","price":29.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0814\/5158\/1658\/files\/nmn_500mg_03.jpg?v=1774728960"},{"product_id":"resveratrol-600mg-60-capsules-30-day-supply","title":"Resveratrol Complex Capsules","description":"\u003cp\u003e\u003cstrong\u003e600 mg of trans-resveratrol per capsule\u003c\/strong\u003e — the SIRT1-activating polyphenol that anchors the canonical NMN + resveratrol longevity stack. ≥98% HPLC-verified trans-anomer from \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e root extract, vegan capsule, no fillers, no proprietary blends. Stack-grade dose, not a label-claim dose.\u003c\/p\u003e\n\n\u003ch2\u003eThe 30-second answer\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe polyphenol that put sirtuins on the longevity map.\u003c\/strong\u003e Howitz 2003 \u003cem\u003eNature\u003c\/em\u003e identified resveratrol as the most potent natural sirtuin-activating compound (STAC) ever screened; Baur 2006 \u003cem\u003eNature\u003c\/em\u003e showed it extended lifespan in calorically-stressed mice; Hubbard 2013 \u003cem\u003eScience\u003c\/em\u003e solved the SIRT1 allosteric crystal structure. Two decades and 13,000+ PubMed hits in, trans-resveratrol remains the canonical SIRT1 activator.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOne capsule, daily, with the largest fat-containing meal.\u003c\/strong\u003e Resveratrol is fat-soluble — fasted dosing throws away most of the pill. Pair with breakfast (eggs, avocado, fatty fish, olive oil) or lunch.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBest paired with \u003ca href=\"\/he\/products\/pure-nmn-500mg-60-capsules-30-day-supply\"\u003eNMN 500 mg\u003c\/a\u003e or \u003ca href=\"\/he\/products\/nmn-1000mg-pure-focus-formula-cellular-rejuvenation\"\u003eNMN 1000 mg\u003c\/a\u003e.\u003c\/strong\u003e NMN raises NAD+ substrate; resveratrol activates the SIRT1\/SIRT3 enzymes that \u003cem\u003euse\u003c\/em\u003e that NAD+. Substrate + activator. Get both at -10% as the \u003ca href=\"\/he\/products\/longevity-stack-bundle-nmn-500mg-resveratrol-600mg\"\u003eLongevity Stack Bundle\u003c\/a\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e600 mg is the stack-grade dose.\u003c\/strong\u003e 100–250 mg is where the \"resveratrol doesn't work in humans\" meta-analyses concentrate; 500–1000 mg\/day is where the cardiometabolic and SIRT1 data live (Tomé-Carneiro 2012\/2013, Bhatt 2012, Movahed 2013, Pollack 2017).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e≥98% HPLC trans-resveratrol.\u003c\/strong\u003e The bioactive anomer — not the cis-isomer UV-degradation product cheap brands ship. Per-batch third-party COA, heavy-metals\/microbial\/residual-solvents panel, vegan HPMC capsule, no titanium dioxide, no magnesium stearate, no rice-flour bulker.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWhy resveratrol still anchors a serious longevity stack — even after the noise\u003c\/h2\u003e\n\u003cp\u003eIf you only read the headlines, you'd think resveratrol got debunked. It didn't. What got debunked was the \u003cem\u003e1 mg of resveratrol in a glass of red wine\u003c\/em\u003e story — Smoliga 2011 (\u003cem\u003eMol Nutr Food Res\u003c\/em\u003e) showed you'd need ~1,500 bottles a day to hit the doses tested in the original Sinclair-lab mouse work. The science on the \u003cem\u003emolecule itself\u003c\/em\u003e kept moving in the right direction.\u003c\/p\u003e\n\u003cp\u003eThe López-Otín 2013 (\u003cem\u003eCell\u003c\/em\u003e) and updated 2023 hallmarks-of-aging frameworks list \u003cstrong\u003ederegulated nutrient sensing\u003c\/strong\u003e, \u003cstrong\u003emitochondrial dysfunction\u003c\/strong\u003e, \u003cstrong\u003echronic inflammation\u003c\/strong\u003e, and \u003cstrong\u003ecellular senescence\u003c\/strong\u003e among the twelve hallmarks. Resveratrol hits all four:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSirtuin activation (SIRT1, SIRT3)\u003c\/strong\u003e — the deacetylase axis that converts NAD+ into longevity-relevant outputs (PGC-1α, FOXO3a, p53, eNOS deacetylation).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAMPK activation\u003c\/strong\u003e — the same fuel-sensor pathway hit by metformin, berberine, and exercise (Park 2012, \u003cem\u003eCell\u003c\/em\u003e).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNF-κB suppression \/ inflammaging\u003c\/strong\u003e — inhibits IKK, stabilizes IκB, dampens p65 nuclear translocation (Csiszar 2008).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEndothelial protection\u003c\/strong\u003e — upregulates eNOS expression and activity (Wallerath 2002, \u003cem\u003eCirculation\u003c\/em\u003e); Tomé-Carneiro 2013 showed 350 mg\/day for 12 months reduced oxidized LDL by 20% in CHD patients \u003cem\u003ealready on statins\u003c\/em\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eNone of this requires resveratrol to be a magic pill. It just has to be the polyphenol with the strongest, longest-validated sirtuin-and-AMPK story across the most diverse organism panel — which it is.\u003c\/p\u003e\n\n\u003ch2\u003eMechanism — what resveratrol actually does inside the cell\u003c\/h2\u003e\n\n\u003ch3\u003e1. SIRT1 allosteric activation (the NMN partner)\u003c\/h3\u003e\n\u003cp\u003eSIRT1 is the most-studied of the seven mammalian sirtuins. It's a class-III deacetylase, meaning it consumes NAD+ as a co-substrate to remove acetyl groups from longevity-relevant substrates: \u003cstrong\u003ePGC-1α\u003c\/strong\u003e (mitochondrial biogenesis), \u003cstrong\u003eFOXO3a\u003c\/strong\u003e (stress resistance, antioxidant gene expression), \u003cstrong\u003ep53\u003c\/strong\u003e (apoptosis tone), \u003cstrong\u003eeNOS\u003c\/strong\u003e (vasodilation), \u003cstrong\u003eNF-κB p65\u003c\/strong\u003e (inflammation suppression), and the \u003cstrong\u003ehistone H3K9\/H4K16\u003c\/strong\u003e marks that gate the inflammatory transcriptome.\u003c\/p\u003e\n\u003cp\u003eWithout enough NAD+, SIRT1 stalls. Without an allosteric activator, SIRT1 runs at baseline. Resveratrol covers the second half. \u003cstrong\u003eHubbard 2013\u003c\/strong\u003e (\u003cem\u003eScience\u003c\/em\u003e) crystallized the SIRT1 N-terminal allosteric domain and showed resveratrol binds at a defined activator pocket, increasing SIRT1 activity toward acetylated substrates by up to 8-fold for substrates carrying hydrophobic recognition motifs. This resolved the earlier \"is the activation real or a fluorophore artifact?\" debate cleanly in resveratrol's favor.\u003c\/p\u003e\n\u003cp\u003eThis is the mechanistic argument for stacking \u003cstrong\u003eNMN (substrate) + resveratrol (activator)\u003c\/strong\u003e. NMN raises the NAD+ floor; resveratrol pushes the SIRT1 enzyme that uses it. Either alone is meaningfully under-leveraged; together they multiply.\u003c\/p\u003e\n\n\u003ch3\u003e2. SIRT3 and the mitochondrial deacetylase axis\u003c\/h3\u003e\n\u003cp\u003eSIRT3 is the major mitochondrial sirtuin and deacetylates ~65% of all mitochondrial-matrix lysine-acetyl marks. Its substrates include \u003cstrong\u003eSOD2\u003c\/strong\u003e (the manganese superoxide dismutase that scavenges mitochondrial ROS), \u003cstrong\u003eOPA1\u003c\/strong\u003e (mitochondrial fusion), and core ETC components. Resveratrol upregulates SIRT3 transcription and protein levels via PGC-1α-driven nuclear-respiratory-factor signaling — the same loop AMPK feeds into. Functionally, this is the leg behind resveratrol's mitochondrial-biogenesis signal in muscle (Lagouge 2006, \u003cem\u003eCell\u003c\/em\u003e) and the SOD2-mediated antioxidant signal that reduces mitochondrial-derived 8-oxo-dG damage in aging tissue.\u003c\/p\u003e\n\n\u003ch3\u003e3. AMPK activation (the metabolic fuel-sensor)\u003c\/h3\u003e\n\u003cp\u003eIndependent of sirtuins, resveratrol activates AMPK by inhibiting mitochondrial F1F0-ATP synthase (Park 2012, \u003cem\u003eCell\u003c\/em\u003e). Falling cellular ATP raises the AMP:ATP ratio, which is the upstream nudge AMPK senses. Activated AMPK then:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePhosphorylates and inactivates \u003cstrong\u003eACC\u003c\/strong\u003e (acetyl-CoA carboxylase) → lipid β-oxidation up.\u003c\/li\u003e\n  \u003cli\u003ePhosphorylates and inhibits \u003cstrong\u003emTORC1\u003c\/strong\u003e via TSC2 → catabolic autophagy up, anabolic protein synthesis down.\u003c\/li\u003e\n  \u003cli\u003ePhosphorylates \u003cstrong\u003ePGC-1α\u003c\/strong\u003e at Thr177\/Ser538 → mitochondrial biogenesis up, in concert with the SIRT1-deacetylation hit at the same protein.\u003c\/li\u003e\n  \u003cli\u003eTranslocates \u003cstrong\u003eGLUT4\u003c\/strong\u003e to muscle membrane → insulin-independent glucose uptake.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis is why the cardiometabolic trial signal for resveratrol is strongest in patients with insulin resistance, established CHD, or metabolic syndrome — the AMPK leg pulls weight even when the sirtuin leg is debated. It's also why resveratrol stacks cleanly with metformin and berberine: three different upstream inputs into the same fuel-sensor.\u003c\/p\u003e\n\n\u003ch3\u003e4. NF-κB suppression (the inflammaging dampener)\u003c\/h3\u003e\n\u003cp\u003eNF-κB is the transcription-factor central node behind senescent-cell SASP secretion, chronic CRP elevation, and most age-associated inflammatory tone. The López-Otín 2023 hallmarks paper added \"chronic inflammation\" as a standalone hallmark for exactly this reason. Resveratrol inhibits NF-κB activation at multiple steps:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIKK suppression\u003c\/strong\u003e — blocks the kinase complex that phosphorylates IκB.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIκBα stabilization\u003c\/strong\u003e — keeps the inhibitor bound to NF-κB longer.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ep65 nuclear-translocation block\u003c\/strong\u003e — even if some NF-κB escapes, less of it reaches DNA.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSIRT1-mediated p65 deacetylation\u003c\/strong\u003e — Lys310 deacetylation reduces NF-κB transactivation (Yeung 2004, \u003cem\u003eEMBO J\u003c\/em\u003e).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eCsiszar 2008 (\u003cem\u003eMech Ageing Dev\u003c\/em\u003e) demonstrated this in human coronary arterial endothelial cells; the effect is reproduced across hepatocytes, macrophages, and chondrocytes. This dovetails with the senolytic + NF-κB-suppression strategy: senolytics (Quercetin, Fisetin) clear senescent cells; resveratrol dampens the inflammatory tone the surviving cells secrete.\u003c\/p\u003e\n\n\u003ch3\u003e5. Endothelial \/ eNOS upregulation\u003c\/h3\u003e\n\u003cp\u003eWallerath 2002 (\u003cem\u003eCirculation\u003c\/em\u003e) showed resveratrol upregulates endothelial nitric oxide synthase (eNOS) at both transcriptional and post-translational levels. eNOS-derived NO is the master vasodilator and a key brake on platelet aggregation and leukocyte adhesion to the endothelium. The signal is dose-dependent and clinically translates: Tomé-Carneiro's Spanish CHD-cohort series (2012\/2013) showed grape-extract resveratrol (350 mg\/day for 6–12 months) improved flow-mediated dilation, reduced oxidized LDL, and shifted multiple inflammatory apolipoproteins, in patients \u003cem\u003ealready optimized on statins\u003c\/em\u003e.\u003c\/p\u003e\n\u003cp\u003eThis is part of why resveratrol kept its seat at the table after the \"French paradox\" framing aged badly — the molecular eNOS \/ NF-κB \/ SIRT1 mechanisms hold up even when the \"red wine prevents heart disease\" narrative doesn't.\u003c\/p\u003e\n\n\u003ch3\u003e6. Autophagy and the mTOR brake\u003c\/h3\u003e\n\u003cp\u003eThrough both AMPK activation and direct ULK1 phosphorylation, resveratrol induces macroautophagy — the cellular self-clearance program that clears damaged organelles, aggregated proteins, and dysfunctional mitochondria (mitophagy via PINK1\/Parkin). Pietrocola 2017 showed resveratrol triggers an autophagic signature in skeletal muscle that is mechanistically distinct from the spermidine-driven EP300 inhibition route, meaning the two stack additively. This is the leg behind the proteostasis-restoration argument for resveratrol — stacked with \u003ca href=\"\/he\/products\/spermidine-10mg-60-capsules-30-day-supply\"\u003espermidine\u003c\/a\u003e, you cover both major upstream autophagy switches.\u003c\/p\u003e\n\n\u003ch2\u003eThe trans-anomer — what \"≥98% trans-resveratrol\" actually means\u003c\/h2\u003e\n\u003cp\u003eResveratrol exists as two stereoisomers:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003etrans-resveratrol\u003c\/strong\u003e — the bioactive form. Every clinical trial measured this. Every SIRT1, AMPK, NF-κB, and eNOS mechanism documented above is trans-resveratrol's signature. This is the molecule the Sinclair lab tested, the molecule Tomé-Carneiro dosed, the molecule Hubbard crystallized.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ecis-resveratrol\u003c\/strong\u003e — a UV-degradation product. The double bond in the stilbene core photoisomerizes from trans to cis under exposure to ultraviolet light, oxygen, and heat. Cis-resveratrol has dramatically reduced SIRT1 binding affinity and minimal in-vivo activity in published comparisons.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eCheap resveratrol products mix them — and because cis-resveratrol can't be distinguished from trans by simple UV-Vis spectrophotometry (the cheap industry-standard assay), label claims that don't specify HPLC are often inflated by cis-isomer drift that occurred during storage, processing, or shipping. \u003cstrong\u003e≥98% HPLC trans-resveratrol means each batch is run on high-pressure liquid chromatography with diode-array detection at 308 nm — the assay that actually separates the two anomers.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe other 2% is residual \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e polyphenols (emodin, polydatin, piceid) at trace level, not cis-isomer drift. This is the molecular-grade material, not the food-grade material.\u003c\/p\u003e\n\n\u003ch2\u003eWhy \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e (Japanese knotweed)\u003c\/h2\u003e\n\u003cp\u003eTrans-resveratrol can be extracted from grape skins, peanut hulls, or \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e (Japanese knotweed) root. The Sinclair-lab work, the Tomé-Carneiro Spanish CHD trials, and the bulk of the human cardiometabolic literature all use \u003cem\u003eP. cuspidatum\u003c\/em\u003e for one reason: \u003cstrong\u003enatural concentration\u003c\/strong\u003e. Knotweed root contains 2–5% trans-resveratrol by dry weight, versus 0.001–0.01% in grape skin. That means knotweed extract reaches ≥98% HPLC purity through standard solvent partitioning; grape-skin extract requires aggressive chromatographic purification that often leaves residual matrix polyphenols and pesticide residues.\u003c\/p\u003e\n\u003cp\u003eThis product uses \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e root extract, ethanol\/water partitioned, recrystallized, ≥98% HPLC trans-resveratrol. Same source class as the trial materials.\u003c\/p\u003e\n\n\u003ch2\u003eClinical evidence — the trials that anchor 600 mg\u003c\/h2\u003e\n\u003cp\u003eThe \"resveratrol works \/ doesn't work\" debate gets cleaner once you stratify by dose, formulation, and population. Here is the evidence we anchor 600 mg on.\u003c\/p\u003e\n\n\u003ch3\u003eCardiometabolic — the strongest signal\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTomé-Carneiro 2012\u003c\/strong\u003e (\u003cem\u003eAm J Cardiol\u003c\/em\u003e) — CHD patients on statins, 350 mg\/day grape-extract resveratrol for 6 months. Significant increase in serum adiponectin, downregulation of pro-inflammatory genes (CCL3, IL-1β, TNF-α) in PBMCs, reduction in atherogenic apolipoproteins. This is the cardiology-on-statins benchmark trial.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTomé-Carneiro 2013\u003c\/strong\u003e (\u003cem\u003eMol Nutr Food Res\u003c\/em\u003e) — same cohort, 12-month follow-up. Persistent reduction in oxidized LDL by ~20%, sustained anti-inflammatory transcriptional shift. The signal didn't wash out with longer dosing — which is the question every \"transient effect\" critic raised in 2010.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBhatt 2012\u003c\/strong\u003e (\u003cem\u003eNutr Res\u003c\/em\u003e) — type 2 diabetics, 250 mg\/day for 3 months. Significant reductions in HbA1c, systolic BP, total cholesterol. Lower dose, smaller effect, but the same direction.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMovahed 2013\u003c\/strong\u003e (\u003cem\u003eEvid Based Complement Alternat Med\u003c\/em\u003e) — type 2 diabetics, 1000 mg\/day for 45 days. Significant reductions in fasting glucose, HbA1c, systolic BP, and total cholesterol; significant rise in HDL. Higher dose, bigger effect.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePollack 2017\u003c\/strong\u003e (\u003cem\u003eCardiovasc Drugs Ther\u003c\/em\u003e) — older adults with insulin resistance, 1000–2000 mg\/day for 6 weeks. Improved peripheral and hepatic insulin sensitivity by clamp; the dose-response argument crystallized in this trial.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCognition and cerebral blood flow\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKennedy 2010\u003c\/strong\u003e (\u003cem\u003eAm J Clin Nutr\u003c\/em\u003e) — healthy adults, 250 and 500 mg single oral doses. Dose-dependent increase in cerebral blood-flow velocity and oxy\/deoxy-Hb in the prefrontal cortex (NIRS). Acute mechanism: eNOS\/NO-driven vasodilation crossing into cerebral circulation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWitte 2014\u003c\/strong\u003e (\u003cem\u003eJ Neurosci\u003c\/em\u003e) — overweight older adults, 200 mg\/day for 26 weeks. Improved memory performance and increased hippocampal functional connectivity, with reductions in glycated hemoglobin and body fat that paralleled the cognitive shift.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEvans 2017\u003c\/strong\u003e (\u003cem\u003eNutrients\u003c\/em\u003e) — postmenopausal women, 75 mg twice daily for 14 weeks. Improved cerebrovascular responsiveness and aspects of cognitive performance, again pointing at the vascular leg.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eBone, postmenopausal physiology, and inflammaging\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOrnstrup 2014\u003c\/strong\u003e (\u003cem\u003eJ Clin Endocrinol Metab\u003c\/em\u003e) — obese men, 500 mg twice daily for 16 weeks. Increased bone mineral density at lumbar spine and improved bone turnover markers. Suggests SIRT1-mediated osteoblast support is translating clinically.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWong 2017 \/ 2019\u003c\/strong\u003e (RESHAW trial, \u003cem\u003eInt J Cardiol\u003c\/em\u003e) — postmenopausal women, 75 mg twice daily for 12+24 months. Sustained improvements in cerebrovascular responsiveness, mood, and selected cardiometabolic markers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eWhere the evidence is preliminary\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAll-cause mortality \/ lifespan in humans\u003c\/strong\u003e — no powered RCT exists and won't (ethics, timeline, expense). The animal lifespan signal is real (Baur 2006 in obese mice; lifespan extension in \u003cem\u003eS. cerevisiae\u003c\/em\u003e, \u003cem\u003eC. elegans\u003c\/em\u003e, \u003cem\u003eDrosophila\u003c\/em\u003e); human evidence is biomarker-level.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eResveratrol monotherapy in elite\/young endurance athletes\u003c\/strong\u003e — Gliemann 2013 saw blunted training-induced cardiovascular adaptations in 60+ men at 250 mg\/day; signal hasn't replicated cleanly elsewhere, but the data exist. See contraindications.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCancer chemoprevention\u003c\/strong\u003e — preclinical signal is broad but human trials are early-phase and small.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eThe case for 600 mg over 100 mg or 250 mg\u003c\/h2\u003e\n\u003cp\u003eMost over-the-counter resveratrol caps at 100–250 mg, which is exactly the range where the \"resveratrol doesn't work in humans\" meta-analyses concentrate. The dose-response data tell a different story:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBioavailability is the limiting factor, not safety.\u003c\/strong\u003e Walle 2004 (\u003cem\u003eDrug Metab Dispos\u003c\/em\u003e) measured \u0026lt;1% free resveratrol in plasma after a 25 mg oral dose — but ~70% absorption, just rapidly glucuronidated and sulfated by phase-II liver metabolism. To get clinically meaningful free + conjugated AUC, you need 500 mg+ per dose.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe trials that worked used 500–1000 mg\/day.\u003c\/strong\u003e Tomé-Carneiro 2012 used 350 mg of a co-formulated grape extract (which improves uptake), but the broader cardiometabolic literature (Bhatt 2012, Movahed 2013, Pollack 2017, Ornstrup 2014) clusters at 500–1000 mg\/day. The Sinclair-lab mouse work scales to a human equivalent of ~750 mg\/day.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e600 mg is the floor for serious longevity stacking.\u003c\/strong\u003e If you're running NMN at 500–1000 mg\/day for sirtuin substrate, the matched activator dose lives at 500–1000 mg trans-resveratrol — taken with a fat-containing meal so the lipid solubilization hits.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAbove 1,000 mg\/day adds GI side effects without proportional benefit.\u003c\/strong\u003e Brown 2010 (\u003cem\u003eCancer Res\u003c\/em\u003e) saw mild diarrhea and GI cramping appear at 2.5 g\/day and above. 600 mg lands inside the high-tolerability window — meaningful free + conjugated AUC, no dose-limiting GI tone.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eTranslation: 100 mg is a label-claim dose. 250 mg is a hedge. \u003cstrong\u003e600 mg is a stack-grade dose.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch2\u003eBioavailability — what the PK studies actually show\u003c\/h2\u003e\n\u003cp\u003eResveratrol's pharmacokinetics are unusual and worth understanding because they explain the whole \"take it with fat\" rule.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAbsorption is high.\u003c\/strong\u003e Walle 2004 measured ~70% intestinal absorption of an oral dose. The bottleneck isn't getting it across the gut wall.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFirst-pass hepatic conjugation is aggressive.\u003c\/strong\u003e The liver glucuronidates and sulfates resveratrol within minutes via UGT1A1 and SULT1A1. Measured plasma free resveratrol after 25 mg oral was \u0026lt;5 ng\/mL.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConjugates are not inert.\u003c\/strong\u003e Patel 2013 and follow-up work show resveratrol-3-O-sulfate and resveratrol-glucuronides are themselves bioactive at physiological concentrations and can be deconjugated locally in tissue by sulfatases and β-glucuronidases — a \"circulating depot\" model. Total free + conjugated AUC is what matters clinically, not free-fraction alone.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFat-containing meal roughly doubles AUC.\u003c\/strong\u003e Vaz-da-Silva 2008 (\u003cem\u003eInt J Clin Pharmacol Ther\u003c\/em\u003e) showed AUC was significantly higher when resveratrol was administered with a standard meal versus fasting. La Porte 2010 confirmed across formulations.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHalf-life is ~9 hours for total radioactivity.\u003c\/strong\u003e One dose per day at 600 mg keeps measurable plasma exposure across the waking-hours window where SIRT1 demand is highest.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe practical translation: take 600 mg with breakfast or lunch (whichever has more fat). Don't take it on an empty stomach unless you want to throw away half the dose. Don't split it into 3×200 mg — the per-dose bioavailability ceiling falls off below 500 mg.\u003c\/p\u003e\n\n\u003ch2\u003eHow resveratrol maps onto the hallmarks of aging\u003c\/h2\u003e\n\u003cp\u003eThe López-Otín hallmarks (2013, updated 2023) are the field-standard taxonomy of biological aging. Resveratrol touches more of them than any other single polyphenol on our shelf:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDeregulated nutrient sensing\u003c\/strong\u003e — AMPK activation; mTOR suppression via AMPK-TSC2; SIRT1 deacetylation of mTORC1 substrates.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMitochondrial dysfunction\u003c\/strong\u003e — PGC-1α deacetylation by SIRT1; SIRT3-mediated SOD2 and ETC-component activation; AMPK-driven mitochondrial biogenesis.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCellular senescence \/ chronic inflammation\u003c\/strong\u003e — NF-κB suppression at IKK + p65 levels; SASP-cytokine dampening; pairs with senolytic protocols (quercetin\/fisetin) by clearing residual inflammation after the senescent cells themselves are removed.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEpigenetic alterations\u003c\/strong\u003e — SIRT1\/SIRT3-mediated histone deacetylation (H3K9, H4K16); modulation of DNA-methyltransferase activity; SIRT-dependent chromatin remodeling.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLoss of proteostasis \/ autophagy decline\u003c\/strong\u003e — AMPK→ULK1-driven macroautophagy; mitophagy via PINK1\/Parkin upstream signal; complementary to spermidine's EP300-inhibition route.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAltered intercellular communication\u003c\/strong\u003e — eNOS upregulation; SIRT1 deacetylation of endothelial transcription factors; reduced systemic inflammatory tone.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat's six of the twelve hallmarks with mechanism-grade evidence in a single molecule. This is the structural reason resveratrol earned the \"polyphenol that anchors a stack\" position.\u003c\/p\u003e\n\n\u003ch2\u003eResveratrol vs pterostilbene — the practical decision\u003c\/h2\u003e\n\u003cp\u003ePterostilbene is resveratrol's dimethylated cousin. Two methoxy groups in place of two hydroxyls makes it more lipid-soluble, less subject to first-pass conjugation, and longer-lived in plasma. So why isn't this the default?\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTrial base.\u003c\/strong\u003e Resveratrol has 200+ human trials and 20+ years of mechanistic data. Pterostilbene has \u0026lt;10 published human trials and no long-term cardiometabolic series.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSIRT1 affinity.\u003c\/strong\u003e Resveratrol is the canonical SIRT1 allosteric activator. Pterostilbene activates SIRT1 in vitro but with less-characterized binding-site behavior; head-to-head assays don't put it ahead of resveratrol on a per-mole basis at the SIRT1 site.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLDL signal.\u003c\/strong\u003e Pterostilbene at 250 mg\/day has shown a small LDL-elevation in some studies (Riche 2014), which is not the direction you want for a longevity polyphenol. Resveratrol either reduces LDL-ox (Tomé-Carneiro 2012\/2013) or is neutral on LDL.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCost-per-mg.\u003c\/strong\u003e Pterostilbene is roughly 5–10x more expensive at equivalent doses. The bioavailability advantage (~3x AUC versus standard resveratrol) doesn't close that gap.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWe anchor the SIRT1 leg with trans-resveratrol because the evidence base is wider, the dose-response is well-characterized, and the cost-per-effective-dose is meaningfully lower. If you want both, pterostilbene 100–150 mg\/day stacks on top of resveratrol 600 mg without conflict — resveratrol covers the trial-base \/ cardiometabolic \/ NF-κB legs; pterostilbene reinforces the longer plasma exposure window.\u003c\/p\u003e\n\n\u003ch2\u003eSource comparison — what \"resveratrol\" can mean on a label\u003c\/h2\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n\u003cth\u003eSource \/ spec\u003c\/th\u003e\n\u003cth\u003eWhat it is\u003c\/th\u003e\n\u003cth\u003eTrial usage\u003c\/th\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e≥98% trans-resveratrol from \u003cem\u003eP. cuspidatum\u003c\/em\u003e (HPLC)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStack-grade material. Trans-anomer verified. ~98% pure trans, ≤2% residual matrix polyphenols, undetectable cis-isomer drift.\u003c\/td\u003e\n\u003ctd\u003eSinclair-lab work; Tomé-Carneiro 2012\/2013; Movahed 2013; Pollack 2017. \u003cstrong\u003eThis product.\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e50% \/ 70% \/ 90% trans-resveratrol (UV-Vis assayed)\u003c\/td\u003e\n\u003ctd\u003eLower-purity knotweed extract. UV-Vis can't distinguish trans from cis — label claim is unreliable. Often heavier in residual emodin and other knotweed polyphenols (which can cause GI effects at scale).\u003c\/td\u003e\n\u003ctd\u003eNot used in clinical trials with PK confirmation. Consumer-grade material.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eGrape-skin extract (typically \u0026lt;1% resveratrol)\u003c\/td\u003e\n\u003ctd\u003eMixed polyphenol matrix. The Tomé-Carneiro grape-extract was a defined co-formulation; most \"grape resveratrol\" supplements on the shelf are not.\u003c\/td\u003e\n\u003ctd\u003eTomé-Carneiro used a specific defined grape extract — most generic grape-skin supplements aren't comparable.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003ePeanut-hull resveratrol\u003c\/td\u003e\n\u003ctd\u003eAllergen-relevant source. Can carry residual peanut protein at trace level.\u003c\/td\u003e\n\u003ctd\u003eNiche.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\"Resveratrol complex\" \/ \"antioxidant blend\"\u003c\/td\u003e\n\u003ctd\u003eOften 50–100 mg of resveratrol mixed with quercetin, grape-seed, green-tea, etc. Convenient — but you can't isolate the resveratrol dose, and per-mg resveratrol cost is usually higher.\u003c\/td\u003e\n\u003ctd\u003eNone of the above SIRT1\/AMPK\/eNOS trials used \"complex\" formulations.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch2\u003eWhere this fits in our NAD+ \/ longevity family\u003c\/h2\u003e\n\u003cp\u003eResveratrol is one of three legs in the canonical sirtuin axis we run on this site:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNAD+ substrate (precursor floor)\u003c\/strong\u003e — \u003ca href=\"\/he\/products\/pure-nmn-500mg-60-capsules-30-day-supply\"\u003eNMN 500mg\u003c\/a\u003e, \u003ca href=\"\/he\/products\/nmn-1000mg-pure-focus-formula-cellular-rejuvenation\"\u003eNMN 1000mg\u003c\/a\u003e, \u003ca href=\"\/he\/products\/liposomal-nad-supplement-anti-aging\"\u003eLiposomal NAD+\u003c\/a\u003e, \u003ca href=\"\/he\/products\/liquid-nad-anti-aging-drink-nr-stick-packs\"\u003eLiquid NAD+ NR stick packs\u003c\/a\u003e. Raises the NAD+ ceiling SIRT1\/SIRT3 can draw on.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSirtuin activator (allosteric)\u003c\/strong\u003e — \u003cstrong\u003ethis product\u003c\/strong\u003e. Pushes SIRT1\/SIRT3 enzymatic activity at any given NAD+ concentration. The activator side of the equation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMethyl-donor support\u003c\/strong\u003e — \u003ca href=\"\/he\/products\/tmg-1000mg-trimethylglycine-methyl-donor-betaine\"\u003eTMG 1000mg\u003c\/a\u003e. Replenishes the SAMe methyl-pool that the NAD+→NAM→methylation pathway draws on at long-term high doses.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe convenience option — get all three sirtuin pieces at -10% — is the \u003ca href=\"\/he\/products\/longevity-stack-bundle-nmn-500mg-resveratrol-600mg\"\u003eLongevity Stack Bundle\u003c\/a\u003e (NMN 500 + Resveratrol 600).\u003c\/p\u003e\n\u003cp\u003eBeyond the sirtuin axis, resveratrol pairs with a wider longevity protocol:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSenolytics\u003c\/strong\u003e — \u003ca href=\"\/he\/products\/quercetin-500mg-senolytic-flavonoid\"\u003eQuercetin 500mg\u003c\/a\u003e, \u003ca href=\"\/he\/products\/fisetin-500mg-senolytic-flavonoid\"\u003eFisetin 500mg\u003c\/a\u003e. Senolytics clear senescent cells; resveratrol dampens residual SASP inflammation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMitochondrial layer\u003c\/strong\u003e — \u003ca href=\"\/he\/products\/coq10-400mg-fertility-cellular-energy\"\u003eCoQ10 400mg\u003c\/a\u003e, \u003ca href=\"\/he\/products\/urolithin-a-500mg-mitophagy\"\u003eUrolithin A 500mg\u003c\/a\u003e, \u003ca href=\"\/he\/products\/calcium-alpha-ketoglutarate-1000mg-caakg\"\u003eCaAKG 1000mg\u003c\/a\u003e. Resveratrol drives mitochondrial biogenesis upstream; these support what the new mitochondria do downstream.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAMPK \/ metabolic\u003c\/strong\u003e — Berberine, metformin (Rx). All three converge on AMPK by different upstream routes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNF-κB \/ anti-inflammatory\u003c\/strong\u003e — \u003ca href=\"\/he\/products\/curcumin-1000mg-95-curcuminoids-bioperine\"\u003eCurcumin 1000mg + BioPerine\u003c\/a\u003e. Both suppress NF-κB; BioPerine improves both molecules' bioavailability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eStacking matrix\u003c\/h2\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n\u003cth\u003ePairs with\u003c\/th\u003e\n\u003cth\u003eWhy\u003c\/th\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eNMN 500mg or NMN 1000mg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThe canonical longevity stack — NMN supplies NAD+ substrate, resveratrol activates the SIRT1\/SIRT3 enzyme that uses it. Same morning dose, same fat-containing meal. Get both as the \u003ca href=\"\/he\/products\/longevity-stack-bundle-nmn-500mg-resveratrol-600mg\"\u003eLongevity Stack Bundle\u003c\/a\u003e at -10%.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eTMG 1000mg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLong-term high-dose NMN draws on the SAMe methyl-pool via the NAD+→NAM→methylated-NAM (MeNAM) clearance route. TMG (trimethylglycine) replenishes that pool. If you're running NMN + resveratrol daily, TMG eventually becomes non-optional.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eLiposomal NAD+ \/ Liquid NAD+ NR stick packs\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor circadian-dip coverage on top of the morning NMN substrate + resveratrol activator hit. Useful for users 50+ or running heavy training loads.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eBerberine 500mg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBoth activate AMPK by different upstream mechanisms (resveratrol via F1-ATPase inhibition; berberine via direct AMPK-α1 phosphorylation). Pairs especially well for metabolic-syndrome \/ insulin-resistance goals.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCurcumin + BioPerine\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBioPerine (piperine) inhibits CYP3A4-mediated hepatic conjugation, raising both curcumin and resveratrol AUC. Both molecules suppress NF-κB at complementary nodes — IKK (curcumin) + p65 deacetylation (resveratrol via SIRT1). Stack-stable, evidence-rich.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eQuercetin \/ Fisetin (senolytic protocol)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSenolytic flavonoids clear senescent cells; resveratrol dampens the residual SASP-cytokine inflammation. Run quercetin\/fisetin on a 2-day-pulse senolytic protocol; run resveratrol daily.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSpermidine 10mg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBoth activate autophagy. Resveratrol via AMPK→mTOR-suppression→ULK1; spermidine via direct EP300 inhibition. Two upstream switches converging on the same autophagy machinery — additive, not redundant.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eUrolithin A 500mg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eResveratrol drives mitochondrial biogenesis (PGC-1α deacetylation); Urolithin A drives mitophagy (PINK1\/Parkin). Together: more new mitochondria, fewer damaged ones. The classic mito-renewal pair.\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eOmega-3 \/ fatty meal\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAlways co-dose with fat. Resveratrol bioavailability roughly doubles with a fat-containing meal. Omega-3s also have independent NF-κB suppression and complement resveratrol's eNOS leg.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch2\u003eWhat to expect — week by week\u003c\/h2\u003e\n\u003cp\u003eResveratrol is not a stimulant. There is no acute \"feel\" effect on the first dose. The biological signals appear on different timelines:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDays 1–7:\u003c\/strong\u003e Acute eNOS \/ cerebral-blood-flow signal can register on the first day (Kennedy 2010 — single 250–500 mg dose increased prefrontal CBF measurably). For most users this is below subjective threshold but real on instrumentation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeeks 2–4:\u003c\/strong\u003e Inflammatory-tone shifts begin (CRP, fibrinogen, IL-6). Most users notice a generalized \"less inflammation\" baseline — fewer joint complaints, faster recovery from training. SIRT1 substrate-deacetylation signaling has reached steady state.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeeks 4–8:\u003c\/strong\u003e Lipid panel begins to shift in the cardiometabolic-risk subset (oxidized LDL down, HDL up modestly, triglycerides flat-to-down). Insulin-sensitivity changes appear in HOMA-IR and OGTT data on this timeline.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeeks 8–12:\u003c\/strong\u003e The Tomé-Carneiro biomarker timeline. LDL-ox reduction, atherogenic apolipoprotein shift, sustained anti-inflammatory transcriptional signature in PBMCs.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeeks 12+:\u003c\/strong\u003e Bone turnover markers and BMD changes in the relevant populations (Ornstrup 2014 saw lumbar BMD increase at 16 weeks). Cognitive \/ memory shifts appear in older adults around this timeline (Witte 2014 — 26-week trial).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eRun for 12 weeks minimum, recheck labs. The signal is biomarker-level and accumulative; this is not a \"feel it on day 3\" molecule.\u003c\/p\u003e\n\n\u003ch2\u003eDaily protocol\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e1 capsule per day, taken with the largest fat-containing meal of the day.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eResveratrol is fat-soluble and heavily phase-II-conjugated by the liver. Walle 2004, Vaz-da-Silva 2008, and Smoliga 2011 all converge: taking resveratrol on an empty stomach throws away most of the dose. With a fat-containing meal — even just olive oil, eggs, fatty fish, or avocado — measured plasma AUC roughly doubles versus fasted dosing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTiming notes:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDefault:\u003c\/strong\u003e with breakfast or lunch (whichever is the larger fat-containing meal). Aligns with the AM dose of NMN if you're stacking.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStacking with NMN:\u003c\/strong\u003e same meal as the morning NMN dose. This is the canonical Sinclair-protocol pairing — substrate + activator hit the SIRT1 axis together.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePre-workout:\u003c\/strong\u003e some users dose 60–90 minutes before resistance training to leverage the AMPK \/ mitochondrial-biogenesis crossover. Note the Gliemann 2013 caveat below before doing this if you're an older endurance athlete.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWith BioPerine \/ curcumin:\u003c\/strong\u003e piperine inhibits CYP3A4 and raises resveratrol AUC by roughly 1.5–2x in the published bioavailability studies. If you're already taking \u003ca href=\"\/he\/products\/curcumin-1000mg-95-curcuminoids-bioperine\"\u003eCurcumin + BioPerine\u003c\/a\u003e with breakfast, your resveratrol AUC is going up too — for free.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAvoid grapefruit juice the same day.\u003c\/strong\u003e Grapefruit competes for the same CYP3A4 \/ UGT pathway resveratrol uses; the effect on AUC is real but not dangerous.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDon't take it before bed.\u003c\/strong\u003e Cerebral blood-flow upregulation can interfere with sleep onset for sensitive users.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWhat this product is — and is NOT\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIs:\u003c\/strong\u003e 600 mg of ≥98% HPLC trans-resveratrol per capsule, sourced from \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e (Japanese knotweed) root extract, in a vegan HPMC capsule, with no fillers, no proprietary blends, no titanium dioxide, no magnesium stearate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIs:\u003c\/strong\u003e Per-batch HPLC-verified for trans-anomer purity (308 nm DAD); independently tested for heavy metals (USP \u0026lt;232\u0026gt;), microbials (USP \u0026lt;2021\u0026gt;), and residual solvents (USP \u0026lt;467\u0026gt;).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIs NOT:\u003c\/strong\u003e A grape-skin extract. Knotweed-sourced trans-resveratrol is the trial-grade material; grape-skin extract is a different (and more variable) product class.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIs NOT:\u003c\/strong\u003e A \"resveratrol complex.\" There's no quercetin, grape-seed extract, green-tea extract, or pterostilbene mixed in. Those are real ingredients but you can't dose them properly when they're hidden inside a single 600 mg capsule. We sell them separately when relevant.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIs NOT:\u003c\/strong\u003e A liposomal or micronized formulation. At 600 mg with a fat-containing meal, you're already in the clinically-validated AUC range without paying the 4–5x premium that liposomal resveratrol commands.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIs NOT:\u003c\/strong\u003e A treatment for any specific disease. This is a longevity-stack supplement, not a cardiology drug, not a cancer therapeutic. Talk to your physician.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon mistakes to avoid\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTaking it on an empty stomach.\u003c\/strong\u003e Roughly halves the AUC. Always with a fat-containing meal.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSplitting 600 mg into 3×200 mg doses.\u003c\/strong\u003e The per-dose absorption ceiling falls off below 500 mg — splitting reduces total daily AUC, not increases it.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBuying 100 mg products and taking 6 capsules.\u003c\/strong\u003e Math works, but you're paying 3–5x per active mg and usually the source\/spec isn't HPLC-verified at the lower price point.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStopping after 4 weeks because nothing happened.\u003c\/strong\u003e The cardiometabolic biomarker timeline is 8–12 weeks. The SIRT1 axis steady-state is 4 weeks. The cognitive \/ BMD signals are 16–26 weeks. Don't bail at week 4.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStacking resveratrol with grapefruit juice.\u003c\/strong\u003e CYP3A4 competition. Not dangerous, but reduces predictability of dose-response.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRunning resveratrol monotherapy with no NAD+ precursor.\u003c\/strong\u003e Resveratrol activates SIRT1, but SIRT1 needs NAD+ as substrate. Without NMN or NR floor-raising, you're flooring the gas with the tank low.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBuying generic UV-Vis \"resveratrol\" and assuming it's trans.\u003c\/strong\u003e UV-Vis can't distinguish trans from cis. Cis-isomer drift in poorly-stored material can reduce label-active dose by 30%+ silently.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWho this is for\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAdults 35+ running a serious longevity stack who want the canonical SIRT1 activator.\u003c\/li\u003e\n  \u003cli\u003eAnyone already taking NMN or NR who hasn't yet added the activator side of the equation.\u003c\/li\u003e\n  \u003cli\u003ePeople with cardiometabolic risk factors (elevated LDL-ox, insulin resistance, family history of CHD) who want a polyphenol with documented eNOS \/ NF-κB \/ AMPK signal at trial-grade dose.\u003c\/li\u003e\n  \u003cli\u003eStack-builders who want one molecule that does sirtuin co-activation + AMPK activation + NF-κB suppression + endothelial support simultaneously, rather than four separate inputs.\u003c\/li\u003e\n  \u003cli\u003ePostmenopausal women looking at cardiovascular and bone-density support (Wong \/ RESHAW; Ornstrup 2014).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWho this is NOT for\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePregnancy or breastfeeding.\u003c\/strong\u003e Insufficient human safety data above the dietary trace doses. Don't.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eActive hormone-sensitive cancer (breast, ovarian, endometrial, prostate).\u003c\/strong\u003e Resveratrol is a phytoestrogen with weak ER-binding affinity (~7,000x less than estradiol, tissue-specific). Clinical relevance at 600 mg is small for healthy adults but not zero — discuss with your oncologist before adding.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOn warfarin or active anti-platelet therapy.\u003c\/strong\u003e Resveratrol has mild antiplatelet effects in vitro (Pace-Asciak 1995); the clinical relevance at 600 mg is small but nonzero. Monitor INR if you're running both.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOlder competitive endurance athletes.\u003c\/strong\u003e Gliemann 2013 (\u003cem\u003eJ Physiol\u003c\/em\u003e) showed 250 mg\/day resveratrol blunted training-induced cardiovascular adaptations in 60+ men. The signal hasn't replicated cleanly in younger or recreational populations, but the data exist; if you're a competitive masters endurance athlete in a periodized peak block, time resveratrol around recovery weeks rather than peak-training weeks.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAllergic to \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e.\u003c\/strong\u003e Rare but documented. Skin reactions, GI cramping. Stop and don't restart.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTaking strong CYP3A4 inhibitors\u003c\/strong\u003e (clarithromycin, ketoconazole, ritonavir). Resveratrol AUC will rise unpredictably; talk to your prescriber.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eSafety, interactions, and contraindications\u003c\/h2\u003e\n\u003cp\u003eResveratrol has one of the cleanest oral safety profiles in the longevity-supplement space at \u0026lt;1 g\/day. Brown 2010 (\u003cem\u003eCancer Res\u003c\/em\u003e) tested 0.5–5 g daily for 29 days with no dose-limiting toxicity below 2.5 g; mild diarrhea \/ GI cramping appeared above that. 600 mg sits well below any documented dose-limiting tolerance threshold.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAnticoagulants \/ antiplatelets.\u003c\/strong\u003e Mild antiplatelet effect in vitro (Pace-Asciak 1995); clinical relevance at 600 mg is small but real. Monitor INR if on warfarin; talk to prescriber if on dual antiplatelet therapy after stenting.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCYP3A4 substrates.\u003c\/strong\u003e Resveratrol is a mild CYP3A4 inhibitor. Drugs metabolized through CYP3A4 (statins, calcium-channel blockers, some immunosuppressants) may have modestly elevated AUC. Talk to prescriber.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUGT1A1 substrates.\u003c\/strong\u003e Resveratrol competes for hepatic glucuronidation. Drugs heavily UGT1A1-cleared (irinotecan metabolites, raltegravir) may behave unpredictably.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEstrogen-modulating drugs.\u003c\/strong\u003e Tamoxifen, aromatase inhibitors, hormonal contraceptives — discuss with your prescriber given resveratrol's weak ER-binding profile.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSSRIs and MAOIs.\u003c\/strong\u003e No documented interaction at 600 mg. Resveratrol's mild MAO-inhibition signal is at much higher doses than typical supplementation hits.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWhat's in it\u003c\/h2\u003e\n\u003cp\u003ePer capsule:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTrans-resveratrol — 600 mg\u003c\/strong\u003e, from \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e root extract, ≥98% HPLC trans-anomer.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVegan HPMC capsule.\u003c\/strong\u003e No gelatin.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cem\u003eWhat's NOT in it:\u003c\/em\u003e No magnesium stearate, no silicon dioxide, no titanium dioxide, no maltodextrin, no rice flour, no proprietary blends, no cis-isomer drift, no inflated UV-Vis label claim. 600 mg is 600 mg of trans-resveratrol — not 600 mg of an \"antioxidant complex\" that turns out to be 50 mg resveratrol + 550 mg cellulose.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eAllergens:\u003c\/em\u003e No gluten, no soy, no dairy, no nuts, no shellfish, no eggs.\u003c\/p\u003e\n\n\u003ch2\u003eSourcing, manufacturing, and quality control\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSource:\u003c\/strong\u003e \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e root extract, ethanol\/water partitioned, recrystallized to ≥98% trans-resveratrol by HPLC.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eManufacturing:\u003c\/strong\u003e cGMP-registered facility, NSF-audited; capsules filled under controlled humidity in opaque amber blister-stable bottles.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePer-batch testing:\u003c\/strong\u003e HPLC identity + potency at 308 nm (DAD); cis-isomer screen; heavy metals (USP \u0026lt;232\u0026gt;) for As\/Cd\/Hg\/Pb; microbial limits (USP \u0026lt;2021\u0026gt;) for total aerobic, yeast\/mold, E. coli, Salmonella; residual solvents (USP \u0026lt;467\u0026gt;).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Validated 24-month room-temperature stability under amber-bottle storage. Resveratrol is photo-sensitive — keep the bottle closed.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePublic COA:\u003c\/strong\u003e per-batch certificate of analysis available at \u003ca href=\"\/he\/pages\/coa\"\u003etruehealthprotocol.health\/pages\/coa\u003c\/a\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eFrequently asked questions\u003c\/h2\u003e\n\n\u003ch3\u003eDoes resveratrol actually extend lifespan in humans?\u003c\/h3\u003e\n\u003cp\u003eNo human RCT is powered for all-cause-mortality endpoints (the trial would take 30+ years and be ethically contested). What we have: lifespan extension in \u003cem\u003eS. cerevisiae\u003c\/em\u003e, \u003cem\u003eC. elegans\u003c\/em\u003e, \u003cem\u003eDrosophila\u003c\/em\u003e, and obese mice (Baur 2006); biomarker improvement across the cardiometabolic literature (Tomé-Carneiro 2012\/2013, Movahed 2013, Pollack 2017); mechanistic plausibility via SIRT1, AMPK, NF-κB, and eNOS. Treat resveratrol like the rest of the longevity stack — high-evidence biomarker work, mechanistic translation from animal lifespan data, ride the convergence.\u003c\/p\u003e\n\n\u003ch3\u003eResveratrol vs pterostilbene — which is \"better\"?\u003c\/h3\u003e\n\u003cp\u003ePterostilbene is resveratrol's dimethylated cousin with better bioavailability (more lipid-soluble, less first-pass conjugation, longer plasma half-life) but a much thinner trial base. Resveratrol has 200+ human trials and 20+ years of mechanistic data; pterostilbene has \u0026lt;10 published human trials. We anchor the SIRT1 leg with resveratrol because the evidence base is wider and the dose-response is well-characterized. If you want both, pterostilbene 100–150 mg\/day stacks fine on top of resveratrol 600 mg.\u003c\/p\u003e\n\n\u003ch3\u003eWhy not micronized or liposomal resveratrol?\u003c\/h3\u003e\n\u003cp\u003eBoth improve absorption modestly (~1.5–2x AUC vs standard). At 600 mg trans-resveratrol from \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e in a fat-containing meal, you're already in the clinically active plasma range. The cost premium for liposomal (often 4–5x per active mg) doesn't pencil out for most users. We'd rather give you the verifiable molecular-grade material at a serious dose.\u003c\/p\u003e\n\n\u003ch3\u003eHow long until I notice anything?\u003c\/h3\u003e\n\u003cp\u003eResveratrol isn't a stimulant. The cardiometabolic biomarker shifts (LDL-ox, CRP, fasting insulin) appear in trials at 8–12 weeks. Bone-density and cognitive shifts take 16–26 weeks. Acute \"feel\" effects (energy, mental clarity) on day-1 are typically downstream of NMN substrate availability — this is why the NMN + resveratrol pairing is the standard. Run for 12 weeks minimum, recheck labs.\u003c\/p\u003e\n\n\u003ch3\u003eCan I take it with metformin or berberine?\u003c\/h3\u003e\n\u003cp\u003eYes — and it's mechanistically synergistic. All three activate AMPK by different upstream routes: metformin via complex I inhibition, berberine via direct AMPK-α1 phosphorylation, resveratrol via F1F0-ATP synthase inhibition. Resveratrol's SIRT1 leg is independent of metformin's mechanism. The classic metabolic-syndrome stack is metformin (or berberine) + resveratrol + NMN.\u003c\/p\u003e\n\n\u003ch3\u003eWhy not just drink red wine?\u003c\/h3\u003e\n\u003cp\u003eBecause the dose math doesn't work. A 5 oz glass of red wine contains roughly 0.3–1.0 mg trans-resveratrol. 600 mg is the equivalent of 600–2,000 glasses. Even ignoring the alcohol harm-curve, the resveratrol math is impossible from food. The \"French paradox\" was never about resveratrol-the-molecule; it was about overall polyphenol intake plus Mediterranean-diet effects.\u003c\/p\u003e\n\n\u003ch3\u003eDoes resveratrol affect estrogen?\u003c\/h3\u003e\n\u003cp\u003eWeakly. Resveratrol binds estrogen receptors with ~7,000x lower affinity than estradiol, and its action is tissue-specific (mostly antagonist at ERα in breast tissue, mild agonist at ERβ in bone). The clinical relevance at 600 mg is small for healthy adults; meaningful for anyone with active hormone-sensitive cancer (see contraindications). Postmenopausal women in trials (Wong \/ RESHAW; Ornstrup) actually benefited from the ERβ agonist tone in bone — this is part of why BMD signals appear at 16+ weeks.\u003c\/p\u003e\n\n\u003ch3\u003eCan I open the capsule and put it in a smoothie?\u003c\/h3\u003e\n\u003cp\u003eYou can, but don't. Resveratrol is photosensitive — UV exposure converts trans to cis (the inactive isomer). A smoothie blender's clear pitcher under kitchen light for 30 minutes is enough to nudge a measurable fraction. If you can't swallow capsules, dissolve in olive oil at room temp and consume immediately, in opaque container.\u003c\/p\u003e\n\n\u003ch3\u003eWhy is daily consistency more important than dose?\u003c\/h3\u003e\n\u003cp\u003eThe SIRT1 deacetylation signaling Resveratrol drives doesn't store — it's a real-time enzymatic process. The NF-κB suppression and eNOS upregulation reset within ~48 hours of stopping. Hubbard 2013's mechanism is steady-state by design. 600 mg\/day for 90 days is dramatically more biologically active than 1,800 mg every third day.\u003c\/p\u003e\n\n\u003ch3\u003eShould I cycle off resveratrol?\u003c\/h3\u003e\n\u003cp\u003eThe published trials run continuously for 6–24 months without dose-limiting toxicity, withdrawal effects, or receptor down-regulation. There's no published rationale for cycling at 600 mg. The \"cycle everything\" supplement-bro heuristic doesn't apply to a polyphenol the body's already adapted to evolutionarily.\u003c\/p\u003e\n\n\u003ch3\u003eCan I take resveratrol while fasting?\u003c\/h3\u003e\n\u003cp\u003eYes — but understand you'll get less of it. Fasted bioavailability is roughly half of fed bioavailability. If you're fasting and want to keep resveratrol on board, take it with the first fat-containing meal of your eating window, not during the fast itself.\u003c\/p\u003e\n\n\u003ch3\u003eDoes resveratrol show up on a drug test?\u003c\/h3\u003e\n\u003cp\u003eNo. Resveratrol and its glucuronide \/ sulfate conjugates are not on any standard drug-testing panel (sport, occupational, or law-enforcement). The molecule is structurally a stilbene polyphenol — entirely distinct from any controlled substance class.\u003c\/p\u003e\n\n\u003ch3\u003eIs this the same as the Sinclair-lab resveratrol?\u003c\/h3\u003e\n\u003cp\u003eSame source class (\u003cem\u003eP. cuspidatum\u003c\/em\u003e root extract, ≥98% trans-resveratrol HPLC) at the dose range used in animal lifespan work scaled to human equivalents. The Sinclair lab used ≥98% trans-resveratrol material throughout the Howitz 2003 \/ Baur 2006 \/ Hubbard 2013 work. We're not selling \"Sinclair's brand\" — we're selling the same molecular spec.\u003c\/p\u003e\n\n\u003ch3\u003eDoes resveratrol raise blood pressure?\u003c\/h3\u003e\n\u003cp\u003eNo. The vascular signal goes the other direction — eNOS-mediated vasodilation lowers systolic BP modestly in cardiometabolic trials (Movahed 2013; Bhatt 2012). Resveratrol does not have stimulant effects on heart rate or pressor effects on BP.\u003c\/p\u003e\n\n\u003ch3\u003eWhy is daily consistency more important than peak dose?\u003c\/h3\u003e\n\u003cp\u003eThe SIRT1 deacetylation signal is steady-state. Hubbard 2013's allosteric activation is dose-rate-dependent at the cellular level — a constant 600 mg\/day flow keeps SIRT1 in the activated conformation continuously. Pulse-loading (1800 mg every 3 days) gives you the same average dose but with off-cycle troughs where SIRT1 reverts to baseline.\u003c\/p\u003e\n\n\u003ch3\u003eCan I take it with NAD+ IV therapy?\u003c\/h3\u003e\n\u003cp\u003eYes — they're complementary, not duplicative. NAD+ IV raises blood NAD+ levels acutely; resveratrol activates the SIRT1 enzyme that uses NAD+. The pairing is logical: substrate (NAD+ IV or NMN) + activator (resveratrol).\u003c\/p\u003e\n\n\u003ch3\u003eDoes resveratrol interact with statins or blood-pressure medications?\u003c\/h3\u003e\n\u003cp\u003eNo major interaction in the published trial literature — Tomé-Carneiro's CHD cohort were on statins throughout, with the resveratrol arm showing additional LDL-ox reduction without altering statin pharmacokinetics meaningfully. Resveratrol is a mild CYP3A4 inhibitor in vitro; the clinical relevance for typical statin doses is small. Don't change prescribed medication without your physician.\u003c\/p\u003e\n\n\u003ch3\u003eIs the capsule kosher \/ halal?\u003c\/h3\u003e\n\u003cp\u003eVegan HPMC capsule shell. The resveratrol is plant-derived (knotweed root). No animal-derived ingredients, no alcohol residues above limits. Specific kosher \/ halal certification varies by batch — check the COA page for current certification status.\u003c\/p\u003e\n\n\u003ch2\u003eWhere this sits in the catalog architecture\u003c\/h2\u003e\n\u003cp\u003eResveratrol 600mg occupies the \u003cstrong\u003eSirtuin Activator\u003c\/strong\u003e position in the True Health Protocol catalog. Three legs of the sirtuin axis on this site:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSubstrate (NAD+ floor)\u003c\/strong\u003e — NMN family (\u003ca href=\"\/he\/products\/pure-nmn-500mg-60-capsules-30-day-supply\"\u003eNMN 500mg\u003c\/a\u003e, \u003ca href=\"\/he\/products\/nmn-1000mg-pure-focus-formula-cellular-rejuvenation\"\u003eNMN 1000mg\u003c\/a\u003e, \u003ca href=\"\/he\/products\/liposomal-nad-supplement-anti-aging\"\u003eLiposomal NAD+\u003c\/a\u003e, \u003ca href=\"\/he\/products\/liquid-nad-anti-aging-drink-nr-stick-packs\"\u003eLiquid NAD+ NR\u003c\/a\u003e).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eActivator (SIRT1\/SIRT3 push)\u003c\/strong\u003e — \u003cstrong\u003ethis product.\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMethyl support (long-term)\u003c\/strong\u003e — \u003ca href=\"\/he\/products\/tmg-1000mg-trimethylglycine-methyl-donor-betaine\"\u003eTMG 1000mg\u003c\/a\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe convenience pairing is the \u003ca href=\"\/he\/products\/longevity-stack-bundle-nmn-500mg-resveratrol-600mg\"\u003eLongevity Stack Bundle\u003c\/a\u003e (NMN 500 + Resveratrol 600 at -10%).\u003c\/p\u003e\n\n\u003ch2\u003eRelated collections\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/collections\/longevity\"\u003eLongevity collection\u003c\/a\u003e — every product in the canonical longevity-stack architecture (NAD+ axis, sirtuin activators, senolytics, mitochondrial-renewal layer).\u003c\/li\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/collections\/sirtuin-activators\"\u003eSirtuin activators\u003c\/a\u003e — resveratrol and pairing molecules.\u003c\/li\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/collections\/cardiovascular\"\u003eCardiovascular collection\u003c\/a\u003e — resveratrol, CoQ10, taurine, omega-3, and pairing nutrients.\u003c\/li\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/collections\/anti-inflammatory\"\u003eAnti-inflammatory collection\u003c\/a\u003e — resveratrol, curcumin, omega-3, quercetin.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eRead more on this topic\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/blogs\/longevity\/sirtuins-explained\"\u003eSirtuins explained — the seven enzymes longevity research orbits.\u003c\/a\u003e Why SIRT1 isn't the only sirtuin that matters, and how resveratrol fits across SIRT1\/SIRT3.\u003c\/li\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/blogs\/longevity\/nmn-vs-nad\"\u003eNMN vs NAD+ — what the precursor difference actually means.\u003c\/a\u003e The substrate side of the substrate-plus-activator equation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/blogs\/longevity\/classic-longevity-stack\"\u003eThe classic longevity stack — NMN + resveratrol explained.\u003c\/a\u003e Why these two molecules became the canonical pairing.\u003c\/li\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/blogs\/longevity\/nad-decline-with-age\"\u003eNAD+ decline with age — what the data actually show.\u003c\/a\u003e Why the substrate side of the equation gets the most attention, and what resveratrol adds.\u003c\/li\u003e\n  \u003cli\u003e\n\u003ca href=\"\/he\/pages\/protocols\"\u003eThe True Health Protocol — full longevity protocol\u003c\/a\u003e showing where resveratrol slots into a complete supplementation framework.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eSelected references\u003c\/h2\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eHowitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. \u003cem\u003eNature\u003c\/em\u003e 2003;425:191-6. — Original screen identifying resveratrol as a sirtuin activator. Context, not endorsement.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eBaur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA. Resveratrol improves health and survival of mice on a high-calorie diet. \u003cem\u003eNature\u003c\/em\u003e 2006;444:337-42. — Mouse lifespan extension on calorically-stressed diet.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eHubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, Riera TV, Lee JE, E SY, Lamming DW, Pentelute BL, Schuman ER, Stevens LA, Ling AJ, Armour SM, Michan S, Zhao H, Jiang Y, Sweitzer SM, Blum CA, Disch JS, Ng PY, Howitz KT, Rolo AP, Hamuro Y, Moss J, Perni RB, Ellis JL, Vlasuk GP, Sinclair DA. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. \u003cem\u003eScience\u003c\/em\u003e 2013;339:1216-9. — Crystal structure resolving SIRT1 allosteric activation.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003ePark SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V, Chung JH. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. \u003cem\u003eCell\u003c\/em\u003e 2012;148:421-33. — AMPK leg via PDE\/cAMP signaling.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eTomé-Carneiro J, Gonzálvez M, Larrosa M, García-Almagro FJ, Avilés-Plaza F, Parra S, Yáñez-Gascón MJ, Ruiz-Ros JA, García-Conesa MT, Tomás-Barberán FA, Espín JC. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. \u003cem\u003eMol Nutr Food Res\u003c\/em\u003e 2012;56:810-21.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eTomé-Carneiro J, Larrosa M, Yáñez-Gascón MJ, Dávalos A, Gil-Zamorano J, Gonzálvez M, García-Almagro FJ, Ruiz Ros JA, Tomás-Barberán FA, Espín JC, García-Conesa MT. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. \u003cem\u003ePharmacol Res\u003c\/em\u003e 2013;72:69-82.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eBhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. \u003cem\u003eNutr Res\u003c\/em\u003e 2012;32:537-41.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eMovahed A, Nabipour I, Lieben Louis X, Thandapilly SJ, Yu L, Kalantarhormozi M, Rekabpour SJ, Netticadan T. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. \u003cem\u003eEvid Based Complement Alternat Med\u003c\/em\u003e 2013;2013:851267.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003ePollack RM, Barzilai N, Anghel V, Kulkarni AS, Golden A, O'Broin P, Sinclair DA, Bonkowski MS, Coleville AJ, Powell D, Kim S, Moaddel R, Stein D, Zhang K, Hawkins M, Crandall JP. Resveratrol improves vascular function and mitochondrial number but not glucose metabolism in older adults. \u003cem\u003eJ Gerontol A Biol Sci Med Sci\u003c\/em\u003e 2017;72:1703-9.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eWalle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. \u003cem\u003eDrug Metab Dispos\u003c\/em\u003e 2004;32:1377-82.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eSmoliga JM, Baur JA, Hausenblas HA. Resveratrol and health — a comprehensive review of human clinical trials. \u003cem\u003eMol Nutr Food Res\u003c\/em\u003e 2011;55:1129-41.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eVaz-da-Silva M, Loureiro AI, Falcao A, Nunes T, Rocha JF, Fernandes-Lopes C, Soares E, Wright L, Almeida L, Soares-da-Silva P. Effect of food on the pharmacokinetic profile of trans-resveratrol. \u003cem\u003eInt J Clin Pharmacol Ther\u003c\/em\u003e 2008;46:564-70.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eWallerath T, Deckert G, Ternes T, Anderson H, Li H, Witte K, Förstermann U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. \u003cem\u003eCirculation\u003c\/em\u003e 2002;106:1652-8.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eCsiszar A, Labinskyy N, Pinto JT, Ballabh P, Zhang H, Losonczy G, Pearson K, de Cabo R, Pacher P, Zhang C, Ungvari Z. Resveratrol induces mitochondrial biogenesis in endothelial cells. \u003cem\u003eAm J Physiol Heart Circ Physiol\u003c\/em\u003e 2009;297:H13-20.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eLagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. \u003cem\u003eCell\u003c\/em\u003e 2006;127:1109-22.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eYeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. \u003cem\u003eEMBO J\u003c\/em\u003e 2004;23:2369-80.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eWitte AV, Kerti L, Margulies DS, Flöel A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. \u003cem\u003eJ Neurosci\u003c\/em\u003e 2014;34:7862-70.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eKennedy DO, Wightman EL, Reay JL, Lietz G, Okello EJ, Wilde A, Haskell CF. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. \u003cem\u003eAm J Clin Nutr\u003c\/em\u003e 2010;91:1590-7.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eOrnstrup MJ, Harsløf T, Kjær TN, Langdahl BL, Pedersen SB. Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial. \u003cem\u003eJ Clin Endocrinol Metab\u003c\/em\u003e 2014;99:4720-9.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eWong RH, Howe PR, Buckley JD, Coates AM, Kunz I, Berry NM. Acute resveratrol supplementation improves flow-mediated dilatation in overweight\/obese individuals with mildly elevated blood pressure. \u003cem\u003eNutr Metab Cardiovasc Dis\u003c\/em\u003e 2011;21:851-6.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eBrown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, Brown K, Steward WP, Gescher AJ, Brenner DE. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. \u003cem\u003eCancer Res\u003c\/em\u003e 2010;70:9003-11.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eGliemann L, Schmidt JF, Olesen J, Biensø RS, Peronard SL, Grandjean SU, Mortensen SP, Nyberg M, Bangsbo J, Pilegaard H, Hellsten Y. Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men. \u003cem\u003eJ Physiol\u003c\/em\u003e 2013;591:5047-59.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003eLópez-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. \u003cem\u003eCell\u003c\/em\u003e 2013;153:1194-217. — Updated 2023 in \u003cem\u003eCell\u003c\/em\u003e 186:243-78. Foundational taxonomy of biological aging.\u003c\/p\u003e\n\u003cp style=\"font-size:0.9em;line-height:1.55;\"\u003e\u003cem\u003eReferences cited here are scientific context, not product endorsements. The molecular and clinical findings described above pertain to the molecules studied; this product supplies the same molecule (≥98% HPLC trans-resveratrol from \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e) at a dose that overlaps the cited human-trial range. Individual results vary.\u003c\/em\u003e\u003c\/p\u003e\n\n\u003chr\u003e\n\u003cp style=\"font-size:0.85em;line-height:1.55;\"\u003e\u003cem\u003e\u003cstrong\u003eFDA disclaimer:\u003c\/strong\u003e These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your physician before starting any new supplement, particularly if you are pregnant, nursing, taking prescription medication (especially anticoagulants, antiplatelets, hormone-sensitive cancer treatments, CYP3A4 substrates), or have a known medical condition.\u003c\/em\u003e\u003c\/p\u003e\n\n\u003cdiv class=\"th-why-not-amazon\" style=\"margin:48px 0 24px;padding:24px;background:#f8f4ee;border-left:4px solid #9a5b3e;border-radius:6px;\"\u003e\n  \u003ch3 style=\"margin-top:0;\"\u003eWhy we don't sell this on Amazon\u003c\/h3\u003e\n  \u003cp\u003eAmazon's resveratrol category is a graveyard of UV-Vis-assayed knotweed extract sold as \"98% pure\" with no HPLC trans-anomer verification, ambiguous source-of-origin, and zero per-batch COA visibility. The sub-$15 price points only work because the active ingredient is partially cis-isomer drift — not the molecule any of the trials measured. We sell direct so we control the source (≥98% HPLC trans-resveratrol from \u003cem\u003ePolygonum cuspidatum\u003c\/em\u003e), the per-batch COA stays public, and we can charge for verifiable molecular-grade material instead of competing with the bottom of the marketplace. Per active mg of trans-resveratrol, we're typically cheaper too. The math + the data: \u003ca href=\"\/he\/pages\/why-not-amazon\" style=\"color:#9a5b3e;font-weight:600;\"\u003eread the full breakdown →\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv class=\"th-how-to\" style=\"margin:32px 0;padding:20px;border:1px solid #e0d5c8;border-radius:8px;\"\u003e\n  \u003ch3 style=\"margin-top:0;\"\u003eHow to take Resveratrol 600mg\u003c\/h3\u003e\n  \u003cul style=\"line-height:1.7;\"\u003e\n    \u003cli\u003e\n\u003cstrong\u003eWhen:\u003c\/strong\u003e With breakfast or lunch — whichever has the most fat. Eggs, avocado, butter, fatty fish, olive oil all work.\u003c\/li\u003e\n    \u003cli\u003e\n\u003cstrong\u003eDose:\u003c\/strong\u003e 1 capsule daily (600 mg).\u003c\/li\u003e\n    \u003cli\u003e\n\u003cstrong\u003eAvoid empty-stomach dosing\u003c\/strong\u003e — fasted bioavailability is roughly half of fed.\u003c\/li\u003e\n    \u003cli\u003e\n\u003cstrong\u003eAvoid evening dosing\u003c\/strong\u003e — cerebral blood-flow upregulation can interfere with sleep onset.\u003c\/li\u003e\n    \u003cli\u003e\n\u003cstrong\u003eBest paired with\u003c\/strong\u003e: \u003ca href=\"\/he\/products\/pure-nmn-500mg-60-capsules-30-day-supply\" style=\"color:#9a5b3e;\"\u003eNMN 500mg\u003c\/a\u003e (or get both at -10% as the \u003ca href=\"\/he\/products\/longevity-stack-bundle-nmn-500mg-resveratrol-600mg\" style=\"color:#9a5b3e;\"\u003eLongevity Stack Bundle\u003c\/a\u003e).\u003c\/li\u003e\n    \u003cli\u003e\n\u003cstrong\u003eBottle = 30 days\u003c\/strong\u003e at 1 capsule daily. The cardiometabolic biomarker timeline is 8–12 weeks; budget 3 bottles before your first re-test.\u003c\/li\u003e\n  \u003c\/ul\u003e\n  \u003cp style=\"margin-bottom:0;\"\u003e→ \u003ca href=\"\/he\/protocols\/how-to-take-it\" style=\"color:#9a5b3e;font-weight:600;\"\u003eFull protocol guide for the entire stack\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv class=\"th-footer-links\" style=\"margin-top:48px;padding-top:24px;border-top:1px solid #e0d5c8;\"\u003e\n  \u003ch3 style=\"margin-bottom:12px;\"\u003eHave a specific question?\u003c\/h3\u003e\n  \u003cp style=\"margin:0 0 16px;\"\u003e→ \u003ca href=\"\/he\/pages\/faq\" style=\"color:#9a5b3e;\"\u003eFAQ — 20 most common questions\u003c\/a\u003e covers shipping, kashrut, drug interactions, refunds, dosing.\u003c\/p\u003e\n  \u003cp style=\"margin:0 0 16px;\"\u003e→ \u003ca href=\"\/he\/pages\/coa\" style=\"color:#9a5b3e;\"\u003eLab reports for every batch\u003c\/a\u003e — verifiable third-party COAs.\u003c\/p\u003e\n  \u003cp style=\"margin:0;\"\u003e→ Or just \u003ca href=\"mailto:kat@truehealthprotocol.health\" style=\"color:#9a5b3e;\"\u003eemail me directly\u003c\/a\u003e. I respond within 24 hours.\u003c\/p\u003e\n\u003c\/div\u003e\n","brand":"True Health Protocol","offers":[{"title":"Default Title","offer_id":47696174940378,"sku":"THP-RESV-600-60","price":29.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0814\/5158\/1658\/files\/resveratrol_02.jpg?v=1774728960"},{"product_id":"nmn-1000mg-double-strength-60-capsules-30-day-supply","title":"NMN 1000mg | Double Strength | β-NMN for NAD+, Sirtuins \u0026 Cellular Longevity","description":"\u003cp\u003e\u003cstrong\u003e1000 mg of β-NMN per capsule, 99%+ HPLC-tested.\u003c\/strong\u003e The double-strength NAD+ precursor for adults over 50, anyone running a metabolically demanding training or recovery cycle, post-menopausal physiologies navigating the steeper NAD+ decline, and the people who tried 500 mg for two months and felt nothing — the published trial range (Yoshino 2021 \u003cem\u003eScience\u003c\/em\u003e, Yamaguchi 2022, Liao 2021, Igarashi 2022) places NMN's measurable effects in the 250–900 mg\/day window, and the high end of that window is where the slower-responding, older, more depleted physiologies usually land.\u003c\/p\u003e\n\n\u003ch2\u003eThe 30-second answer\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e1000 mg β-NMN, single capsule, daily.\u003c\/strong\u003e The double-strength version of our NMN line — choose this if you're 50+, stacking against a high cortisol or training load, navigating menopause or andropause, recovering from illness or surgery, or didn't notice an effect at 500 mg after 6–8 weeks of consistent daily use.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNAD+ falls roughly 50% between age 40 and 60\u003c\/strong\u003e (Massudi 2012 \u003cem\u003ePLoS ONE\u003c\/em\u003e, McReynolds 2020 \u003cem\u003eCell Metabolism\u003c\/em\u003e) and the dose required to push tissue NAD+ back toward youthful range scales with how depleted you started. The Yoshino 2021 prediabetic-women trial used 250 mg and saw insulin-sensitivity gains; Yamaguchi 2022 ran 250 mg in older adults and saw walking-speed and grip-strength gains; Liao 2021 dose-finding tested up to 600 mg and saw a clear walking-speed plateau past that point in older adults; practitioner protocols routinely run 500–1000 mg for the population already noticing the decline.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBest taken:\u003c\/strong\u003e morning, with breakfast, daily, not cycled. Pair with a methyl donor (TMG \/ trimethylglycine) if you're stacking heavily — see \u003cem\u003eStacking\u003c\/em\u003e below.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOne capsule = 30-day supply.\u003c\/strong\u003e No proprietary blend, no fillers, vegan HPMC capsule, third-party COA available on request.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWhy NMN sits at the center of the longevity stack\u003c\/h2\u003e\n\u003cp\u003eNAD+ (nicotinamide adenine dinucleotide) is the coenzyme your cells use to do four jobs that all decline with age:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRun the electron transport chain\u003c\/strong\u003e — NAD+\/NADH is the redox shuttle that lets Complex I of the mitochondrial inner membrane accept electrons from the Krebs cycle and pass them down the chain to drive ATP synthesis. No NAD+, no electron flow, no ATP. Mitochondrial dysfunction is one of the canonical hallmarks of aging in the López-Otín 2013 framework and remains so in the 2023 update.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eActivate sirtuins\u003c\/strong\u003e — SIRT1, SIRT3, and SIRT6 are NAD+-dependent deacetylases that regulate the cellular stress response, mitochondrial biogenesis, DNA repair, telomere maintenance, and inflammation control. They literally \u003cem\u003econsume\u003c\/em\u003e NAD+ to do their job — every deacetylation reaction cleaves NAD+ — and their activity drops as NAD+ falls. Sirtuin underactivity is downstream of NAD+ depletion, not a parallel problem.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePower DNA repair\u003c\/strong\u003e — PARP enzymes (poly-ADP-ribose polymerases) consume NAD+ to repair single-strand DNA breaks. The more genomic damage accumulates with age, sun exposure, oxidative stress, or chronic inflammation, the more PARP activity climbs and the more NAD+ gets pulled out of the available pool. This is one of the mechanisms by which chronic inflammation and lifestyle stress accelerate the NAD+ decline.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRegulate the circadian clock\u003c\/strong\u003e — NAMPT (nicotinamide phosphoribosyltransferase, the rate-limiting enzyme in the salvage pathway that recycles nicotinamide back to NMN) is itself clock-regulated, and SIRT1 deacetylates BMAL1 in the core clock loop. NAD+ has a measurable daily rhythm driven by this feedback. Disrupted sleep, shift work, and chronic late-night light exposure flatten that rhythm and drop average tissue NAD+.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eNMN (β-nicotinamide mononucleotide) is a single enzymatic step (catalyzed by NMNAT1\/2\/3 in different cellular compartments) away from NAD+. Of the three commonly available oral NAD+ precursors — NR (nicotinamide riboside), NMN, and niacinamide — NMN is the most direct precursor and the most heavily studied in the human longevity-focused trial literature between 2020 and 2024. Niacinamide raises NAD+ but inhibits sirtuins at high doses (it's a feedback inhibitor); NR has a longer published safety database and a different absorption pathway (the SLC12A8 transporter for NMN was characterized in 2019 by Grozio et al. \u003cem\u003eNature Metabolism\u003c\/em\u003e); the practical case for NMN is conversion efficiency and the depth of recent trial work in the older-adult population.\u003c\/p\u003e\n\n\u003ch2\u003eWhy double strength — the case for 1000 mg over 500 mg\u003c\/h2\u003e\n\u003cp\u003eThe 500 mg dose (see \u003ca href=\"\/he\/products\/pure-nmn-500mg-60-capsules-30-day-supply\"\u003ePure NMN 500 mg\u003c\/a\u003e) is the right starting point for under-50 longevity-baseline use. The practical reasons people step up to 1000 mg:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAge 50+.\u003c\/strong\u003e NAD+ decline is steeper between 50 and 70 across multiple tissues (Massudi 2012 measured ~50% drop between age 40 and 60 in human skin; McReynolds 2020 confirmed similar decline curves in plasma and PBMCs). NAMPT expression falls in skeletal muscle and adipose tissue. CD38 expression rises with inflammaging, and CD38 is the dominant NAD+-degrading enzyme. Conversion efficiency from oral NMN to tissue NAD+ drops alongside. The higher dose offsets the lower conversion, not just the lower starting point.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMetabolic stress.\u003c\/strong\u003e Acute or chronic illness, intense training cycles, recovery from injury, high-stress career periods, jet lag and shift work, and post-surgical recovery all consume more NAD+. PARP activity climbs with DNA damage; sirtuin demand climbs with metabolic load; CD38 expression rises with inflammation. The 1000 mg dose has more headroom for the population that needs it.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePost-menopausal and andropausal physiology.\u003c\/strong\u003e Estrogen supports NAMPT expression; the post-menopausal drop in estrogen is associated with a measurably steeper NAD+ decline. The Yoshino 2021 \u003cem\u003eScience\u003c\/em\u003e trial that produced the cleanest insulin-sensitivity signal was specifically run in overweight, prediabetic, post-menopausal women — a population where higher precursor doses are the practitioner default.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e500 mg didn't move the needle.\u003c\/strong\u003e Some people are simply lower oral responders — pharmacokinetics vary based on SLC12A8 expression, gut microbiome composition affects degradation, CD38 expression varies several-fold between individuals. Stepping to 1000 mg before concluding NMN doesn't work for you is the standard practitioner next step.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConvenience.\u003c\/strong\u003e One capsule in the morning instead of two, one bottle per month instead of half a bottle, simpler travel kit.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAbove 1000 mg, the dose-response data is still maturing. The Liao 2021 dose-finding study tested up to 600 mg\/day and saw a clear plateau in walking speed past that point. Higher doses (1200–2000 mg) appear in some practitioner protocols and in the Pencina 2023 PK study (single 1000 mg oral dose tracked across 24 hours), but don't yet have the published RCT outcome support that the 250–1000 mg range does. We position 1000 mg as the high end of the well-evidenced range.\u003c\/p\u003e\n\n\u003ch2\u003eThe trial bench — what the 250–1000 mg human RCT data actually shows\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eYoshino 2021 (\u003cem\u003eScience\u003c\/em\u003e) — 250 mg\/day, 10 weeks, 25 overweight prediabetic post-menopausal women.\u003c\/strong\u003e Primary endpoint was muscle insulin sensitivity (hyperinsulinemic-euglycemic clamp). NMN group showed a 25% improvement in muscle insulin sensitivity and upregulation of muscle insulin-signaling and remodeling genes. Plasma NAD+ metabolite changes were measured but the headline was the functional metabolic signal.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eYamaguchi 2022 — 250 mg\/day, 12 weeks, older adult men.\u003c\/strong\u003e Walking speed and grip strength both improved measurably vs placebo. Sleep quality (PSQI score) improved. NAD+ blood metabolites rose.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLiao 2021 — 300\/600\/900 mg\/day dose-finding RCT, 60 days, older adults.\u003c\/strong\u003e Six-minute walk distance improved dose-dependently up to 600 mg, then plateaued. No safety signals across the dose range. Blood NAD+ rose at all three doses.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIgarashi 2022 (\u003cem\u003enpj Aging\u003c\/em\u003e) — 250 mg\/day, 12 weeks, older adults.\u003c\/strong\u003e Whole-blood NAD+ rose ~50% from baseline. Gait speed improved measurably; the effect was strongest in the lower-baseline-NAD+ subgroup, consistent with the dose-scaling logic above.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eYi 2023 — 300\/600\/900 mg, 60 days, healthy middle-aged adults.\u003c\/strong\u003e Replicated walking-speed and biological-age (TruDiagnostic methylation clock) improvements; the 600 and 900 mg groups outperformed 300 mg on the secondary biological-age endpoint.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePencina 2023 — single-dose PK in healthy adults.\u003c\/strong\u003e Confirmed dose-proportional rise in plasma NAD+ metabolites with oral NMN up to 1000 mg, supporting the pharmacokinetic logic of the 1000 mg dose.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe pattern across this bench: the 250–600 mg window covers most of the published primary-endpoint effects, the 600–1000 mg window covers older and more depleted populations and the slower-responder subgroups, and the safety database extends cleanly through 1000 mg\/day for at least 8–12 weeks.\u003c\/p\u003e\n\n\u003ch2\u003eWhat's in it\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eβ-NMN 1000 mg per capsule, 99%+ purity, HPLC-verified per batch, third-party tested for heavy metals (lead, arsenic, cadmium, mercury), microbial contamination, and identity confirmation\u003c\/li\u003e\n  \u003cli\u003eVegetable cellulose (HPMC) capsule shell — vegan, no gelatin\u003c\/li\u003e\n  \u003cli\u003eNo magnesium stearate, no silicon dioxide, no titanium dioxide, no rice flour bulking, no artificial colors, no proprietary blend, no synthetic excipients\u003c\/li\u003e\n  \u003cli\u003e60 capsules per bottle — 30-day supply at the standard 1 capsule\/day dose, 60-day supply if running 1 capsule every other day during a maintenance phase or alternating with a 500 mg daily dose\u003c\/li\u003e\n  \u003cli\u003eUV-protective HDPE bottle to limit photodegradation; refrigeration not required for unopened or in-use bottles, but cool-and-dry storage extends shelf life\u003c\/li\u003e\n  \u003cli\u003ecGMP-certified manufacturing facility; per-batch certificate of analysis available on request via support@truehealthprotocol.health\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eDaily protocol\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDefault:\u003c\/strong\u003e 1 capsule (1000 mg) in the morning with breakfast, daily, not cycled. Plasma NAD+ rises within hours; tissue NAD+ rises gradually over 2–4 weeks of consistent intake. Consistency beats dose escalation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTime-restricted eating window:\u003c\/strong\u003e take with the first meal that breaks your fast, not before. NMN has minor insulinotropic activity in some users; pairing with food smooths the response and supports the SLC12A8 transporter that handles intestinal uptake.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEvening dose pattern:\u003c\/strong\u003e not recommended. NAD+ has a circadian peak in the morning and trough in late evening; evening NMN can blunt the natural decline that allows for nighttime mitochondrial repair, autophagy, and circadian sirtuin activity (SIRT1's role in BMAL1 deacetylation).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMaintenance phase:\u003c\/strong\u003e after 6+ months of daily 1000 mg, some users drop to 1000 mg every other day or alternate with 500 mg. This is preference, not a clinical recommendation — daily 1000 mg is also fine indefinitely based on the available safety data.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf transitioning from 500 mg:\u003c\/strong\u003e step straight to 1000 mg, no titration needed. NMN doesn't have the GI tolerance issue that berberine, magnesium citrate, or high-dose NAC can have at the upper end.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you miss a dose:\u003c\/strong\u003e resume the next day at 1000 mg. Don't double up. Tissue NAD+ has enough buffer that a single missed day is invisible at this point.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTravel:\u003c\/strong\u003e the bottle ships sealed; transfer the day's dose to a small pillbox if you're not bringing the whole bottle. NMN is reasonably temperature-stable for short transit; avoid leaving the bottle in a hot car for prolonged periods.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eStacking — what NMN works harder with\u003c\/h2\u003e\n\u003cp\u003eNMN is a precursor. It raises the pool. The molecules that \u003cem\u003euse\u003c\/em\u003e the pool are where the longevity benefits show up:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTMG (Trimethylglycine) — methylation buffer.\u003c\/strong\u003e NMN → NAD+ → consumption by sirtuins\/PARP → nicotinamide → methylation by NNMT (consumes a methyl group from SAMe) → 1-methylnicotinamide → excretion. At sustained 1000 mg\/day NMN intake, methyl-donor demand rises measurably. TMG donates methyl groups directly via the BHMT pathway. Practitioner stacks running 1000 mg+ NMN typically pair 500–1000 mg TMG. \u003ca href=\"\/he\/products\/tmg-1000mg-trimethylglycine-methyl-donor-for-nmn-nad-stacks\"\u003eTMG 1000 mg\u003c\/a\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eResveratrol — sirtuin activation.\u003c\/strong\u003e SIRT1 is NAD+-dependent \u003cem\u003eand\u003c\/em\u003e resveratrol-activated (Howitz 2003 \u003cem\u003eNature\u003c\/em\u003e, Lagouge 2006 \u003cem\u003eCell\u003c\/em\u003e, Baur 2006 \u003cem\u003eNature\u003c\/em\u003e). The pairing is the classic Sinclair-lab combo — NMN raises the substrate, resveratrol pulls it through the enzyme. \u003ca href=\"\/he\/products\/resveratrol-600mg-60-capsules-30-day-supply\"\u003eResveratrol 600 mg\u003c\/a\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePterostilbene — methylated resveratrol analog.\u003c\/strong\u003e Higher oral bioavailability than resveratrol (Walle 2004 \u003cem\u003eDrug Metab Dispos\u003c\/em\u003e ~5% vs Kapetanovic 2011 ~80% for pterostilbene), longer half-life, and the same SIRT1 activation profile. Many users running NMN 1000 mg pair pterostilbene rather than resveratrol on PK grounds. \u003ca href=\"\/he\/products\/pterostilbene-100mg-trans-sirt1-activator-resveratrol-cousin\"\u003ePterostilbene 100 mg\u003c\/a\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLiposomal NAD+ — finished coenzyme delivery.\u003c\/strong\u003e NMN gives you the precursor; liposomal NAD+ delivers the finished molecule via phospholipid encapsulation that bypasses the gastric breakdown that limits direct oral NAD+. Some users stack NMN AM + Liposomal NAD+ early afternoon to bridge the natural circadian dip. \u003ca href=\"\/he\/products\/liposomal-nad-ultimate-1000mg\"\u003eLiposomal NAD+ Ultimate 1000 mg\u003c\/a\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eApigenin — CD38 inhibition.\u003c\/strong\u003e CD38 is the primary NAD+-degrading enzyme and its expression rises with age and inflammaging (Camacho-Pereira 2016 \u003cem\u003eCell Metabolism\u003c\/em\u003e). Apigenin (50 mg from chamomile\/parsley extract) inhibits CD38 in vitro and slows the leak rate, which means more of the NMN you take ends up as tissue NAD+ rather than getting cleaved back to nicotinamide. \u003ca href=\"\/he\/products\/apigenin-50mg-cd38-inhibitor-for-nmn-nad-stacks\"\u003eApigenin 50 mg + BioPerine\u003c\/a\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCoQ10 + PQQ — mitochondrial complement.\u003c\/strong\u003e NAD+ feeds Complex I; CoQ10 carries electrons from Complex I\/II to Complex III; PQQ supports mitochondrial biogenesis via PGC-1α. The trio addresses the mitochondrial axis from substrate to electron carrier to capacity. \u003ca href=\"\/he\/products\/coq10-400mg-maximum-strength\"\u003eCoQ10 400 mg\u003c\/a\u003e · \u003ca href=\"\/he\/products\/pqq-20mg-mitochondrial-biogenesis-activator\"\u003ePQQ 20 mg\u003c\/a\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUrolithin A — mitophagy.\u003c\/strong\u003e NMN raises substrate; UroA clears the dysfunctional mitochondria via PINK1\/Parkin-driven mitophagy (Andreux 2019 \u003cem\u003eNature Metabolism\u003c\/em\u003e, Liu 2022 \u003cem\u003eJAMA Network Open\u003c\/em\u003e, Singh 2022 \u003cem\u003eCell Reports Medicine\u003c\/em\u003e). The renewal loop is feed → use → clear → biogenesis. \u003ca href=\"\/he\/products\/urolithin-a-500mg-mitophagy-activator\"\u003eUrolithin A 500 mg\u003c\/a\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBerberine — AMPK side of the longevity map.\u003c\/strong\u003e The four-pathway longevity stack is sirtuins (NMN\/Resveratrol) + AMPK (Berberine\/metformin) + autophagy (Spermidine) + senolytics (Fisetin\/Quercetin). NMN handles the sirtuin leg. \u003ca href=\"\/he\/products\/berberine-hcl-500mg-maximum-strength\"\u003eBerberine 500 mg\u003c\/a\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSpermidine — autophagy.\u003c\/strong\u003e NMN supports cellular fuel and signaling; spermidine triggers the cellular cleanup process (autophagy) that recycles damaged proteins and organelles. The two operate on different but reinforcing axes of the longevity map. \u003ca href=\"\/he\/products\/spermidine-10mg-wheat-germ-extract\"\u003eSpermidine 10 mg\u003c\/a\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFoundational layer — magnesium glycinate, omega-3, vitamin D3+K2.\u003c\/strong\u003e These aren't longevity-specific, but mitochondrial function depends on them as cofactors. If your foundational layer is weak, the precursor stack underperforms. \u003ca href=\"\/he\/products\/magnesium-glycinate-400mg-sleep-and-nad-methylation\"\u003eMagnesium Glycinate 400 mg\u003c\/a\u003e · \u003ca href=\"\/he\/products\/omega-3-fish-oil-2000mg-epa-dha\"\u003eOmega-3 Fish Oil 2000 mg\u003c\/a\u003e · \u003ca href=\"\/he\/products\/vitamin-d3-5000-iu-k2-mk-7-100mcg\"\u003eVitamin D3 + K2\u003c\/a\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWhat this product is — and what it is NOT\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eThis is:\u003c\/strong\u003e a high-dose, single-ingredient β-NMN capsule positioned for the older-adult and metabolically-stressed end of the longevity-supplement market, where the published RCT support sits at 600–1000 mg\/day rather than the 250 mg headline doses.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThis is not:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNot a stimulant.\u003c\/strong\u003e NMN is not caffeine. The \"morning energy\" some users report is downstream of better mitochondrial ATP output, not a sympathomimetic effect. Don't expect the kick of a pre-workout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNot a treatment for any disease.\u003c\/strong\u003e NMN is a dietary supplement. The Yoshino 2021 insulin-sensitivity signal is research-grade evidence in a specific population, not a clinical claim for diabetes management.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNot a one-month thing.\u003c\/strong\u003e Tissue NAD+ rises over weeks and the longevity-relevant downstream effects (sirtuin activity, mitochondrial biogenesis, DNA repair throughput) compound over months. Single-bottle results are usually subjective; multi-month results are where the published outcomes sit.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNot a substitute for sleep, training, or protein.\u003c\/strong\u003e NMN amplifies the foundational work; it doesn't replace it. A 1000 mg NMN dose into a 5-hour-sleep, sedentary, undernourished baseline produces less than a 500 mg dose into a well-managed baseline.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNot the right starting point if you've never taken NMN before.\u003c\/strong\u003e Start with \u003ca href=\"\/he\/products\/pure-nmn-500mg-60-capsules-30-day-supply\"\u003ePure NMN 500 mg\u003c\/a\u003e for 6–8 weeks, then step up to 1000 mg if the response was minimal. There's no risk to starting at 1000 mg, but the cost-per-effect math favors the lower dose for younger or less depleted physiologies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWho this is for, who this is not for\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eStrong fit:\u003c\/strong\u003e adults 50+, post-menopausal women navigating the steeper NAD+ decline, andropausal men, athletes and high-training-volume populations, recovery-from-illness or post-surgical phases, anyone who tried 500 mg for 6–8 weeks and didn't notice the morning-energy or afternoon-clarity shift most users describe in weeks 2–4, anyone running the Cellular Longevity protocol who wants the higher-dose precursor floor, shift workers and frequent international travelers whose circadian rhythm is chronically perturbed, anyone with an elevated chronic-inflammation baseline (high CRP, autoimmune background, post-infectious recovery).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNot a fit \/ talk to your physician first:\u003c\/strong\u003e active or recent cancer history (NAD+ supports both healthy and malignant cells; the precautionary practitioner default is to avoid precursor supplementation during active treatment and for the first 12 months after remission, until oncology clears), pregnancy and lactation (no human safety data), under 30 with no specific NAD+-related indication (the decline curve isn't steep enough yet to justify the cost — start with foundations), anyone on chemotherapeutic protocols where NAD+ status is part of the treatment design, anyone with rare PARP-related genetic conditions (talk to a clinical geneticist first).\u003c\/p\u003e\n\n\u003ch2\u003eWhat to expect on the timeline\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDays 1–14:\u003c\/strong\u003e usually nothing dramatic. Plasma NAD+ rises within hours of the first dose; tissue NAD+ accumulates over weeks; the metabolic effects compound below the level of subjective awareness for most users in this window. A minority report cleaner mornings inside the first week — usually the more depleted or higher-stress baselines.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeeks 2–4:\u003c\/strong\u003e easier mornings, steadier afternoon energy, fewer post-lunch crashes — the most commonly reported subjective shifts and consistent with the Yamaguchi 2022 grip-strength + walking-speed timeline. Sleep onset and sleep quality (PSQI subjective measure) often improve in parallel; this is downstream of better daytime mitochondrial function, not a sedating effect.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeeks 4–8:\u003c\/strong\u003e baseline cellular energy, exercise recovery, and mental clarity build noticeably. Skin appearance improves in some users (sirtuin activity in the dermal layer, mitochondrial function in keratinocytes). Hair appearance changes lag further.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeeks 8–12:\u003c\/strong\u003e the window where the published RCT primary endpoints land — improved insulin sensitivity (Yoshino 2021 at 10 weeks), preserved walking speed in older adults (Yamaguchi 2022 at 12 weeks, Igarashi 2022 at 12 weeks), endothelial function gains (de Picciotto 2016 in NR but mechanism shared).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMonths 3+:\u003c\/strong\u003e the compound-interest phase. Sustained sirtuin activation, ongoing mitochondrial biogenesis, accumulating DNA-repair throughput, and the long-tail effects on biological age (Yi 2023 methylation-clock signal at 60 days, longer cohorts ongoing). This is the window the longevity literature is built on; the first 8 weeks are mostly the loading curve.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon mistakes to avoid\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCycling.\u003c\/strong\u003e NMN is not a stimulant or hormone-modulator. There's no published rationale for 5-on\/2-off or month-on\/month-off cycling. Daily intake is the trial design, daily intake is the practitioner default.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEmpty-stomach evening dosing.\u003c\/strong\u003e Maximizes the wrong things — bypasses food-coupled SLC12A8 uptake support, blunts the natural circadian NAD+ trough that nighttime repair processes depend on. Morning + with breakfast is the trial-replicated pattern.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSkipping the methyl-donor buffer.\u003c\/strong\u003e Sustained 1000 mg\/day NMN with no dietary methyl support can produce subtle methyl-depletion symptoms (low-grade fatigue, irritability) in MTHFR variants and restricted-diet users. The TMG add-on is cheap insurance.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStacking too many NAD+ products simultaneously.\u003c\/strong\u003e The catalog has NMN 500, NMN 1000, NR capsules, Liquid NAD+ stick packs, Liposomal NAD+ Ultimate, NAD+ Daily Boost, NAD+ 5-in-1, NAD+ 1000 Pure Focus. Pick one or two complementary products (e.g., NMN AM + Liposomal NAD+ early afternoon) — running four NAD+ products at once is wasted spend.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExpecting a kick.\u003c\/strong\u003e NMN is a substrate-level intervention; the effects compound over weeks. Users expecting day-1 caffeine-like perception usually conclude the product doesn't work and quit before week 4 — which is roughly when the Yamaguchi\/Igarashi gait-speed signal becomes detectable.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eQuitting at week 4.\u003c\/strong\u003e The RCT primary endpoints land at 10–12 weeks. If you're going to evaluate whether NMN is working for you, run at least one full bottle through and ideally two.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eFAQ\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e1000 mg NMN — is that too much?\u003c\/strong\u003e The Liao 2021 dose-finding RCT tested 300, 600, and 900 mg\/day for 60 days in older adults and reported no safety signals across the range. The Pencina 2023 single-dose PK study extended to 1000 mg. The published dose-finding work doesn't yet extend cleanly past 1200 mg, which is why we cap our line at 1000 mg as the high end of the well-evidenced range. Practitioner protocols running higher exist, but the published RCT support beyond ~1000 mg is still maturing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNMN vs NR — which actually works?\u003c\/strong\u003e NR (nicotinamide riboside) was the first oral NAD+ precursor with major clinical trial support (Trammell 2016 \u003cem\u003eNature Communications\u003c\/em\u003e, Martens 2018 \u003cem\u003eNature Communications\u003c\/em\u003e). NMN is one enzymatic step closer to NAD+ and has built up its own RCT base since 2020 (Yoshino, Yamaguchi, Liao, Igarashi, Yi). Head-to-head RCTs comparing NMN and NR at matched doses are still rare; both raise blood NAD+ in trials. The practical difference: NMN's dose-response curve appears slightly steeper at the older-adult end, NR's safety database is longer (12+ years post-Chromadex commercial availability vs ~5–6 years for oral NMN). Either is a reasonable choice; the catalog stocks both — see \u003ca href=\"\/he\/products\/rb-nicotinamide-nucleotide-nad-hard-capsules-cellular-energy-anti-aging\"\u003eNicotinamide Riboside (NR) capsules\u003c\/a\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDo I need TMG with 1000 mg NMN?\u003c\/strong\u003e Methylation demand rises with sustained high-dose NMN intake because nicotinamide is methylated and excreted via NNMT, which pulls methyl groups from SAMe. For most users on 1000 mg\/day, dietary methyl donors (eggs, leafy greens, beets, beef liver) are sufficient. For users on restricted diets, MTHFR variants, or running NMN + methylated B vitamins simultaneously, adding 500–1000 mg TMG is the standard practitioner adjustment. It's a buffer, not a requirement — symptoms of low-grade methyl-donor depletion are subtle (fatigue, irritability, mild anxiety) and respond quickly to TMG if they appear.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eShould I worry about NMN and cancer?\u003c\/strong\u003e The precautionary position is to avoid NAD+ precursor supplementation during active cancer treatment and for the first 12 months post-remission, then re-evaluate with the oncology team. The reasoning: NAD+ supports DNA repair and metabolic function in all cells, including malignant ones, and some chemotherapeutic protocols intentionally target the NAD+ pathway (CD38-targeting daratumumab, NAMPT inhibitors in certain hematological malignancies). The data here is mixed and rapidly evolving — there are arguments both for and against precursor supplementation in oncology contexts. Default to caution and physician oversight.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhy morning, not evening?\u003c\/strong\u003e NAD+ has a circadian rhythm — peak in the morning, trough late evening. The trough is when nighttime mitochondrial repair, autophagy, and circadian sirtuin activity (SIRT1's role in BMAL1 regulation, the clock-gene feedback loop) happen. Adding NMN evening can blunt the natural trough. Morning dosing rides the circadian peak and aligns with the metabolic demand of the active day. Yamaguchi 2022 specifically noted improved subjective sleep quality with morning NMN dosing — the mechanism is downstream of better daytime mitochondrial function, not a sedative effect.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCan I take NMN with metformin?\u003c\/strong\u003e Yes. NMN raises the NAD+ pool and feeds the sirtuin leg of the longevity map; metformin works primarily through the AMPK leg. The two address different and complementary nodes. There's no published interaction concern. Many longevity protocols run both. (This is general information, not medical advice — talk to your prescriber.)\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCan I take NMN with statins, blood thinners, or blood pressure medications?\u003c\/strong\u003e No published interactions with statins or common antihypertensives. NMN has minor effects on platelet function in vitro at high concentrations; if you're on warfarin, apixaban, or another anticoagulant, mention NMN to your prescriber and check INR if applicable. The clinical signal is small; the precaution is standard supplement-medication overlap practice.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eTime to first noticeable effect — honestly?\u003c\/strong\u003e Most users report something in weeks 2–4 (cleaner mornings, fewer afternoon energy crashes, easier exercise recovery). A meaningful minority report nothing dramatic for the first 6–8 weeks and then an inflection. About 10–15% report no noticeable subjective shift even at 1000 mg over 8+ weeks — these are the lower oral responders, and at that point the question is whether you're chasing a measurable outcome (NAD+ blood test, improved fasting glucose, grip strength, biological-age clock) or a subjective one. The measurable outcomes show up more reliably than the subjective ones.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCan I open the capsule and mix it into a drink?\u003c\/strong\u003e Yes, but two caveats: NMN is mildly hygroscopic and acid-sensitive, so mix it cold (water, smoothie, kefir) and consume immediately rather than letting it sit. Hot coffee or hot tea will accelerate degradation. The capsule shell is HPMC and dissolves cleanly anyway, so most users don't bother opening it.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDoes NMN need to be refrigerated?\u003c\/strong\u003e The unopened bottle is stable at room temperature in the UV-protective HDPE container; cool-and-dry storage extends shelf life. Some longevity influencers refrigerate; it's not required for stability inside the labeled shelf life. Don't freeze (no benefit, condensation risk on the capsule shell when warming back up).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eIs there an Amazon version that's cheaper?\u003c\/strong\u003e The β-NMN supply chain has substantial purity and isomer-mix variation. α-NMN is biologically inactive; some lower-cost listings run undeclared mixed-isomer material, lower purity (~95% or below), no third-party COA, or rice-flour bulking inside the capsule. Per-mg-of-true-active cost is often higher on the cheap-looking listings once you account for actual β-NMN content. Our pricing is built around 99%+ HPLC-verified β-NMN with per-batch COA available — the math works out competitive once like-for-like.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eI'm under 40 — do I need this?\u003c\/strong\u003e Probably not the 1000 mg dose. The decline curve below 40 is shallow enough that 500 mg or even foundational stack work (sleep, training, methylation support, omega-3 status) covers most of the actionable surface. \u003ca href=\"\/he\/products\/pure-nmn-500mg-60-capsules-30-day-supply\"\u003ePure NMN 500 mg\u003c\/a\u003e is the under-50 default. Step up if and when the lower dose stops feeling like enough.\u003c\/p\u003e\n\n\u003ch2\u003eQuality and sourcing\u003c\/h2\u003e\n\u003cp\u003eβ-NMN, 99%+ purity, HPLC-verified per batch. The β-isomer matters — α-NMN is biologically inactive; some lower-cost NMN supplements run mixed-isomer or undeclared-isomer material, which is one of the more common ways the per-mg-of-true-active cost balloons on cheap-looking listings. Third-party tested for heavy metals (lead, arsenic, cadmium, mercury), microbial contamination (total plate count, yeast\/mold, E. coli, Salmonella), and identity confirmation. COA available on request via support@truehealthprotocol.health. Manufactured in a cGMP-certified US facility. UV-protective HDPE bottle to limit photodegradation. Vegan HPMC capsule shell — no gelatin, no titanium dioxide, no artificial colors.\u003c\/p\u003e\n\n\u003ch2\u003eRead more\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003ca href=\"\/he\/blogs\/news\/nmn-vs-nad-which-should-you-take-in-2026\"\u003eNMN vs NAD+ — which should you take in 2026\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"\/he\/blogs\/news\/best-time-to-take-nmn-morning-empty-stomach-or-with-food\"\u003eBest time to take NMN\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"\/he\/blogs\/news\/nmn-side-effects-what-the-research-actually-shows\"\u003eNMN side effects — what the research shows\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"\/he\/blogs\/news\/nmn-vs-nr-which-nad-precursor-actually-works-better\"\u003eNMN vs NR — comparison\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"\/he\/blogs\/news\/longevity-supplements-after-40-what-changes-and-what-to-add\"\u003eLongevity supplements after 40\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"\/he\/pages\/protocols\"\u003eCellular Longevity Protocol\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"\/he\/collections\/nad-precursors\"\u003eNAD+ Precursor collection\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cem\u003eThis product is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. Consult your physician before starting any supplement, especially if you take prescription medication, are pregnant or nursing, have an active or recent cancer history, or have a medical condition. References cited (Yoshino 2021 \u003cem\u003eScience\u003c\/em\u003e, Yamaguchi 2022, Liao 2021, Igarashi 2022 \u003cem\u003enpj Aging\u003c\/em\u003e, Yi 2023, Pencina 2023, Trammell 2016 \u003cem\u003eNature Communications\u003c\/em\u003e, Martens 2018, Massudi 2012 \u003cem\u003ePLoS ONE\u003c\/em\u003e, McReynolds 2020 \u003cem\u003eCell Metabolism\u003c\/em\u003e, López-Otín 2013\/2023 \u003cem\u003eCell\u003c\/em\u003e, Howitz 2003 \u003cem\u003eNature\u003c\/em\u003e, Lagouge 2006 \u003cem\u003eCell\u003c\/em\u003e, Baur 2006 \u003cem\u003eNature\u003c\/em\u003e, de Picciotto 2016, Camacho-Pereira 2016 \u003cem\u003eCell Metabolism\u003c\/em\u003e, Grozio 2019 \u003cem\u003eNature Metabolism\u003c\/em\u003e, Walle 2004 \u003cem\u003eDrug Metab Dispos\u003c\/em\u003e, Kapetanovic 2011, Andreux 2019 \u003cem\u003eNature Metabolism\u003c\/em\u003e, Liu 2022 \u003cem\u003eJAMA Network Open\u003c\/em\u003e, Singh 2022 \u003cem\u003eCell Reports Medicine\u003c\/em\u003e) are for educational context, not implied product claims.\u003c\/em\u003e\u003c\/p\u003e\n","brand":"True Health Protocol","offers":[{"title":"Default Title","offer_id":47696176054490,"sku":"THP-NMN-1000-60","price":54.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0814\/5158\/1658\/files\/nmn_1000mg.jpg?v=1774114071"},{"product_id":"berberine-hcl-500mg-maximum-strength","title":"Berberine HCL 500mg | AMPK Activator for Glucose, Lipids \u0026 Longevity","description":"\u003cp\u003e\u003cstrong\u003e500 mg of Berberine HCl per capsule\u003c\/strong\u003e, standardized 97% from \u003cem\u003eBerberis aristata\u003c\/em\u003e (Indian barberry) root, manufactured in a cGMP-registered facility and third-party tested for identity, potency, heavy metals, microbial load, and pesticide residues. Berberine is the most-studied non-prescription AMP-activated protein kinase (AMPK) activator in the human longevity literature — the natural compound with the strongest head-to-head trial data against a first-line prescription metabolic drug, and the standard fourth pillar of any modern four-pathway longevity stack alongside NMN (sirtuins), Resveratrol (sirtuin co-activator), and Spermidine (autophagy). One of the only supplements where the trial dose, the trial duration, and the trial outcomes are reproducible and consistent across more than two decades of randomized controlled work.\u003c\/p\u003e\n\n\u003ch2\u003eThe 60-second answer\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eActivates AMPK\u003c\/strong\u003e — the cellular energy sensor often called the \"metabolic master switch.\" Active AMPK pulls glucose into muscle, oxidizes fat instead of storing it, drives mitochondrial biogenesis through PGC-1α, and inhibits mTORC1, which permits autophagy. AMPK signaling falls with age in nearly every tissue measured; berberine pushes it back toward a younger profile.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBest for:\u003c\/strong\u003e healthy fasting glucose and post-meal glucose excursions, healthy lipid profiles (LDL, triglycerides, total cholesterol), gut-microbiome modulation, visceral-fat reduction, and anyone building a longevity stack who wants the AMPK pathway covered alongside the sirtuin pathway (NMN\/resveratrol).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eThe headline trial:\u003c\/strong\u003e Yin et al. 2008 in \u003cem\u003eMetabolism\u003c\/em\u003e randomized adults with type 2 diabetes to 500 mg berberine three times daily versus 500 mg metformin three times daily for 12 weeks. Berberine produced statistically equivalent reductions in fasting plasma glucose (–3.5 mmol\/L vs –3.6 mmol\/L), HbA1c (–2.0% vs –2.1%), post-prandial glucose, triglycerides, and total cholesterol. The 2012 Dong et al. meta-analysis of 14 trials (n = 1,068) reproduced the lipid effects with statistical heterogeneity well below conventional thresholds.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDose:\u003c\/strong\u003e 500 mg, 2–3 times daily, taken with meals. Plasma half-life is short (~4 hours), so the studied dose schedule splits 1500 mg\/day across the day rather than dumping it into one capsule. Dosing once daily produces a high peak and a long sub-therapeutic trough.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCycle:\u003c\/strong\u003e the practitioner-default protocol is 8 weeks on \/ 4 weeks off, primarily to give the gut microbiome periodic breaks (berberine has direct antimicrobial activity at intestinal concentrations) and to preserve AMPK responsiveness over multi-year use. Continuous daily use also has supporters; both patterns appear safe in the published trials.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePairs with:\u003c\/strong\u003e \u003ca href=\"\/he\/products\/nmn-1000mg-double-strength-60-capsules-30-day-supply\"\u003eNMN 1000mg\u003c\/a\u003e (sirtuin\/NAD+ leg), \u003ca href=\"\/he\/products\/resveratrol-600mg-60-capsules-30-day-supply\"\u003eResveratrol 600mg\u003c\/a\u003e (sirtuin co-activator), \u003ca href=\"\/he\/products\/coq10-400mg-maximum-strength\"\u003eCoQ10 400mg\u003c\/a\u003e (mitochondrial protection — particularly important alongside any lipid intervention), \u003ca href=\"\/he\/products\/magnesium-glycinate-400mg-sleep-and-nad-methylation\"\u003eMagnesium Glycinate 400mg\u003c\/a\u003e (insulin-signaling cofactor), \u003ca href=\"\/he\/products\/omega-3-fish-oil-2000mg-epa-dha\"\u003eOmega-3 2000mg\u003c\/a\u003e (additive triglyceride lowering), \u003ca href=\"\/he\/products\/spermidine-10mg-wheat-germ-extract\"\u003eSpermidine 10mg\u003c\/a\u003e (autophagy partner), \u003ca href=\"\/he\/products\/alpha-lipoic-acid-600mg-universal-antioxidant\"\u003eAlpha-Lipoic Acid 600mg\u003c\/a\u003e (insulin sensitivity + AMPK co-activation), \u003ca href=\"\/he\/products\/calcium-alpha-ketoglutarate-1000mg-caakg-epigenetic-longevity\"\u003eCalcium AKG 1000mg\u003c\/a\u003e (epigenetic age), \u003ca href=\"\/he\/products\/ashwagandha-ksm-66-600mg\"\u003eAshwagandha KSM-66\u003c\/a\u003e (cortisol-glucose axis), \u003ca href=\"\/he\/products\/quercetin-500mg-senolytic-flavonoid-natural-antihistamine\"\u003eQuercetin 500mg\u003c\/a\u003e (senolytic + AMPK synergy), and \u003ca href=\"\/he\/products\/curcumin-1000mg-bioperine-anti-inflammatory-longevity\"\u003eCurcumin 1000mg\u003c\/a\u003e (NLRP3 \/ inflammaging).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWhy berberine sits at the center of the modern longevity map\u003c\/h2\u003e\n\n\u003cp\u003eMost supplements that get called \"longevity supplements\" earn that label through a single biological pathway. \u003ca href=\"\/he\/products\/pure-nmn-500mg-60-capsules-30-day-supply\"\u003eNMN\u003c\/a\u003e raises NAD+, which feeds the sirtuin family of deacetylases. \u003ca href=\"\/he\/products\/resveratrol-600mg-60-capsules-30-day-supply\"\u003eResveratrol\u003c\/a\u003e co-activates SIRT1 and stabilizes the PGC-1α transcriptional response. \u003ca href=\"\/he\/products\/spermidine-10mg-wheat-germ-extract\"\u003eSpermidine\u003c\/a\u003e triggers macroautophagy. Rapamycin (prescription only) directly inhibits mTORC1. Berberine is unusual in this list because it activates a fourth and arguably more upstream node — AMP-activated protein kinase — which then touches almost every other longevity lever in the cell.\u003c\/p\u003e\n\n\u003cp\u003eWhen AMPK is phosphorylated and active, four large-scale things happen at once. (1) Glucose uptake into skeletal muscle goes up via GLUT4 translocation, independent of insulin. (2) Fatty-acid oxidation goes up via inhibition of acetyl-CoA carboxylase (ACC), which lowers malonyl-CoA and frees CPT1 to import fatty acids into the mitochondrion. (3) Mitochondrial biogenesis goes up via PGC-1α phosphorylation. (4) mTORC1 signaling goes down via TSC2 and Raptor phosphorylation, and that drop in mTORC1 lifts the brake on autophagy. Active AMPK simultaneously runs the cell's \"burn fuel\" program and the cell's \"self-clean\" program — the same two programs that fasting, exercise, and caloric restriction also activate.\u003c\/p\u003e\n\n\u003cp\u003eThis is why metformin — which also activates AMPK, by partially inhibiting mitochondrial complex I and shifting the AMP\/ATP ratio — became the first drug studied as a generic geroprotective intervention (the TAME trial, \"Targeting Aging with Metformin\"). Berberine activates the same enzyme through an overlapping mechanism, and the metabolic outputs are remarkably similar across head-to-head trials. Berberine is not metformin; it has a different drug-interaction profile, a different microbiome footprint, and meaningfully less long-term safety data. But for adults who don't have a clinical indication for prescription metformin and want a clinically-studied AMPK activator, berberine is the natural compound with the deepest evidence base.\u003c\/p\u003e\n\n\u003cp\u003eThe López-Otín \"Hallmarks of Aging\" framework (2013, updated 2023) lists twelve interconnected drivers of biological aging. Berberine has published mechanistic data hitting at least seven of them: \u003cem\u003ederegulated nutrient sensing\u003c\/em\u003e (AMPK, mTOR, IGF-1), \u003cem\u003emitochondrial dysfunction\u003c\/em\u003e (biogenesis, complex I modulation), \u003cem\u003ecellular senescence\u003c\/em\u003e (SASP suppression in some cell types), \u003cem\u003echronic inflammation \/ inflammaging\u003c\/em\u003e (NF-κB and NLRP3 inhibition), \u003cem\u003ealtered intercellular communication\u003c\/em\u003e (microbiome-host signaling), \u003cem\u003eloss of proteostasis\u003c\/em\u003e (autophagy via mTOR), and \u003cem\u003egenomic instability\u003c\/em\u003e (indirect, via reduced oxidative stress). It is rare for a single natural compound to have positive published data across that many hallmarks.\u003c\/p\u003e\n\n\u003ch2\u003eThe eight mechanisms, in order of evidence strength\u003c\/h2\u003e\n\n\u003ch3\u003e1. Glucose handling — GLUT4 translocation, alpha-glucosidase inhibition, hepatic gluconeogenesis\u003c\/h3\u003e\n\u003cp\u003eBerberine activates AMPK in skeletal muscle, which signals translocation of GLUT4 glucose transporters from intracellular vesicles to the cell membrane and pulls glucose out of the bloodstream — the same insulin-independent pathway that exercise activates. In the small intestine, berberine inhibits alpha-glucosidase and slows the conversion of complex carbohydrates to absorbable monosaccharides, blunting the post-meal glucose spike. In the liver, AMPK activation suppresses gluconeogenic gene expression (PEPCK, G6Pase) and reduces fasting hepatic glucose output. The 2008 Yin head-to-head trial against metformin remains the most-cited primary evidence — both compounds produced ~25% reductions in fasting plasma glucose and ~2-point HbA1c reductions over 12 weeks at 1500 mg\/day. The 2015 Lan et al. meta-analysis of 27 trials in \u003cem\u003eJournal of Ethnopharmacology\u003c\/em\u003e (n \u0026gt; 2,500) reproduced the findings in pooled analysis with a mean fasting glucose reduction of 0.8 mmol\/L and HbA1c reduction of 0.7 percentage points.\u003c\/p\u003e\n\n\u003ch3\u003e2. Lipid profile — LDL receptor upregulation, distinct from statins\u003c\/h3\u003e\n\u003cp\u003eBerberine upregulates LDL receptor (LDLR) expression in hepatocytes through ERK \/ JNK signaling and post-transcriptional mRNA stabilization — a mechanism completely distinct from statins (which inhibit HMG-CoA reductase upstream of cholesterol synthesis). Because the mechanisms are different, the lipid effects of berberine and statins appear to be at least partially additive in the clinical literature. The 2012 Dong et al. meta-analysis pooled 14 RCTs and reported average reductions of 24 mg\/dL in LDL-C, 30 mg\/dL in triglycerides, and 16 mg\/dL in total cholesterol across berberine arms versus placebo or no intervention. The 2013 Pirillo and Catapano review in \u003cem\u003eAtherosclerosis\u003c\/em\u003e summarized berberine's lipid mechanism as \"the closest natural-compound analogue to a PCSK9-style approach to LDL reduction\" — referring to the receptor-upregulation route rather than the synthesis-inhibition route.\u003c\/p\u003e\n\n\u003ch3\u003e3. Gut microbiome remodeling — Akkermansia, SCFA, BSH\u003c\/h3\u003e\n\u003cp\u003eBerberine has direct antimicrobial activity at the intestinal concentrations achieved by oral dosing (its absolute oral bioavailability is only ~5%, which means most of an oral dose stays in the gut). It selectively reshapes microbial composition — generally reducing pro-inflammatory species in some \u003cem\u003eFirmicutes\u003c\/em\u003e phyla, reducing bile-salt-hydrolase-active species (which raises conjugated bile acids and engages FXR signaling), and supporting expansion of short-chain-fatty-acid producers and the mucin-degrading commensal \u003cem\u003eAkkermansia muciniphila\u003c\/em\u003e. The 2018 Zhang et al. trial in \u003cem\u003emBio\u003c\/em\u003e and the 2020 Sun et al. paper in \u003cem\u003ePhytomedicine\u003c\/em\u003e both linked the metabolic improvements partly to this microbiome shift, with separate effects on host AMPK and on host bile-acid metabolism through the gut-liver axis. This is one reason berberine's clinical effects often appear stronger than its tiny systemic plasma exposure would predict.\u003c\/p\u003e\n\n\u003ch3\u003e4. Insulin sensitivity beyond glucose — HOMA-IR and adipose signaling\u003c\/h3\u003e\n\u003cp\u003eThe metabolic effects of berberine are not limited to glucose entering muscle. The 2008 Yin trial reported HOMA-IR (a composite of fasting glucose and fasting insulin used as an insulin-resistance index) dropped by ~45% in the berberine arm, comparable to metformin. The 2010 Pérez-Rubio et al. trial in metabolic-syndrome patients reproduced the HOMA-IR drop. Mechanistically, berberine lowers the lipotoxic load on insulin-target tissues (by promoting fatty-acid oxidation and reducing intracellular ceramide accumulation) and raises adiponectin in some patient populations.\u003c\/p\u003e\n\n\u003ch3\u003e5. AMPK–mTOR–autophagy axis (the longevity leg)\u003c\/h3\u003e\n\u003cp\u003eThis is the mechanism that puts berberine in longevity stacks alongside NMN, resveratrol, and spermidine. AMPK phosphorylates TSC2 and Raptor, which suppresses mTORC1, which lifts the brake on ULK1 — the kinase that initiates autophagy. The downstream output is the same self-clearing program activated by fasting, caloric restriction, exercise, and rapamycin. The point isn't that berberine alone extends human lifespan (no supplement has that evidence in humans). The point is that AMPK is one of four canonical longevity-pathway nodes, and berberine is the most-studied natural way to push it. \u003ca href=\"\/he\/products\/spermidine-10mg-wheat-germ-extract\"\u003eSpermidine\u003c\/a\u003e works on a downstream parallel autophagy pathway through hypusinated eIF5A; the two are commonly stacked together rather than chosen between.\u003c\/p\u003e\n\n\u003ch3\u003e6. Cardiovascular and endothelial signaling\u003c\/h3\u003e\n\u003cp\u003eBeyond lipid effects, berberine has direct vascular actions: it increases endothelial NO synthase (eNOS) expression and phosphorylation, which improves flow-mediated dilation in clinical studies; it lowers TMAO (trimethylamine-N-oxide) by reshaping the gut microbes that produce it from dietary choline and L-carnitine; and it has modest blood-pressure-lowering activity in hypertensive cohorts. The 2015 Lan meta-analysis included blood pressure as a secondary endpoint and reported small but statistically significant reductions in systolic and diastolic BP. None of this should substitute for cardiovascular medications when those are clinically indicated, but it stacks coherently with \u003ca href=\"\/he\/products\/omega-3-fish-oil-2000mg-epa-dha\"\u003eOmega-3 fish oil\u003c\/a\u003e and \u003ca href=\"\/he\/products\/coq10-400mg-maximum-strength\"\u003eCoQ10\u003c\/a\u003e as a foundation cardiovascular-support set.\u003c\/p\u003e\n\n\u003ch3\u003e7. Inflammation and inflammaging — NF-κB, NLRP3, SASP\u003c\/h3\u003e\n\u003cp\u003eBerberine inhibits NF-κB activation and NLRP3 inflammasome assembly in multiple tissue types, reducing the downstream production of IL-1β, IL-6, TNF-α, and other pro-inflammatory cytokines that constitute the senescence-associated secretory phenotype (SASP) and the broader \"inflammaging\" signature. In aged tissues, low-grade chronic inflammation appears to be both a downstream consequence of senescent-cell accumulation and an upstream driver of further age-related pathology. The 2017 Ehteshamfar et al. review in \u003cem\u003eInflammopharmacology\u003c\/em\u003e compiled the human and animal data on berberine's anti-inflammatory profile across cardiovascular, hepatic, neuronal, and joint tissues. Pairs cleanly with \u003ca href=\"\/he\/products\/curcumin-1000mg-bioperine-anti-inflammatory-longevity\"\u003eCurcumin\u003c\/a\u003e (also an NLRP3 inhibitor) and \u003ca href=\"\/he\/products\/quercetin-500mg-senolytic-flavonoid-natural-antihistamine\"\u003eQuercetin\u003c\/a\u003e (senolytic + NLRP3).\u003c\/p\u003e\n\n\u003ch3\u003e8. Body composition — visceral fat over subcutaneous fat\u003c\/h3\u003e\n\u003cp\u003eSeveral trials have measured body composition before and after berberine intervention. The pattern is consistent: berberine produces modest total-weight changes but disproportionate reductions in visceral fat mass (the metabolically active fat depot around abdominal organs that drives most of the cardiometabolic risk attributed to \"weight\"). The 2012 Hu et al. trial in metabolic-syndrome patients reported a –3.6% change in waist circumference and a measurable drop in visceral-fat ratio over 12 weeks. The mechanism is consistent with AMPK-driven shifts toward fat oxidation and away from de novo lipogenesis, and with adipose-tissue browning signals seen in animal studies.\u003c\/p\u003e\n\n\u003ch2\u003eClinical evidence at a glance\u003c\/h2\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eStudy (year)\u003c\/th\u003e\n\u003cth\u003ePopulation (n)\u003c\/th\u003e\n\u003cth\u003eDose \/ duration\u003c\/th\u003e\n\u003cth\u003ePrimary outcome\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eYin et al. 2008, \u003cem\u003eMetabolism\u003c\/em\u003e\n\u003c\/td\u003e\n\u003ctd\u003eType 2 diabetes (n=36)\u003c\/td\u003e\n\u003ctd\u003e500 mg 3×\/day vs metformin 500 mg 3×\/day, 12 weeks\u003c\/td\u003e\n\u003ctd\u003eEquivalent reductions in FPG, HbA1c, post-prandial glucose, TG, total chol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZhang et al. 2008, \u003cem\u003eJCEM\u003c\/em\u003e\n\u003c\/td\u003e\n\u003ctd\u003eType 2 diabetes (n=84)\u003c\/td\u003e\n\u003ctd\u003e500 mg 3×\/day, 3 months\u003c\/td\u003e\n\u003ctd\u003eFPG –31%, HbA1c –24%, fasting insulin –28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePérez-Rubio et al. 2013, \u003cem\u003eMetab Syndr Relat Disord\u003c\/em\u003e\n\u003c\/td\u003e\n\u003ctd\u003eMetabolic syndrome (n=24)\u003c\/td\u003e\n\u003ctd\u003e500 mg 3×\/day, 3 months\u003c\/td\u003e\n\u003ctd\u003eHOMA-IR –45%, waist circumference reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKong et al. 2004, \u003cem\u003eNat Med\u003c\/em\u003e\n\u003c\/td\u003e\n\u003ctd\u003eHypercholesterolemia (n=32)\u003c\/td\u003e\n\u003ctd\u003e500 mg 2×\/day, 3 months\u003c\/td\u003e\n\u003ctd\u003eLDL-C –25%, TG –35%, total chol –29%; LDLR upregulation mechanism described\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDong et al. 2012 meta-analysis, \u003cem\u003ePlanta Med\u003c\/em\u003e\n\u003c\/td\u003e\n\u003ctd\u003e14 RCTs pooled (n=1,068)\u003c\/td\u003e\n\u003ctd\u003e0.5–1.5 g\/day, 4–24 weeks\u003c\/td\u003e\n\u003ctd\u003eLDL –24 mg\/dL, TG –30 mg\/dL, total chol –16 mg\/dL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLan et al. 2015 meta-analysis, \u003cem\u003eJ Ethnopharmacol\u003c\/em\u003e\n\u003c\/td\u003e\n\u003ctd\u003e27 RCTs pooled (n \u0026gt; 2,500)\u003c\/td\u003e\n\u003ctd\u003eVariable\u003c\/td\u003e\n\u003ctd\u003eFPG –0.8 mmol\/L, HbA1c –0.7%, modest BP reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHu et al. 2012, \u003cem\u003ePhytomedicine\u003c\/em\u003e\n\u003c\/td\u003e\n\u003ctd\u003eObesity (n=37)\u003c\/td\u003e\n\u003ctd\u003e500 mg 3×\/day, 12 weeks\u003c\/td\u003e\n\u003ctd\u003eWaist circumference –3.6%, visceral-fat ratio reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZhang et al. 2018, \u003cem\u003emBio\u003c\/em\u003e\n\u003c\/td\u003e\n\u003ctd\u003eType 2 diabetes microbiome (n=80)\u003c\/td\u003e\n\u003ctd\u003e0.6 g 3×\/day, 3 months\u003c\/td\u003e\n\u003ctd\u003eMicrobiome shift: ↓ pro-inflammatory species, ↑ \u003cem\u003eAkkermansia\u003c\/em\u003e, ↑ SCFA producers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCicero et al. 2007, \u003cem\u003eClin Pharm Ther\u003c\/em\u003e\n\u003c\/td\u003e\n\u003ctd\u003eStatin-intolerant hypercholesterolemia (n=40)\u003c\/td\u003e\n\u003ctd\u003e500 mg 2×\/day + low-dose statin\u003c\/td\u003e\n\u003ctd\u003eAdditive LDL reduction beyond statin alone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSun et al. 2020, \u003cem\u003ePhytomedicine\u003c\/em\u003e\n\u003c\/td\u003e\n\u003ctd\u003eMicrobiome cross-talk study\u003c\/td\u003e\n\u003ctd\u003eMechanistic\u003c\/td\u003e\n\u003ctd\u003eBile-acid \/ FXR axis identified as parallel mechanism beyond AMPK\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWei et al. 2012, \u003cem\u003eEur J Endocrinol\u003c\/em\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePCOS (n=89)\u003c\/td\u003e\n\u003ctd\u003e500 mg 3×\/day, 3 months\u003c\/td\u003e\n\u003ctd\u003eHOMA-IR, LH\/FSH improvement; comparable to metformin in this cohort\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYang et al. 2012, \u003cem\u003eEvid Based Complement Alternat Med\u003c\/em\u003e\n\u003c\/td\u003e\n\u003ctd\u003eType 2 diabetes (n=116)\u003c\/td\u003e\n\u003ctd\u003e1.0 g\/day, 12 weeks\u003c\/td\u003e\n\u003ctd\u003eFPG, HbA1c, insulin sensitivity improvement vs placebo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch2\u003eBerberine HCl vs dihydroberberine vs goldenseal — what you're actually buying\u003c\/h2\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eForm\u003c\/th\u003e\n\u003cth\u003eSource\u003c\/th\u003e\n\u003cth\u003eBioavailability\u003c\/th\u003e\n\u003cth\u003eTrial coverage\u003c\/th\u003e\n\u003cth\u003eBest for\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eBerberine HCl 97% (this product)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cem\u003eBerberis aristata\u003c\/em\u003e root, the \"Indian barberry\"\u003c\/td\u003e\n\u003ctd\u003e~5% absolute, plasma-detectable; effective at 500 mg ×3\/day\u003c\/td\u003e\n\u003ctd\u003eEssentially all the major RCTs — Yin 2008, Zhang 2008, Kong 2004, Dong 2012 meta — used this form\u003c\/td\u003e\n\u003ctd\u003eAnyone trying to reproduce the published clinical outcomes; the studied form for studied results\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDihydroberberine (DHB)\u003c\/td\u003e\n\u003ctd\u003eSemi-synthetic reduction of berberine\u003c\/td\u003e\n\u003ctd\u003e~5× higher than berberine HCl in animal pharmacokinetics\u003c\/td\u003e\n\u003ctd\u003eLimited human RCT evidence; mostly small open-label or animal data\u003c\/td\u003e\n\u003ctd\u003ePeople with severe GI sensitivity to berberine HCl; lower-dose supplementation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBerberine + silymarin \/ phytosome\u003c\/td\u003e\n\u003ctd\u003eBerberine HCl complexed with milk-thistle phospholipids\u003c\/td\u003e\n\u003ctd\u003e2–3× higher plasma exposure\u003c\/td\u003e\n\u003ctd\u003eA handful of Italian-led trials; mostly cardiometabolic\u003c\/td\u003e\n\u003ctd\u003eLower-dose convenience formulations; ratio-blends rather than head-to-head trial reproduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGoldenseal (\u003cem\u003eHydrastis canadensis\u003c\/em\u003e)\u003c\/td\u003e\n\u003ctd\u003eNorth American herb containing 0.5–6% berberine plus hydrastine\u003c\/td\u003e\n\u003ctd\u003eExtremely variable, low standardization\u003c\/td\u003e\n\u003ctd\u003eNone of the head-to-head metformin or lipid trials\u003c\/td\u003e\n\u003ctd\u003eTraditional herbal use; not the form to use if you want the clinical outcomes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOregon grape (\u003cem\u003eMahonia aquifolium\u003c\/em\u003e)\u003c\/td\u003e\n\u003ctd\u003eBark and root, contains berberine plus other isoquinolines\u003c\/td\u003e\n\u003ctd\u003eVariable\u003c\/td\u003e\n\u003ctd\u003eNot used in major metabolic RCTs\u003c\/td\u003e\n\u003ctd\u003eTopical \/ dermatological traditional use, not metabolic\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThis product is the studied form: 97% berberine HCl from \u003cem\u003eBerberis aristata\u003c\/em\u003e, the same form used in Yin 2008, Zhang 2008, Kong 2004, and the Dong and Lan meta-analyses. If your goal is to reproduce the published clinical outcomes, the form matters as much as the dose.\u003c\/p\u003e\n\n\u003ch2\u003eWho this is for\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdults building a four-pathway longevity stack\u003c\/strong\u003e — covering NAD+\/sirtuins (\u003ca href=\"\/he\/products\/nmn-1000mg-double-strength-60-capsules-30-day-supply\"\u003eNMN\u003c\/a\u003e + \u003ca href=\"\/he\/products\/resveratrol-600mg-60-capsules-30-day-supply\"\u003eResveratrol\u003c\/a\u003e), AMPK (Berberine), mTOR\/autophagy (\u003ca href=\"\/he\/products\/spermidine-10mg-wheat-germ-extract\"\u003eSpermidine\u003c\/a\u003e), and senolytics (\u003ca href=\"\/he\/products\/fisetin-500mg-senolytic-flavonoid-for-cellular-cleanup\"\u003eFisetin\u003c\/a\u003e\/\u003ca href=\"\/he\/products\/quercetin-500mg-senolytic-flavonoid-natural-antihistamine\"\u003eQuercetin\u003c\/a\u003e). Berberine is the AMPK leg.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdults with elevated fasting glucose, prediabetes-range HbA1c, or post-meal glucose excursions\u003c\/strong\u003e — looking for a clinically-studied non-prescription option, often as a complement to (not replacement for) physician-directed care.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdults with elevated LDL or triglycerides\u003c\/strong\u003e — wanting natural lipid support, particularly people who can't tolerate statins or who want an additive natural complement to a low-dose statin protocol (Cicero et al. 2007).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdults running an NMN protocol\u003c\/strong\u003e — pairing AMPK activation with sirtuin activation is one of the most-studied longevity-stack combinations because the two pathways feed each other (AMPK regenerates NAD+ in some tissues via NAMPT upregulation, and NAD+-dependent SIRT1 deacetylates and activates AMPK).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdults working on visceral fat \/ metabolic flexibility\u003c\/strong\u003e — AMPK activation favors fat oxidation over fat storage; the trial signal is concentrated in visceral fat rather than subcutaneous.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdults with PCOS or insulin-resistant ovulatory dysfunction\u003c\/strong\u003e — Wei 2012 demonstrated comparable HOMA-IR and LH\/FSH improvement to metformin in this population. Co-management with a physician is appropriate.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdults building a gut-microbiome reset protocol\u003c\/strong\u003e — short-term cycled berberine has direct antimicrobial activity that can shift a dysbiotic microbiome composition, particularly when paired with a fiber-forward diet that supports SCFA-producing commensals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWho this is \u003cem\u003enot\u003c\/em\u003e for\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePregnant or breastfeeding women\u003c\/strong\u003e — berberine crosses the placenta and has been associated with kernicterus risk in newborns at sufficient doses; contraindicated.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNewborns and infants\u003c\/strong\u003e — same kernicterus \/ bilirubin-displacement concern; contraindicated.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAnyone taking cyclosporine\u003c\/strong\u003e — berberine is a potent CYP3A4 inhibitor and will raise cyclosporine blood levels significantly. Same caution applies to tacrolimus.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAnyone on insulin or sulfonylureas\u003c\/strong\u003e — additive hypoglycemic effect; dose adjustment requires physician oversight.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAnyone on statins, calcium-channel blockers, certain anticoagulants, or psychiatric medications metabolized by CYP3A4 \/ CYP2D6\u003c\/strong\u003e — review the interaction list with your pharmacist or physician.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAnyone with chronic GI issues\u003c\/strong\u003e — berberine can cause cramping, loose stools, or constipation in 10–20% of users at full dose, particularly in the first 1–2 weeks. Start at 500 mg once daily and titrate.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAnyone scheduled for surgery in the next 2 weeks\u003c\/strong\u003e — discontinue 14 days before any procedure due to glucose-lowering effects under anesthesia and potential additive effects with surgical-stress-response medications.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eChildren\u003c\/strong\u003e — pediatric data is essentially absent; reserve for adults.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWhat's in each capsule\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e500 mg Berberine HCl\u003c\/strong\u003e — standardized 97% berberine extract from \u003cem\u003eBerberis aristata\u003c\/em\u003e (Indian barberry) root. The HCl salt form is the clinically-studied form and the same form used in Yin 2008 and the Dong 2012 meta-analyzed lipid trials.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eVegetable cellulose capsule\u003c\/strong\u003e — no gelatin, vegan-friendly.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNo undisclosed fillers\u003c\/strong\u003e — no magnesium stearate, no silicon dioxide, no titanium dioxide, no rice-flour bulking agents, no artificial colors, no soy, no gluten, no dairy.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eThird-party tested\u003c\/strong\u003e for identity (HPLC fingerprint), berberine content (≥97% by HPLC), heavy metals (Pb, Hg, As, Cd within USP \u0026lt;232\u0026gt; limits), microbial contamination (USP \u0026lt;2021\u0026gt; \/ \u0026lt;2022\u0026gt;), and pesticide residues.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ecGMP-manufactured\u003c\/strong\u003e in an NSF-registered facility under FDA 21 CFR Part 111 dietary supplement GMP.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSingle-source extraction\u003c\/strong\u003e — same supplier and same extraction lot specifications for repeatable potency batch-to-batch.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eHow to take it\u003c\/h2\u003e\n\n\u003ch3\u003eStandard daily protocol — the trial-aligned dose\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003e1 capsule (500 mg) two to three times daily, with meals.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWhy split dosing matters:\u003c\/strong\u003e berberine's plasma half-life is approximately 4 hours. A single 1500 mg dose produces a high peak then crashes for 12+ hours into a sub-therapeutic trough. Three 500 mg doses across the day keep AMPK activation steadier across waking hours and reproduce the dose schedule used in Yin 2008 and most of the meta-analyzed glucose trials.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWith meals (not fasted):\u003c\/strong\u003e berberine's largest practical effect on post-meal glucose comes from being present in the gut at the same time as the carbohydrate. It's also gentler on the stomach when taken with food.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTiming example:\u003c\/strong\u003e 1 cap with breakfast, 1 cap with lunch, 1 cap with dinner. If you eat 2 meals: 1 cap with each meal, totaling 1000 mg\/day.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eTitration if you're new to berberine\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eWeek 1:\u003c\/strong\u003e 500 mg once daily with the largest meal. This identifies any GI sensitivity at the lowest exposure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWeek 2:\u003c\/strong\u003e 500 mg twice daily (largest meal + dinner).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWeek 3 onward:\u003c\/strong\u003e 500 mg three times daily if tolerated and your goals warrant the full dose. Most lipid and glucose trials used 1500 mg\/day total.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRe-test:\u003c\/strong\u003e repeat fasting glucose, HbA1c, and a full lipid panel at 12 weeks of consistent dosing. Don't draw conclusions before then — most of the trial endpoints were measured at 8 or 12 weeks.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eThree protocol variants\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eDefault (metabolic and lipid coverage):\u003c\/strong\u003e 500 mg with breakfast, lunch, dinner. Cycle 8 weeks on \/ 4 weeks off. Pair with NMN 1000 mg AM + Resveratrol 600 mg AM + Magnesium Glycinate 400 mg PM.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eContinuous (longevity-stack maintenance):\u003c\/strong\u003e 500 mg twice daily (breakfast and dinner) without cycling. Lower total dose, lower microbiome impact, supports a chronic-use profile better suited to multi-year longevity stacking. Used by practitioners who prioritize AMPK activation over peak metabolic effect.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eGlucose-priority (post-meal excursion focus):\u003c\/strong\u003e 500 mg with each carbohydrate-containing meal, including a 4th capsule if you eat a fourth carb-containing meal. Use a continuous glucose monitor for 14–28 days to verify the effect on your post-meal glucose curves before deciding whether the larger dose schedule is worth it for you.\u003c\/p\u003e\n\n\u003ch3\u003eCycling\u003c\/h3\u003e\n\u003cp\u003eThe practitioner-default cycle is 8 weeks on \/ 4 weeks off. The reasoning is threefold. (1) AMPK is a regulatory enzyme; the cell's response to chronic stimulation can attenuate, and a 4-week break appears to restore full responsiveness in anecdotal practitioner reports. (2) Berberine's antimicrobial activity is broad enough that periodic breaks let the gut microbiome rebalance. (3) The longest published RCTs are 8–24 weeks, so multi-year continuous-daily-use safety data is limited compared to cycled use. The 8\/4 cycle is the convention; it's not a hard rule, and adults running it as a continuous low-dose foundation rather than a peak-dose intervention often skip the cycling.\u003c\/p\u003e\n\n\u003ch3\u003eStack pairing — the canonical longevity protocol\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e+ \u003ca href=\"\/he\/products\/nmn-1000mg-double-strength-60-capsules-30-day-supply\"\u003eNMN 1000 mg AM\u003c\/a\u003e:\u003c\/strong\u003e covers the sirtuin\/NAD+ leg while berberine covers the AMPK leg. The two pathways feed each other through SIRT1 deacetylation of AMPK and AMPK-driven NAMPT upregulation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e+ \u003ca href=\"\/he\/products\/resveratrol-600mg-60-capsules-30-day-supply\"\u003eResveratrol 600 mg AM with a fatty meal\u003c\/a\u003e:\u003c\/strong\u003e sirtuin co-activator, lipid-soluble; absorbed alongside dietary fat.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e+ \u003ca href=\"\/he\/products\/coq10-400mg-maximum-strength\"\u003eCoQ10 400 mg\u003c\/a\u003e if you're on a statin:\u003c\/strong\u003e berberine adds to LDL reduction; CoQ10 protects mitochondrial function the statin would otherwise blunt. Q-SYMBIO-grade pairing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e+ \u003ca href=\"\/he\/products\/magnesium-glycinate-400mg-sleep-and-nad-methylation\"\u003eMagnesium Glycinate 400 mg PM\u003c\/a\u003e:\u003c\/strong\u003e magnesium is a cofactor for both insulin signaling and ATP synthesis; pairs well with any glucose-handling protocol.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e+ \u003ca href=\"\/he\/products\/omega-3-fish-oil-2000mg-epa-dha\"\u003eOmega-3 2000 mg with the largest meal\u003c\/a\u003e:\u003c\/strong\u003e additive triglyceride-lowering effect.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e+ \u003ca href=\"\/he\/products\/spermidine-10mg-wheat-germ-extract\"\u003eSpermidine 10 mg AM\u003c\/a\u003e:\u003c\/strong\u003e autophagy partner that works on a parallel hypusinated-eIF5A pathway downstream of AMPK-mTOR.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e+ \u003ca href=\"\/he\/products\/alpha-lipoic-acid-600mg-universal-antioxidant\"\u003eAlpha-Lipoic Acid 600 mg AM fasted\u003c\/a\u003e:\u003c\/strong\u003e insulin sensitivity, AMPK co-activation, mitochondrial cofactor.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e+ \u003ca href=\"\/he\/products\/calcium-alpha-ketoglutarate-1000mg-caakg-epigenetic-longevity\"\u003eCalcium AKG 1000 mg AM\u003c\/a\u003e:\u003c\/strong\u003e epigenetic age (TruDiagnostic data), TCA cycle replenishment.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e+ \u003ca href=\"\/he\/products\/ashwagandha-ksm-66-600mg\"\u003eAshwagandha KSM-66 600 mg PM\u003c\/a\u003e:\u003c\/strong\u003e cortisol-glucose axis; lower cortisol means lower hepatic glucose output, especially in stressed adults.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e+ \u003ca href=\"\/he\/products\/quercetin-500mg-senolytic-flavonoid-natural-antihistamine\"\u003eQuercetin 500 mg\u003c\/a\u003e:\u003c\/strong\u003e senolytic + AMPK co-activation + NLRP3 inhibition. Synergistic with berberine on inflammatory markers.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e+ \u003ca href=\"\/he\/products\/curcumin-1000mg-bioperine-anti-inflammatory-longevity\"\u003eCurcumin 1000 mg\u003c\/a\u003e:\u003c\/strong\u003e NLRP3 \/ inflammaging coverage; complementary anti-inflammatory mechanism.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e+ \u003ca href=\"\/he\/products\/vitamin-d3-5000-iu-k2-mk-7-100mcg\"\u003eVitamin D3 + K2\u003c\/a\u003e:\u003c\/strong\u003e general foundation for calcium-routing, immune, and metabolic function — does not interact with berberine but rounds out the foundation set.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eThe AMPK–NAD+ crosstalk: why berberine and NMN aren't redundant\u003c\/h2\u003e\n\u003cp\u003eOne of the most common questions about a longevity stack is whether AMPK activators and sirtuin activators do the same thing. They do not. They work on different enzymes, on different timescales, and they regulate each other through reciprocal post-translational modification.\u003c\/p\u003e\n\n\u003cp\u003eSIRT1 — the NAD+-dependent deacetylase activated downstream of NMN and resveratrol — directly deacetylates AMPK's upstream kinase LKB1 at multiple lysine residues, increasing LKB1's ability to phosphorylate and activate AMPK. So raising NAD+ tends to raise AMPK activity through SIRT1-LKB1.\u003c\/p\u003e\n\n\u003cp\u003eAMPK in turn upregulates NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway, in skeletal muscle and liver. So raising AMPK tends to raise NAD+ levels in those tissues. This is the AMPK–NAD+ feedback loop documented in Cantó and Auwerx's work in \u003cem\u003eCell\u003c\/em\u003e and \u003cem\u003eCell Metabolism\u003c\/em\u003e (2009–2013).\u003c\/p\u003e\n\n\u003cp\u003eThe implication for stack design is that NMN + resveratrol and berberine are not redundant inputs to one pathway — they are complementary inputs to two reciprocal pathways. Hitting both is qualitatively different from doubling the dose of either one alone. \u003ca href=\"\/he\/products\/longevity-stack-bundle-nmn-500mg-resveratrol-600mg\"\u003eThe Longevity Stack Bundle\u003c\/a\u003e covers the sirtuin half; berberine covers the AMPK half.\u003c\/p\u003e\n\n\u003ch2\u003eInflammaging and the senescence connection\u003c\/h2\u003e\n\u003cp\u003eThe López-Otín 2023 update to the Hallmarks of Aging framework emphasizes \"chronic inflammation\" \/ inflammaging as one of the integrated hallmarks linking the others. Berberine's published mechanism reaches inflammaging through three independent routes: (1) direct NF-κB inhibition in immune and stromal cells, (2) NLRP3 inflammasome inhibition (which blunts IL-1β and IL-18 production), and (3) microbiome reshaping that lowers LPS translocation across the gut barrier — the so-called \"metabolic endotoxemia\" that drives systemic low-grade inflammation in people with poor diet quality and gut dysbiosis. The combined effect in trials is reductions in CRP, IL-6, and TNF-α at clinically relevant magnitudes (10–30% reductions across most trials that measured them). This is part of why berberine pairs cleanly with senolytics — Fisetin and Quercetin clear senescent cells, and berberine quiets the residual SASP signaling that comes from cells the senolytic missed.\u003c\/p\u003e\n\n\u003ch2\u003eBioavailability: why ~5% works\u003c\/h2\u003e\n\u003cp\u003eBerberine's absolute oral bioavailability — the fraction of an oral dose that reaches systemic plasma unchanged — is roughly 5%. This sounds discouraging until you understand that for berberine, the low systemic bioavailability is not just a tolerable feature, it's part of how the compound works. Most of an oral dose remains in the intestinal lumen, where it engages with the microbiome (mechanism 3 above) and with intestinal epithelial alpha-glucosidase (mechanism 1, post-meal glucose). The systemically absorbed fraction is sufficient to engage hepatic LDLR (mechanism 2) and to phosphorylate AMPK in muscle and adipose tissue at the doses used in the trials.\u003c\/p\u003e\n\n\u003cp\u003eSome formulations attempt to raise bioavailability with phospholipid complexes, milk-thistle (silymarin) co-administration, or dihydroberberine reduction. These can be valid choices for adults who want a smaller pill burden, but they trade off a feature: virtually all the head-to-head trial evidence — Yin 2008, Zhang 2008, Kong 2004, Dong 2012, Lan 2015 — was generated on plain berberine HCl at 1500 mg\/day total. Reproducing trial outcomes is most reliable when you reproduce trial dose form. This product is the trial-form berberine HCl 97%.\u003c\/p\u003e\n\n\u003ch2\u003eImportant safety information\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eDrug interactions — CYP3A4 and CYP2D6:\u003c\/strong\u003e berberine inhibits CYP3A4 and CYP2D6, the two enzymes responsible for metabolizing roughly half of all prescription drugs. The clinically important interactions include cyclosporine (do not combine), tacrolimus, several statins (atorvastatin and simvastatin levels can rise meaningfully), some calcium-channel blockers (felodipine, nifedipine), warfarin (effect direction varies; INR monitoring required), some SSRIs and tricyclic antidepressants, several antipsychotics, and some antiarrhythmics. If you take any prescription medication, review the interaction list with your physician or pharmacist before starting berberine.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eP-glycoprotein and OCT1:\u003c\/strong\u003e berberine is also a P-gp inhibitor and an organic-cation-transporter substrate, which extends the interaction surface beyond CYP enzymes alone.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHypoglycemia risk:\u003c\/strong\u003e additive with insulin, sulfonylureas, and metformin. Dose adjustment under physician supervision is required if you're already on a glucose-lowering medication.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePregnancy \/ breastfeeding \/ infants:\u003c\/strong\u003e contraindicated. Berberine crosses the placenta and has been associated with kernicterus (bilirubin-displacement) risk in newborns at sufficient doses.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGI tolerance:\u003c\/strong\u003e 10–20% of users experience cramping, loose stools, or constipation in the first 1–2 weeks. Titration usually resolves it. If symptoms persist past 2 weeks at 500 mg\/day with food, discontinue.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSurgery:\u003c\/strong\u003e discontinue 14 days before any scheduled procedure due to glucose-lowering effects under anesthesia.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eChronic kidney or liver disease:\u003c\/strong\u003e consult your physician before starting; berberine clearance and CYP-interaction profile may differ in compromised hepatic \/ renal function.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eConcurrent antibiotics:\u003c\/strong\u003e berberine has direct antimicrobial activity. Stacking with a course of broad-spectrum antibiotics is not recommended; pause berberine during antibiotic therapy and resume after a recovery interval.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eQuality matters:\u003c\/strong\u003e third-party-tested, HPLC-verified 97% berberine HCl is the form that maps onto the trial outcomes. Lower-purity or undisclosed-source products with no certificate of analysis are not equivalent.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWhat changes, and when — a 12-week subjective timeline\u003c\/h2\u003e\n\n\u003ch3\u003eWeek 1\u003c\/h3\u003e\n\u003cp\u003eYou're titrating. The dominant subjective experience for most people is gut adaptation — possible cramping, loose stools, or constipation as the microbiome encounters berberine for the first time. Take with the largest meal. Don't push the dose. Most of week 1's \"effect\" is identifying whether you tolerate the compound.\u003c\/p\u003e\n\n\u003ch3\u003eWeek 2\u003c\/h3\u003e\n\u003cp\u003eGI symptoms typically settle by day 10–14. You move to 500 mg twice daily. Some people with significant pre-treatment post-meal glucose excursions notice early changes on a continuous glucose monitor (smaller post-meal peaks, faster return to baseline). Subjective \"feel\" is usually unchanged this early.\u003c\/p\u003e\n\n\u003ch3\u003eWeeks 3–4\u003c\/h3\u003e\n\u003cp\u003eFull dose 500 mg three times daily for adults targeting 1500 mg\/day. Fasting glucose may begin to drift downward by 5–10% in adults whose pre-treatment fasting was elevated. Most lipid effects are still building and not yet panel-detectable. Mild visceral-abdominal-circumference reductions sometimes start in adults with significant pre-treatment metabolic-syndrome features.\u003c\/p\u003e\n\n\u003ch3\u003eWeeks 5–8\u003c\/h3\u003e\n\u003cp\u003eThe first real measurement window. By week 8, the major glucose RCTs reported full effect on fasting glucose and HOMA-IR. Lipid changes are now panel-detectable in many users. Energy stability across the day often improves — fewer post-meal crashes, fewer reactive-hypoglycemia symptoms in adults who had them. This is also the window when most cycle-on protocols complete and the 4-week off-cycle begins.\u003c\/p\u003e\n\n\u003ch3\u003eWeeks 9–12\u003c\/h3\u003e\n\u003cp\u003eIf you ran continuously rather than cycling, the meta-analytic-magnitude lipid changes (–24 mg\/dL LDL, –30 mg\/dL TG) are the upper-bound expectation. HbA1c reductions are most visible at 12 weeks because HbA1c reflects 90-day average glucose. This is the right point to pull a full panel: fasting glucose, fasting insulin, HbA1c, lipid panel, hsCRP. If markers haven't moved, troubleshoot — adherence first, dose timing second, food-quality interaction third — before assuming non-response.\u003c\/p\u003e\n\n\u003ch3\u003eBeyond 12 weeks\u003c\/h3\u003e\n\u003cp\u003eFor longevity-stack users, berberine is a chronic-foundation supplement either cycled 8\/4 or run continuously at a lower (500 mg ×2\/day) maintenance dose. The trial endpoints don't extend beyond 24 weeks for most published studies, so retest annually and re-evaluate dose against current biomarkers and goals.\u003c\/p\u003e\n\n\u003ch2\u003eFrequently asked questions\u003c\/h2\u003e\n\n\u003ch3\u003eIs berberine \"nature's metformin\"? Should I take it instead of my prescription?\u003c\/h3\u003e\n\u003cp\u003eThe 2008 Yin trial showed statistically equivalent glucose and lipid effects in a 12-week head-to-head against 1500 mg\/day metformin, and berberine has been called metformin's natural cousin in popular press because of that. \u003cstrong\u003eThat does not mean it's a substitute for prescription medication.\u003c\/strong\u003e If you're already on metformin or any glucose-lowering drug, the conversation about adding or substituting belongs with the physician who prescribed it — partly because of additive hypoglycemia risk, and partly because metformin has decades more long-term safety and outcomes data than berberine has. Most people use berberine as a foundation supplement \u003cem\u003ebefore\u003c\/em\u003e medication is needed, or as a physician-monitored adjunct.\u003c\/p\u003e\n\n\u003ch3\u003eWhy cycle 8 weeks on \/ 4 weeks off instead of taking it daily?\u003c\/h3\u003e\n\u003cp\u003eThree reasons. (1) AMPK is a regulatory enzyme; the cell's response to chronic stimulation can attenuate, and a 4-week break appears to restore full responsiveness in practitioner experience. (2) Berberine has direct antimicrobial activity — useful for reshaping a dysbiotic microbiome short-term, but indefinite continuous use is less well-studied than cycled use. (3) The longest published RCTs are 8–24 weeks, so we have less safety data on continuous multi-year daily dosing than we do on cycled use. The 8\/4 cycle is the practitioner-community default; it's not a hard rule, and adults running a lower 1000 mg\/day continuous foundation dose appear safe in the available data.\u003c\/p\u003e\n\n\u003ch3\u003eBerberine HCl vs dihydroberberine — which is better?\u003c\/h3\u003e\n\u003cp\u003eDihydroberberine (DHB) is a semi-synthetic reduction product with reportedly higher oral bioavailability (~5× in animal pharmacokinetics; smaller doses appear to produce comparable plasma exposure). The trade-off: virtually all the head-to-head clinical evidence — the 2008 Yin metformin comparison, the 2012 Dong meta-analysis, the lipid-modification trials, the microbiome-shift trials — was done on plain berberine HCl, not dihydroberberine. We use the studied form because the studied form has the studied outcomes. DHB is a reasonable choice for adults with severe stomach sensitivity at lower doses; berberine HCl at 1500 mg\/day is the choice that maps onto the published trial results.\u003c\/p\u003e\n\n\u003ch3\u003eCan I take berberine with NMN and resveratrol? Won't they cancel each other out?\u003c\/h3\u003e\n\u003cp\u003eThe opposite — they're the canonical longevity stack precisely because they work on different reciprocal pathways. NMN raises NAD+, which feeds SIRT1; resveratrol allosterically activates SIRT1; SIRT1 deacetylates LKB1 and increases LKB1's ability to phosphorylate and activate AMPK. AMPK then upregulates NAMPT, the rate-limiting enzyme in NAD+ salvage. The two arms feed each other. Stacking them is the standard design, not a redundancy.\u003c\/p\u003e\n\n\u003ch3\u003eShould I add milk thistle or silymarin to boost absorption?\u003c\/h3\u003e\n\u003cp\u003eSome practitioners co-administer silymarin to raise plasma berberine exposure (the BBR-PCA \/ silybin-phytosome literature). It's a reasonable add for adults who want a smaller dose with comparable plasma exposure. The trade-off is that you're moving away from the trial-form dose, so the published outcome magnitudes don't transfer cleanly. The simpler approach for most adults is to dose berberine HCl 500 mg ×3\/day with food — that's the trial dose that produced the trial outcomes.\u003c\/p\u003e\n\n\u003ch3\u003eI'm getting GI cramping at 500 mg. Should I quit?\u003c\/h3\u003e\n\u003cp\u003eTry this first: drop to 500 mg once daily, with the largest meal of the day, for 7–10 days. The GI side effect is a known feature of the antimicrobial \/ motility activity and usually adapts within 1–2 weeks. If you're still uncomfortable after 2 weeks at 500 mg\/day with food, berberine isn't the right fit — discontinue and consider an alternative AMPK-supportive approach (regular fasted exercise, time-restricted eating, \u003ca href=\"\/he\/products\/alpha-lipoic-acid-600mg-universal-antioxidant\"\u003eAlpha-Lipoic Acid\u003c\/a\u003e as a different AMPK-adjacent compound, or physician consultation about prescription metformin).\u003c\/p\u003e\n\n\u003ch3\u003eHow long until I see results in glucose \/ lipid markers?\u003c\/h3\u003e\n\u003cp\u003eMost trials measured outcomes at 8 and 12 weeks. Some users see fasting glucose changes within 2–4 weeks, particularly adults with significantly elevated pre-treatment values. Lipid changes typically take the full 8–12 weeks to show on a standard lipid panel because LDL receptor-driven mechanisms work on hepatic lipoprotein dynamics that turn over slowly. Don't draw conclusions from a 2-week trial. Re-test fasting glucose, HbA1c, and a full lipid panel at 12 weeks of consistent dosing. HbA1c specifically reflects 90-day average glucose, so a 12-week measurement window is the right interval.\u003c\/p\u003e\n\n\u003ch3\u003eWhy split into three doses instead of one big 1500 mg capsule?\u003c\/h3\u003e\n\u003cp\u003eBerberine's plasma half-life is roughly 4 hours. A single 1500 mg dose produces a high peak and a 12-hour trough where AMPK activation has fallen below the therapeutic threshold. Three 500 mg doses across the day keep cellular exposure consistent — and that's how the 2008 Yin trial dosed it, which is the trial most people are trying to reproduce. There's also a practical alpha-glucosidase argument: berberine's effect on post-meal glucose comes from being in the gut at the same time as the carbohydrate. Dosing three times daily with three meals puts berberine in the gut when it's most useful.\u003c\/p\u003e\n\n\u003ch3\u003eCan women take berberine? Does it affect hormones?\u003c\/h3\u003e\n\u003cp\u003eYes. Berberine is widely studied in women, including in the PCOS literature where Wei et al. 2012 demonstrated comparable HOMA-IR and LH\/FSH improvement to metformin. It's contraindicated in pregnancy and breastfeeding, but otherwise the published trials enroll both sexes and report similar metabolic outcomes. Women in perimenopause and menopause often see particularly clear benefit on the metabolic-syndrome features that emerge with the menopausal transition (visceral fat, fasting glucose, triglyceride drift).\u003c\/p\u003e\n\n\u003ch3\u003eDoes berberine interact with antibiotics? What about antifungals?\u003c\/h3\u003e\n\u003cp\u003eBerberine itself has direct antimicrobial activity at intestinal concentrations. Stacking it with a course of broad-spectrum antibiotics is not recommended — the additive antimicrobial pressure on the gut microbiome can disrupt commensal recovery. The cleaner approach is to pause berberine during antibiotic therapy and resume after the gut has had 1–2 weeks to recolonize on its own. Antifungal interactions are not well-characterized; consult your prescriber.\u003c\/p\u003e\n\n\u003ch3\u003eCan I take berberine while fasting (e.g., 16:8 or extended fasts)?\u003c\/h3\u003e\n\u003cp\u003eThe trial dose is taken with meals because the alpha-glucosidase \/ post-meal-glucose mechanism requires food in the gut. During fasting hours, berberine's AMPK activation is still occurring at the systemic level, but you lose the gut-side mechanisms. For 16:8 protocols, dose with the meals inside your eating window. For extended fasts (24+ hours), most practitioners pause berberine because (a) hypoglycemia risk is higher in a fasted state and (b) the meal-paired mechanism is moot.\u003c\/p\u003e\n\n\u003ch3\u003eDoes berberine affect blood pressure?\u003c\/h3\u003e\n\u003cp\u003eModestly. The 2015 Lan meta-analysis included blood pressure as a secondary endpoint and reported small but statistically significant reductions in systolic and diastolic BP across berberine arms. The mechanism is partly endothelial NO-mediated and partly weight\/visceral-fat-mediated. It's not a primary blood-pressure intervention, but it doesn't work against any standard antihypertensive regimen and tends to nudge BP in the favorable direction.\u003c\/p\u003e\n\n\u003ch3\u003eWill berberine show up on a drug test?\u003c\/h3\u003e\n\u003cp\u003eNo. Berberine is a plant alkaloid that is structurally and pharmacologically unrelated to any compound on standard substance-screening panels. It is not a banned compound under WADA, USADA, or NCAA rules.\u003c\/p\u003e\n\n\u003ch3\u003eDoes berberine affect TMAO?\u003c\/h3\u003e\n\u003cp\u003eYes — favorably. TMAO (trimethylamine-N-oxide) is a microbiome-derived metabolite of dietary choline and L-carnitine that has been independently associated with cardiovascular risk in observational data. Berberine reshapes the gut microbes that produce TMA (the precursor of TMAO), and several trials have measured TMAO reductions of 20–40% in adults whose pre-treatment TMAO was elevated. This is consistent with the broader gut-cardiovascular axis mechanism.\u003c\/p\u003e\n\n\u003ch3\u003eIs berberine compatible with a continuous glucose monitor (CGM)?\u003c\/h3\u003e\n\u003cp\u003eYes — and a CGM is one of the most useful objective tools to verify whether berberine is doing what you want it to do at the post-meal-glucose level. Wear a CGM for 14 days at baseline, start berberine, then wear a CGM again at week 4 and week 8. The post-meal AUC reduction, peak glucose reduction, and time-in-range improvement give you a real signal in 2–4 weeks rather than waiting on a 12-week HbA1c.\u003c\/p\u003e\n\n\u003ch2\u003eFDA disclaimer\u003c\/h2\u003e\n\u003cp\u003e\u003cem\u003eThese statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. References to Yin et al. 2008, Kong et al. 2004, Zhang et al. 2008, Dong et al. 2012, Lan et al. 2015, Pérez-Rubio et al. 2013, Hu et al. 2012, Cicero et al. 2007, Wei et al. 2012, Yang et al. 2012, Zhang et al. 2018, Sun et al. 2020, Pirillo \u0026amp; Catapano 2013, and Ehteshamfar et al. 2017 are cited as published research context only and do not constitute treatment claims. Berberine has clinically significant drug interactions; consult a qualified healthcare provider before starting if you take any prescription medication, are pregnant or breastfeeding, are scheduled for surgery, or have a chronic medical condition. Results vary; individual outcomes are not guaranteed. The López-Otín \"Hallmarks of Aging\" framework (Cell 2013, updated Cell 2023) is referenced as a research-context model and not as a clinical claim.\u003c\/em\u003e\u003c\/p\u003e\n","brand":"True Health Protocol","offers":[{"title":"Default Title","offer_id":47696472047834,"sku":"THP-BERB-500-60","price":19.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0814\/5158\/1658\/files\/berberine_02.jpg?v=1774728960"},{"product_id":"alpha-lipoic-acid-600mg-universal-antioxidant","title":"Alpha-Lipoic Acid 600mg | Universal Antioxidant + Mitochondrial Cofactor for Glucose \u0026 Longevity","description":"\u003cp\u003e\u003cstrong\u003e600 mg of Alpha-Lipoic Acid per capsule\u003c\/strong\u003e — the universal antioxidant that works in both water and fat compartments, recycles other antioxidants the body has already used, chelates heavy metals, and sits as a direct cofactor inside two of the mitochondrial enzyme complexes that convert food into ATP. Approved as a prescription drug for diabetic peripheral neuropathy in Germany since 1966 (Thioctacid®); sold as a dietary supplement in the US. The 600 mg dose is the dose used across all four landmark German RCTs — ALADIN, ALADIN III, SYDNEY 2, and NATHAN 1. Standardized purity, vegan capsule, no titanium dioxide, no magnesium stearate.\u003c\/p\u003e\n\n\u003ch2\u003eThe 30-second answer\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUniversal antioxidant\u003c\/strong\u003e — uniquely both water-soluble \u003cem\u003eand\u003c\/em\u003e fat-soluble (the dihydrolipoate ↔ lipoate redox couple is amphipathic), so it works inside the cell membrane \u003cem\u003eand\u003c\/em\u003e in the cytoplasm, mitochondria, and bloodstream. Almost every other antioxidant is restricted to one compartment (Packer 1995, \u003cem\u003eFree Radic Biol Med\u003c\/em\u003e).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRecycles other antioxidants\u003c\/strong\u003e — regenerates the spent (oxidized) forms of Vitamin C, Vitamin E (α-tocopherol), reduced glutathione, and CoQ10 back to their active forms. The whole antioxidant network runs longer per dose with ALA in the picture (Bast \u0026amp; Haenen 1988; Kagan 1992).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMitochondrial cofactor\u003c\/strong\u003e — ALA is the prosthetic group on lipoyllysine residues of pyruvate dehydrogenase (PDH), α-ketoglutarate dehydrogenase (KGDH), and the branched-chain α-keto-acid complex. The cell literally cannot burn glucose, glutamine, or BCAAs for ATP without it (Bustamante 1998).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGlucose \u0026amp; nerve support\u003c\/strong\u003e — the most-studied compound for diabetic peripheral neuropathy in Europe. Four large RCTs (ALADIN, ALADIN III, SYDNEY 2, NATHAN 1) pooled in Ziegler 2004 and Mijnhout 2012 meta-analyses showed a clinically meaningful reduction in Total Symptom Score (TSS) at the 600 mg\/day oral dose this product matches.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAMPK activator + insulin sensitizer\u003c\/strong\u003e — Konrad 2001 and Jacob 1999 showed measurable increase in glucose uptake and GLUT4 translocation in skeletal muscle in lean and Type-2 diabetic adults at 600 mg.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNrf2 pathway\u003c\/strong\u003e — ALA is one of the most reliable Nrf2\/ARE pathway inducers in the supplement world (Suh 2004), upregulating endogenous glutathione synthesis, NQO1, and Phase II detoxification enzymes — the same axis hit by sulforaphane and curcumin.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBest paired with:\u003c\/strong\u003e \u003ca href=\"\/he\/products\/berberine-hcl-500mg-maximum-strength\"\u003eBerberine\u003c\/a\u003e for metabolic-health stacks (different mechanism — same target organ); \u003ca href=\"\/he\/products\/coq10-400mg-maximum-strength\"\u003eCoQ10\u003c\/a\u003e + \u003ca href=\"\/he\/products\/pqq-20mg-mitochondrial-biogenesis-activator\"\u003ePQQ\u003c\/a\u003e for mitochondrial stacks; \u003ca href=\"\/he\/products\/glutathione-500mg-maximum-strength\"\u003eGlutathione\u003c\/a\u003e + \u003ca href=\"\/he\/products\/n-acetyl-cysteine-600mg-nac-glutathione-precursor-for-antioxidant-longevity-support\"\u003eNAC\u003c\/a\u003e + \u003ca href=\"\/he\/products\/liposomal-vitamin-c-1000mg-maximum-absorption-antioxidant-formula\"\u003eVitamin C\u003c\/a\u003e for the antioxidant network; \u003ca href=\"\/he\/products\/nmn-1000mg-double-strength-60-capsules-30-day-supply\"\u003eNMN 1000mg\u003c\/a\u003e for the NAD+ axis (PDH\/KGDH need both NAD+ \u003cem\u003eand\u003c\/em\u003e lipoate to function).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWhy a metabolic supplement ended up in serious longevity research\u003c\/h2\u003e\n\u003cp\u003eAlpha-lipoic acid was discovered in 1937 in \u003cem\u003eLactobacillus casei\u003c\/em\u003e and isolated in pure form by Lester Reed at the University of Texas in 1951. For its first half-century it was studied almost exclusively as a metabolic cofactor — the small disulfide molecule covalently bound to the E2 subunits of the α-keto-acid dehydrogenase complexes. Without it, the cell cannot oxidatively decarboxylate pyruvate to acetyl-CoA (PDH), cannot run the Krebs cycle past α-ketoglutarate (KGDH), and cannot break down leucine, isoleucine, or valine.\u003c\/p\u003e\n\n\u003cp\u003eThe shift into longevity research started in the late 1980s when Lester Packer's lab at UC Berkeley discovered that \u003cem\u003efree\u003c\/em\u003e ALA (not the protein-bound form) and its reduced form dihydrolipoate (DHLA) are extraordinary redox-active compounds with three properties almost no other antioxidant has: (1) they cross the blood-brain barrier, (2) they're equally active in aqueous and lipid compartments, and (3) they reduce the oxidized forms of every other major antioxidant in the cell — vitamin C, vitamin E, glutathione, CoQ10. Packer christened ALA the “universal antioxidant” in his 1995 \u003cem\u003eFree Radical Biology \u0026amp; Medicine\u003c\/em\u003e review, and the field has used that term ever since.\u003c\/p\u003e\n\n\u003cp\u003eThe metabolic-medicine track and the longevity track converged in the 1990s when Hager and Maczurek and others started looking at age-related declines in mitochondrial PDH\/KGDH activity in brain tissue. Aged neurons have less lipoate on their dehydrogenase complexes; supplementing free ALA partially rescues activity in mouse models (Hagen 1999). The same lab showed ALA-fed older rats walk on a rotarod like young rats, reverse age-related declines in carnitine acetyl-transferase, and have lower 8-OHdG (oxidative DNA damage marker) in liver mitochondria.\u003c\/p\u003e\n\n\u003cp\u003eIn humans the longevity case is less direct than the metabolic case — there is no NATHAN 1 for healthspan — but the supporting biomarker work is substantial. ALA has consistently lowered fasting glucose, insulin, HbA1c, triglycerides, total cholesterol, hs-CRP, IL-6, MDA, F2-isoprostanes, and 8-OHdG across dozens of human RCTs in metabolic syndrome, NAFLD, PCOS, MS, and Alzheimer's pilot populations. Every one of those is a mid-life longevity biomarker. ALA's main function in modern protocols is as a foundational layer that hits glucose, lipids, mitochondrial substrate flux, antioxidant recycling, and heavy-metal chelation simultaneously — four mechanisms most other compounds don't combine.\u003c\/p\u003e\n\n\u003ch2\u003eThe four mechanisms in plain language\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e1. The mitochondrial cofactor job (the original reason it exists).\u003c\/strong\u003e ALA is the prosthetic group covalently attached to lysine residues on the E2 subunit of three enzyme complexes: pyruvate dehydrogenase (PDH), α-ketoglutarate dehydrogenase (KGDH), and the branched-chain α-keto-acid dehydrogenase (BCKDH). The lipoyllysine arm physically swings between three active sites, transferring acetyl\/acyl groups and transferring electrons to FAD. PDH gates pyruvate → acetyl-CoA, the bottleneck step where carbohydrates enter the Krebs cycle. KGDH gates α-ketoglutarate → succinyl-CoA, the rate-limiting step of the Krebs cycle itself. BCKDH gates leucine\/isoleucine\/valine catabolism. Without lipoate, none of these complexes function. With age, lipoate content of these complexes drops; supplementing the free precursor partly compensates (Bustamante 1998; Hagen 1999).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e2. The antioxidant-recycling job (Packer's discovery).\u003c\/strong\u003e ALA gets reduced to DHLA inside cells, then DHLA reduces oxidized vitamin C (dehydroascorbate → ascorbate), oxidized vitamin E radicals (via vitamin C), oxidized glutathione (GSSG → GSH), and CoQ10 (ubiquinone → ubiquinol). One ALA molecule can keep the network running through many oxidant exposures because it sits at the top of the recycling cascade. This is the structural reason ALA pairs particularly well with \u003ca href=\"\/he\/products\/glutathione-500mg-maximum-strength\"\u003eglutathione\u003c\/a\u003e, \u003ca href=\"\/he\/products\/n-acetyl-cysteine-600mg-nac-glutathione-precursor-for-antioxidant-longevity-support\"\u003eNAC\u003c\/a\u003e, \u003ca href=\"\/he\/products\/liposomal-vitamin-c-1000mg-maximum-absorption-antioxidant-formula\"\u003evitamin C\u003c\/a\u003e, and \u003ca href=\"\/he\/products\/coq10-400mg-maximum-strength\"\u003eCoQ10\u003c\/a\u003e rather than competing with them.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e3. The Nrf2 pathway job (added in the 2000s).\u003c\/strong\u003e ALA modifies cysteine residues on Keap1, releases Nrf2 to translocate to the nucleus, and turns on the Antioxidant Response Element (ARE) — driving expression of glutathione synthesis enzymes (GCLC\/GCLM), NQO1, heme oxygenase-1 (HO-1), and the Phase II detoxification battery. Suh 2004 showed ALA restores GSH synthesis in old rats by ~50%. This is the same pathway sulforaphane, curcumin, and the SIRT1 activators converge on. Hitting it from multiple angles is why senolytic and longevity stacks layer ALA with \u003ca href=\"\/he\/products\/curcumin-1000mg-bioperine-anti-inflammatory-longevity\"\u003ecurcumin\u003c\/a\u003e and \u003ca href=\"\/he\/products\/quercetin-500mg-senolytic-flavonoid-natural-antihistamine\"\u003equercetin\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e4. The insulin-sensitization \/ AMPK job (the metabolic case).\u003c\/strong\u003e Lee 2005 and Konrad 2001 showed ALA activates AMPK in muscle, increases GLUT4 translocation to the membrane, and increases insulin-mediated glucose uptake. The acute effect of a single 600 mg oral dose is measurable on a euglycemic clamp (Jacob 1999). Repeated dosing for 4 weeks in T2D patients lowered fasting glucose ~20% and triglycerides ~25% in Akbari 2018 meta. ALA and \u003ca href=\"\/he\/products\/berberine-hcl-500mg-maximum-strength\"\u003eberberine\u003c\/a\u003e hit AMPK by different mechanisms (ALA via mitochondrial AMP\/ATP shift, berberine via direct AMPK kinase activation), which is why they stack rather than compete.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBonus mechanism: heavy-metal chelation.\u003c\/strong\u003e ALA's two thiol groups in the reduced (DHLA) form bind mercury, copper, iron, lead, cadmium, and arsenic. Lin 1989 and Patrick 2002 reviewed the chelation work. ALA is the only antioxidant that chelates and recycles Vitamin C\/E\/glutathione simultaneously — a useful property for adults with chronic background metal exposure (older fillings, well water, occupational).\u003c\/p\u003e\n\n\u003ch2\u003eThe trial bench — what 600 mg\/day actually does in humans\u003c\/h2\u003e\n\u003cp\u003eALA has one of the longest, deepest, and best-replicated trial records in supplemental medicine, anchored by four large multi-center German RCTs in diabetic peripheral neuropathy at the 600 mg dose this product matches.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eALADIN (Ziegler 1995, \u003cem\u003eDiabetologia\u003c\/em\u003e):\u003c\/strong\u003e 328 T2D patients with symptomatic distal symmetric polyneuropathy. 1200, 600, or 100 mg\/day IV vs placebo, 3 weeks. 600 mg dose — significant reduction in Total Symptom Score (TSS) and Hamburg Pain Adjective List score; no benefit at 100 mg. The first proof of dose-response.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eALADIN II (Reljanovic 1999):\u003c\/strong\u003e 65 T1D + T2D, 600 or 1200 mg\/day IV for 5 days, then 600\/1200 mg\/day oral for 2 years. Significant improvement in nerve conduction velocity in sural and tibial nerves at both doses. 1200 not better than 600.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eALADIN III (Ziegler 1999):\u003c\/strong\u003e 509 T2D, 600 mg\/day IV for 3 weeks then 1800 mg\/day oral for 6 months. The IV phase reduced TSS; the oral 1800 mg phase failed to maintain that on TSS but improved the Neuropathy Impairment Score for the lower limbs (NIS-LL).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDEKAN (Ziegler 1997):\u003c\/strong\u003e 73 T2D with cardiac autonomic neuropathy. 800 mg\/day oral 4 months. Significant improvement in heart-rate variability vs placebo. The first cardiac-autonomic ALA trial.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eORPIL (Ruhnau 1999):\u003c\/strong\u003e 24 T2D, 1800 mg\/day oral 3 weeks. Significant TSS reduction at 19 days. Established that oral could replicate the IV symptom benefit, opening the door to chronic oral dosing.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSYDNEY (Ametov 2003):\u003c\/strong\u003e 120 diabetics, 600 mg\/day IV 14 infusions over 3 weeks. TSS dropped 5.7 points vs 1.8 placebo — one of the largest absolute symptom reductions on record.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSYDNEY 2 (Ziegler 2006):\u003c\/strong\u003e The dose-finding oral RCT — 181 patients, 600 vs 1200 vs 1800 mg\/day for 5 weeks. \u003cem\u003eAll three doses\u003c\/em\u003e beat placebo on TSS; 1200 and 1800 had more nausea. \u003cstrong\u003e600 mg\/day oral was the optimal risk\/benefit dose\u003c\/strong\u003e — this is the dose this product matches.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNATHAN 1 (Ziegler 2011, \u003cem\u003eDiabetes Care\u003c\/em\u003e):\u003c\/strong\u003e The landmark 4-year trial — 460 T1D + T2D with mild-to-moderate DPN, 600 mg\/day oral. Primary composite endpoint trended favorable (NIS-LL + 7 neurophysiologic tests, p=0.105) and reached significance on NIS, NIS-LL, muscle weakness, and clinical neurologic examination. The longest ALA RCT ever performed; it confirmed durability of effect and a safety profile equivalent to placebo over 4 years of daily use.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMijnhout 2012 meta-analysis (\u003cem\u003eInt J Endocrinol\u003c\/em\u003e):\u003c\/strong\u003e Pooled 5 RCTs at 600 mg\/day. Significant 2.26-point TSS reduction (95%CI -2.83 to -1.69) and significant improvement on NIS-LL.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOutside neuropathy, the human evidence base is broad:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInsulin sensitivity \/ Type-2 diabetes:\u003c\/strong\u003e Akbari 2018 meta-analysis pooled 24 RCTs — significant reductions in fasting glucose, fasting insulin, HOMA-IR, and HbA1c. Effect sizes are modest (~10-15%) but statistically robust and additive on top of standard care.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLipid profile:\u003c\/strong\u003e Mohammadi 2017 and Akbari 2018 meta-analyses showed significant reductions in total cholesterol, LDL, and triglycerides; modest HDL increase.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeight \/ waist circumference:\u003c\/strong\u003e Kucukgoncu 2017 meta-analysis — ALA reduced body weight by 1.27 kg vs placebo across 12 RCTs. Modest but consistent effect.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNAFLD:\u003c\/strong\u003e de Sousa 2019 review of 6 RCTs — ALA reduced ALT, AST, GGT and hepatic steatosis on ultrasound; mechanism likely a combination of insulin sensitization + Nrf2 + lipid lowering.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePCOS:\u003c\/strong\u003e Genazzani 2010 and Masharani 2010 — ALA improved menstrual regularity, lowered insulin\/HOMA-IR, and improved ovulatory function in lean PCOS women, as a metformin alternative or adjunct.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple sclerosis:\u003c\/strong\u003e Khalili 2014 — 1200 mg\/day for 12 weeks significantly increased serum total antioxidant capacity in 52 relapsing-remitting MS patients. A pilot Spain-Mayer 2017 of 1200 mg\/day for 2 years showed a 68% reduction in brain volume loss vs placebo.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAlzheimer's pilot:\u003c\/strong\u003e Hager 2007 — 9-month open-label of 600 mg\/day in mild AD slowed cognitive decline (ADAS-cog stable vs natural-history rate of progression). Maczurek 2008 review summarizes the AD case.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCognitive aging:\u003c\/strong\u003e Gosselin 2019 systematic review of ALA in cognitive function trials — positive signal in MCI\/mild AD, less clear in healthy older adults.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMigraine:\u003c\/strong\u003e Magis 2007 — 600 mg\/day for 3 months reduced migraine frequency and severity vs placebo.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHypertension:\u003c\/strong\u003e Mohammadi 2017 meta — modest 2-3 mmHg systolic reduction across pooled trials.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWhy 600 mg, why once daily, and why R\/S vs R\u003c\/h2\u003e\n\u003cp\u003eThe 600 mg\/day oral dose used in this product is the single most-replicated dose in the human ALA literature. SYDNEY 2 demonstrated that 1200 and 1800 mg\/day weren't more effective than 600 for symptom score, and they had more GI side effects (mostly nausea). NATHAN 1 confirmed 600 mg\/day is safe and effective for 4 years of daily use. Ziegler 2014 (\u003cem\u003eAntioxidants \u0026amp; Redox Signaling\u003c\/em\u003e) summarized: \u003cem\u003e“The therapeutic dose of oral ALA in diabetic neuropathy is 600 mg\/day. Higher doses do not produce additional benefit and are associated with more adverse events.”\u003c\/em\u003e\u003c\/p\u003e\n\n\u003cp\u003eALA exists in two enantiomers — the natural \u003cstrong\u003eR-isomer\u003c\/strong\u003e (R-ALA) and the synthetic \u003cstrong\u003eS-isomer\u003c\/strong\u003e. Most consumer products (and all of the German DPN trials including NATHAN 1) used \u003cstrong\u003eracemic R\/S-ALA\u003c\/strong\u003e — a 50\/50 mix. R-ALA is the form your mitochondria make and use; S-ALA is metabolically inert as a cofactor but is still redox-active and contributes to the antioxidant pool. Some \"stabilized R-ALA\" products claim better absorption per mg, but the trial database that established efficacy was built on racemic ALA. We use racemic R\/S-ALA at 600 mg precisely because that's the molecule and dose the trials validated. (If you specifically want R-ALA, it's available; you'd typically take 200-300 mg of R-ALA to roughly equate to 600 mg of racemic.)\u003c\/p\u003e\n\n\u003cp\u003eThe half-life of oral ALA is short — ~30 minutes plasma, with the antioxidant effect on the GSH\/Nrf2 axis lasting 6-12 hours. Once-daily dosing is what the trials used; some clinicians split into 300 mg twice daily on an empty stomach for steadier exposure. Both schedules are evidence-supported.\u003c\/p\u003e\n\n\u003ch2\u003eWhere ALA fits vs. the other compounds in this catalog\u003c\/h2\u003e\n\u003cp\u003eTrue Health Protocol stacks tend to layer ALA at the foundational antioxidant layer, alongside the GlyNAC pair, vitamin C, and CoQ10. Here's how ALA differs from the closest neighbors:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003evs. \u003ca href=\"\/he\/products\/glutathione-500mg-maximum-strength\"\u003eGlutathione\u003c\/a\u003e + \u003ca href=\"\/he\/products\/n-acetyl-cysteine-600mg-nac-glutathione-precursor-for-antioxidant-longevity-support\"\u003eNAC\u003c\/a\u003e:\u003c\/strong\u003e Glutathione\/NAC give the cell the substrate and precursor for the body's master antioxidant. ALA \u003cem\u003erecycles\u003c\/em\u003e oxidized glutathione back to active form and turns on the Nrf2 axis that drives glutathione \u003cem\u003esynthesis\u003c\/em\u003e. The three are designed to layer — substrate (NAC), product (GSH), and recycler\/upregulator (ALA).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003evs. \u003ca href=\"\/he\/products\/coq10-400mg-maximum-strength\"\u003eCoQ10\u003c\/a\u003e + \u003ca href=\"\/he\/products\/pqq-20mg-mitochondrial-biogenesis-activator\"\u003ePQQ\u003c\/a\u003e:\u003c\/strong\u003e CoQ10 and PQQ live inside the mitochondrial inner membrane — CoQ10 as the mobile electron carrier of complex I→III, PQQ as a redox cofactor and biogenesis activator. ALA sits in the matrix on PDH\/KGDH and recycles ubiquinone ↔ ubiquinol. The three together cover the substrate-flux + electron-transport + redox-recycling axes of mitochondrial energy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003evs. \u003ca href=\"\/he\/products\/berberine-hcl-500mg-maximum-strength\"\u003eBerberine\u003c\/a\u003e:\u003c\/strong\u003e Both lower fasting glucose and improve insulin sensitivity by AMPK activation, but by different upstream mechanisms (ALA via mitochondrial AMP\/ATP ratio; berberine by direct AMPK kinase activation and gut-microbiome shifts). Stacking is additive (Bertuglia 2008 in animals, several human pilot studies). Berberine has the broader metabolic profile (lipids+glucose+gut); ALA has the broader antioxidant + neuropathy profile.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003evs. \u003ca href=\"\/he\/products\/curcumin-1000mg-bioperine-anti-inflammatory-longevity\"\u003eCurcumin\u003c\/a\u003e:\u003c\/strong\u003e Both activate Nrf2 and inhibit NF-κB. Curcumin is more potent on inflammation; ALA is more potent on glucose. Stacking covers both axes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003evs. \u003ca href=\"\/he\/products\/astaxanthin-12mg-120-softgels-antioxidant-skin-support\"\u003eAstaxanthin\u003c\/a\u003e:\u003c\/strong\u003e Both are membrane-active antioxidants but astaxanthin lives in the lipid bilayer fixed at right-angles to the membrane; ALA spans aqueous + lipid. They're complementary, not redundant.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003evs. NAD+ axis (\u003ca href=\"\/he\/products\/nmn-1000mg-double-strength-60-capsules-30-day-supply\"\u003eNMN 1000mg\u003c\/a\u003e, \u003ca href=\"\/he\/products\/liposomal-nad-ultimate-1000mg\"\u003eLiposomal NAD+\u003c\/a\u003e, \u003ca href=\"\/he\/products\/new-nad-hard-capsules-daily-nad-boost-for-energy-longevity\"\u003eNAD+ Daily Boost\u003c\/a\u003e):\u003c\/strong\u003e PDH and KGDH need \u003cem\u003eboth\u003c\/em\u003e lipoate and NAD+ to function. NAD+ precursors raise the pool of the electron acceptor; ALA provides the cofactor that loads that pool. They're substrate-and-cofactor partners, not competitors.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003evs. \u003ca href=\"\/he\/products\/urolithin-a-500mg-mitophagy-activator\"\u003eUrolithin A\u003c\/a\u003e:\u003c\/strong\u003e Urolithin A activates mitophagy — clears damaged mitochondria. ALA helps the surviving mitochondria run cleaner. Sequential, not redundant.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003evs. \u003ca href=\"\/he\/products\/calcium-alpha-ketoglutarate-1000mg-caakg-epigenetic-longevity\"\u003eCaAKG\u003c\/a\u003e:\u003c\/strong\u003e CaAKG provides α-ketoglutarate as a Krebs-cycle intermediate. KGDH then uses lipoate (from ALA) to convert it to succinyl-CoA. They literally work on the same enzyme.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWhat's in this product\u003c\/h2\u003e\n\u003cp\u003eEach capsule delivers \u003cstrong\u003e600 mg of pharmaceutical-grade racemic R\/S Alpha-Lipoic Acid\u003c\/strong\u003e — the exact molecule and dose used in the SYDNEY 2 and NATHAN 1 trials. We chose racemic over R-only stabilized forms because the entire human evidence base was built on the racemic mixture; switching to R-only changes the dose-response curve and we have no equivalent four-year trial on R-only at this dose.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e60 vegetarian capsules\u003c\/strong\u003e per bottle — 60-day supply at the standard 600 mg\/day or 30-day supply at split 300 mg twice-daily.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPMC vegan capsule shell\u003c\/strong\u003e — no gelatin, no animal sourcing.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo titanium dioxide\u003c\/strong\u003e (banned in EU food in 2022, still common in US supplements). No magnesium stearate, no silicon dioxide, no PEG, no dyes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExcipient-minimal formulation\u003c\/strong\u003e — only the active and rice flour as a flow agent. We don't include any “stabilizers” that mask oxidized ALA in old-batch product.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUV-protective amber HDPE bottle\u003c\/strong\u003e with a foil induction seal — ALA is photosensitive and oxidatively self-degrading; clear bottles and over-large headspace are common ways product loses potency on the shelf.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ecGMP-manufactured in a US FDA-registered facility.\u003c\/strong\u003e Per-batch Certificate of Analysis covers ALA assay (HPLC), residual solvents (EU Pharmacopoeia method), heavy metals (USP \u0026lt;232\u0026gt; \/ ICP-MS), microbial limits (USP \u0026lt;2021\u0026gt;), and absence of pesticides.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIdentity confirmed by HPLC.\u003c\/strong\u003e Many ALA products are sold by total-disulfide assay rather than chromatographic identity; we run HPLC against a reference standard so the labeled mg matches the actual mg.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAllergen-free formulation\u003c\/strong\u003e — no gluten, soy, dairy, peanut, tree-nut, egg, fish, or shellfish.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eHow to take it\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStandard protocol:\u003c\/strong\u003e 1 capsule (600 mg) once daily on an empty stomach — either 30 min before breakfast or 2-3 hr after dinner. Empty stomach matters: food (especially dairy and high-mineral meals) reduces ALA absorption ~30-40% (Gleiter 1996). The German DPN trials specified empty-stomach dosing.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTwice-daily option:\u003c\/strong\u003e Some clinicians split into 300 mg morning + 300 mg afternoon, both empty-stomach. Same total exposure with steadier plasma levels. Either schedule is supported.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTake with the rest of the antioxidant-network stack at the same time:\u003c\/strong\u003e \u003ca href=\"\/he\/products\/glutathione-500mg-maximum-strength\"\u003eglutathione\u003c\/a\u003e, \u003ca href=\"\/he\/products\/n-acetyl-cysteine-600mg-nac-glutathione-precursor-for-antioxidant-longevity-support\"\u003eNAC\u003c\/a\u003e, \u003ca href=\"\/he\/products\/liposomal-vitamin-c-1000mg-maximum-absorption-antioxidant-formula\"\u003evitamin C\u003c\/a\u003e, \u003ca href=\"\/he\/products\/coq10-400mg-maximum-strength\"\u003eCoQ10\u003c\/a\u003e. Network compounds work better dosed together.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDon't take it within 2 hours of \u003ca href=\"\/he\/products\/multi-collagen-complex-types-i-ii-iii-v-x-240-capsules\"\u003emulti-collagen\u003c\/a\u003e, iron, or thyroid medication (levothyroxine).\u003c\/strong\u003e ALA chelates metals; that's a mechanism feature, but it can blunt absorption of those products. Separate by ~2-3 hours.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInsulin \/ sulfonylurea users:\u003c\/strong\u003e ALA can additively lower glucose. Talk to your prescriber and start with closer glucose self-monitoring during the first 2-4 weeks of use. The 600 mg dose is typically not problematic alone but stacks with insulin\/sulfonylureas on a same-target.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMissed dose:\u003c\/strong\u003e Take when you remember if it's still on an empty stomach; otherwise skip and resume the next day. Don't double-dose — ALA's symptom benefits build over weeks; missing a single day is not consequential.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCycling:\u003c\/strong\u003e Not required. NATHAN 1 ran 4 years of continuous daily use without dose-related toxicity. Long-term use is the use case the trials validated.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWhat it pairs with — the longevity\/metabolic stack\u003c\/h2\u003e\n\u003ctable border=\"1\" cellpadding=\"6\" cellspacing=\"0\" style=\"border-collapse:collapse;width:100%\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePair with\u003c\/th\u003e\n\u003cth\u003eWhy\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003ca href=\"\/he\/products\/berberine-hcl-500mg-maximum-strength\"\u003eBerberine HCL 500mg\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eDifferent upstream activator of the same AMPK target. Lipid + glucose + gut additive. Take berberine with meals; ALA empty-stomach — the schedules don't conflict.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003ca href=\"\/he\/products\/glutathione-500mg-maximum-strength\"\u003eGlutathione 500mg\u003c\/a\u003e + \u003ca href=\"\/he\/products\/n-acetyl-cysteine-600mg-nac-glutathione-precursor-for-antioxidant-longevity-support\"\u003eNAC 600mg\u003c\/a\u003e\n\u003c\/td\u003e\n\u003ctd\u003eThe GlyNAC + ALA network: substrate + product + recycler. Sechi 2009 GlyNAC + ALA showed measurable GSH:GSSG ratio improvement in older adults.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003ca href=\"\/he\/products\/glycine-1500mg-glynac-partner-glutathione-sleep-longevity\"\u003eGlycine 1500mg\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eCloses the GlyNAC loop — glycine is the third amino acid in glutathione. Kumar 2023 GlyNAC trial showed body-composition + glucose benefit in older adults at 24 weeks.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003ca href=\"\/he\/products\/liposomal-vitamin-c-1000mg-maximum-absorption-antioxidant-formula\"\u003eLiposomal Vitamin C 1000mg\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eALA recycles oxidized vitamin C back to ascorbate. Liposomal form delivers steady plasma vs ascorbic acid; the recycling loop runs longer.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003ca href=\"\/he\/products\/coq10-400mg-maximum-strength\"\u003eCoQ10 400mg\u003c\/a\u003e + \u003ca href=\"\/he\/products\/pqq-20mg-mitochondrial-biogenesis-activator\"\u003ePQQ 20mg\u003c\/a\u003e\n\u003c\/td\u003e\n\u003ctd\u003eMitochondrial energy triad — ALA loads PDH\/KGDH, CoQ10 carries the electrons, PQQ activates biogenesis. Energy + cognition stack.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003ca href=\"\/he\/products\/curcumin-1000mg-bioperine-anti-inflammatory-longevity\"\u003eCurcumin 1000mg\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eBoth activate Nrf2 by different mechanisms; both inhibit NF-κB. Inflammation + metabolic stack.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003ca href=\"\/he\/products\/astaxanthin-12mg-120-softgels-antioxidant-skin-support\"\u003eAstaxanthin 12mg\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eMembrane-fixed antioxidant + amphipathic ALA = full-membrane oxidant defense across both compartments.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003ca href=\"\/he\/products\/quercetin-500mg-senolytic-flavonoid-natural-antihistamine\"\u003eQuercetin 500mg\u003c\/a\u003e + \u003ca href=\"\/he\/products\/fisetin-500mg-senolytic-flavonoid-for-cellular-cleanup\"\u003eFisetin 500mg\u003c\/a\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSenolytic flavonoids drop senescent-cell burden; ALA improves the metabolic environment surrounding the surviving cells.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003ca href=\"\/he\/products\/nmn-1000mg-double-strength-60-capsules-30-day-supply\"\u003eNMN 1000mg\u003c\/a\u003e or \u003ca href=\"\/he\/products\/pure-nmn-500mg-60-capsules-30-day-supply\"\u003eNMN 500mg\u003c\/a\u003e\n\u003c\/td\u003e\n\u003ctd\u003eNAD+ axis substrate. PDH\/KGDH need both NAD+ \u003cem\u003eand\u003c\/em\u003e lipoate. ALA + NMN literally co-fuel the same enzyme step.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003ca href=\"\/he\/products\/calcium-alpha-ketoglutarate-1000mg-caakg-epigenetic-longevity\"\u003eCaAKG 1000mg\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eCaAKG supplies α-ketoglutarate; KGDH uses ALA's lipoyllysine to process it. Substrate + cofactor pair on a single enzyme.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003ca href=\"\/he\/products\/urolithin-a-500mg-mitophagy-activator\"\u003eUrolithin A 500mg\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eMitophagy + cleaner-mitochondria pair — UA clears damaged units, ALA helps the surviving units run cleaner.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003ca href=\"\/he\/products\/magnesium-glycinate-400mg-sleep-and-nad-methylation\"\u003eMagnesium Glycinate 400mg\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eFoundational. Mg is a Krebs-cycle cofactor (isocitrate dehydrogenase, α-KG dehydrogenase, ATP synthesis). ALA + Mg covers cofactor + substrate at the same Krebs step.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003ca href=\"\/he\/products\/omega-3-fish-oil-2000mg-epa-dha\"\u003eOmega-3 2000mg\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eFoundational membrane substrate; ALA recycles α-tocopherol that protects PUFA from peroxidation. The membrane and the substrate together.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003ca href=\"\/he\/products\/vitamin-d3-5000-iu-k2-mk-7-100mcg\"\u003eVitamin D3 5000 IU + K2\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eFoundational longevity layer. D3 governs ~2,000 genes; ALA governs the antioxidant network. Different axes, both essential.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003ca href=\"\/he\/products\/taurine-1000mg-cardiovascular-mitochondrial-longevity\"\u003eTaurine 1000mg\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eMitochondrial sulfur amino acid; cardiovascular + insulin pair with ALA.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003ca href=\"\/he\/products\/resveratrol-600mg-60-capsules-30-day-supply\"\u003eResveratrol 600mg\u003c\/a\u003e + \u003ca href=\"\/he\/products\/pterostilbene-100mg-trans-sirt1-activator-resveratrol-cousin\"\u003ePterostilbene 100mg\u003c\/a\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSIRT1 activators on the longevity axis; ALA on the antioxidant + metabolic axis. Layer both for foundational longevity stacks.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch2\u003eRealistic timeline — what to expect by week\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeek 1-2:\u003c\/strong\u003e A few people notice steadier post-meal glucose (especially diabetics on monitors). Most feel nothing — that's expected. ALA's effect is biochemical, not stimulatory; this product does \u003cem\u003enot\u003c\/em\u003e give a noticeable kick like caffeine or B-vitamins.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeek 3-6:\u003c\/strong\u003e Fasting glucose usually 5-15 mg\/dL lower if elevated at baseline (Akbari 2018 effect size). Triglycerides start dropping. Diabetic neuropathy patients begin reporting early TSS reductions in published trials around week 3.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeek 8-12:\u003c\/strong\u003e The Nrf2\/glutathione-axis turn-on shows up as lower hs-CRP and MDA on labs. HbA1c shifts ~0.2-0.4 points if elevated at baseline. Neuropathy symptom score drops typically peak around week 5-12 (SYDNEY 2 timeline).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMonths 3-6:\u003c\/strong\u003e Lipid normalization stabilizes. NAFLD patients show ALT\/AST drops and ultrasound steatosis reduction. Cognitive aging trials see effect emerge here.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eYear 1+:\u003c\/strong\u003e NATHAN 1 timeline — durable nerve-conduction improvement; safety profile equivalent to placebo across 4 years of daily use.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWhat NOT to expect:\u003c\/strong\u003e A stimulant kick. Sudden weight loss. A cure for diabetes. ALA is a foundational metabolic + antioxidant tool; the value compounds over months and years.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWho this is for\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003eAdults 35+ building a foundational longevity stack (alongside \u003ca href=\"\/he\/products\/vitamin-d3-5000-iu-k2-mk-7-100mcg\"\u003eD3+K2\u003c\/a\u003e, \u003ca href=\"\/he\/products\/magnesium-glycinate-400mg-sleep-and-nad-methylation\"\u003eMg-Glycinate\u003c\/a\u003e, \u003ca href=\"\/he\/products\/omega-3-fish-oil-2000mg-epa-dha\"\u003eOmega-3\u003c\/a\u003e).\u003c\/li\u003e\n  \u003cli\u003ePeople with metabolic syndrome, prediabetes, or T2D wanting an evidence-based adjunct (alongside, not instead of, prescribed care).\u003c\/li\u003e\n  \u003cli\u003ePeople with elevated triglycerides, fatty liver markers, or PCOS.\u003c\/li\u003e\n  \u003cli\u003eDiabetic peripheral neuropathy — the indication ALA is approved for in Germany.\u003c\/li\u003e\n  \u003cli\u003eHeavy-metal-exposure populations (older amalgam fillings, well water, occupational) who want a low-key chelating co-factor.\u003c\/li\u003e\n  \u003cli\u003eAnyone running an NAD+ stack — ALA loads the PDH\/KGDH enzymes that consume that NAD+.\u003c\/li\u003e\n  \u003cli\u003eMitochondrial-energy stack builders pairing ALA with \u003ca href=\"\/he\/products\/coq10-400mg-maximum-strength\"\u003eCoQ10\u003c\/a\u003e + \u003ca href=\"\/he\/products\/pqq-20mg-mitochondrial-biogenesis-activator\"\u003ePQQ\u003c\/a\u003e + \u003ca href=\"\/he\/products\/urolithin-a-500mg-mitophagy-activator\"\u003eUrolithin A\u003c\/a\u003e.\u003c\/li\u003e\n  \u003cli\u003ePeople interested in the Nrf2\/antioxidant network as a whole and stacking with \u003ca href=\"\/he\/products\/curcumin-1000mg-bioperine-anti-inflammatory-longevity\"\u003ecurcumin\u003c\/a\u003e + \u003ca href=\"\/he\/products\/quercetin-500mg-senolytic-flavonoid-natural-antihistamine\"\u003equercetin\u003c\/a\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eWho this is NOT for\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePregnant or breastfeeding women\u003c\/strong\u003e — insufficient safety data; talk to your OB.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eType-1 diabetics on insulin\u003c\/strong\u003e — potential additive hypoglycemia; don't start ALA without your endocrinologist and closer self-monitoring during the first 4 weeks.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eType-2 diabetics on sulfonylureas (glyburide, glipizide, glimepiride)\u003c\/strong\u003e — same hypoglycemia caution.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHypothyroid patients on levothyroxine\u003c\/strong\u003e — ALA can chelate metals and reduce levothyroxine absorption; separate dosing by 2-3 hours.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIron-deficient patients on iron supplements\u003c\/strong\u003e — ALA chelates iron; separate by 2-3 hours.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThiamine-deficient populations\u003c\/strong\u003e — rare reports of insulin autoimmune syndrome (Hirata's disease) in thiamine-deficient subjects on ALA, almost exclusively Japanese reports. Adequate thiamine intake (B-complex or food) eliminates the concern.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChildren\u003c\/strong\u003e — the trial database is in adults.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAnyone with a known sensitivity\u003c\/strong\u003e to ALA. Talk to your physician if you have any doubt.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eQuality, sourcing, and oxidation control\u003c\/h2\u003e\n\u003cp\u003eAlpha-lipoic acid is photosensitive, thermosensitive, and oxidatively self-degrading — bulk ALA powder loses several percent of activity per month if exposed to sunlight, oxygen, or temperatures above ~25°C. Manufacturing and packaging matter more than for almost any other supplement we sell. Our specifications:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSynthesis:\u003c\/strong\u003e Pharmaceutical-grade racemic R\/S ALA, the same molecule used in the German Thioctacid drug product.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIdentity:\u003c\/strong\u003e HPLC against a USP-grade reference standard. Total-disulfide assay alone is not sufficient because it can be confused by oxidized impurities.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHeavy metals:\u003c\/strong\u003e USP \u0026lt;232\u0026gt; \/ ICP-MS panel below all USP elemental impurity limits (Pb \u0026lt;0.5 ppm, As \u0026lt;1.5 ppm, Cd \u0026lt;0.5 ppm, Hg \u0026lt;1.5 ppm).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMicrobial:\u003c\/strong\u003e USP \u0026lt;2021\u0026gt; total aerobic count \u0026lt;1000 CFU\/g; absence of \u003cem\u003eSalmonella\u003c\/em\u003e, \u003cem\u003eE. coli\u003c\/em\u003e, \u003cem\u003eS. aureus\u003c\/em\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eResidual solvents:\u003c\/strong\u003e EU Pharmacopoeia 2.4.24 (gas chromatography). Class 2 and Class 3 solvents below ICH Q3C limits.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePackaging:\u003c\/strong\u003e Amber UV-protective HDPE bottle; nitrogen-flushed at fill; foil induction seal; oxygen scavenger desiccant. The packaging is doing real work.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Cool, dry, dark place. Do not refrigerate (condensation on opening accelerates oxidation). Keep the cap tight.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ecGMP-manufactured\u003c\/strong\u003e in an FDA-registered, NSF-audited facility.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePer-batch CoA\u003c\/strong\u003e available on request.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eFAQ\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eR\/S vs R-ALA — which is “better”?\u003c\/strong\u003e\u003cbr\u003e\nThe honest answer: \u003cem\u003ethe trial database that established ALA as effective was built on R\/S racemic.\u003c\/em\u003e ALADIN, ALADIN II, ALADIN III, DEKAN, ORPIL, SYDNEY, SYDNEY 2, and NATHAN 1 all used racemic. R-only is more bioavailable per mg, but you don't have a NATHAN 1-equivalent four-year trial on R-only at any dose. We chose to match the trial database. If you want pure R-ALA, expect to dose around 200-300 mg to roughly equate to 600 mg of racemic.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIs ALA the same as Lipoic Acid? Thioctic acid?\u003c\/strong\u003e\u003cbr\u003e\nYes. “Alpha-lipoic acid,” “lipoic acid,” and “thioctic acid” are three names for the same molecule (1,2-dithiolane-3-pentanoic acid). Thioctic acid is the older name and the name used in EU pharmacopoeial monographs.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWhy empty stomach?\u003c\/strong\u003e\u003cbr\u003e\nGleiter 1996 and Brufani 2014 showed food (especially mineral- and protein-rich meals) drops ALA absorption ~30-40%. Empty stomach is what the trials specified. 30 minutes before food or 2-3 hours after.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWill it lower my glucose if it's already normal?\u003c\/strong\u003e\u003cbr\u003e\nGenerally not in any way you'd notice. ALA is an insulin sensitizer; it doesn't drop glucose in non-insulin-resistant adults the way insulin or sulfonylureas do. The hypoglycemia risk is on people stacking ALA with insulin, sulfonylureas, or rarely meglitinides.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWhy does my pee smell weird after taking ALA?\u003c\/strong\u003e\u003cbr\u003e\nA common harmless side effect — ALA's two thiol groups produce a sulfur-smelling metabolite that excretes in urine for some people. Like asparagus pee. Doesn't indicate anything wrong.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHeartburn?\u003c\/strong\u003e\u003cbr\u003e\nTake with a small fat-only buffer (a few almonds, a teaspoon of olive oil) if empty-stomach is uncomfortable; or split to 300 mg twice daily. The 1200 and 1800 mg arms in SYDNEY 2 had more nausea, which is one reason 600 mg ended up the standard.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCan I take it with metformin?\u003c\/strong\u003e\u003cbr\u003e\nYes, and it's a common stack. Two different upstream mechanisms (metformin via complex I + AMPK; ALA via mitochondrial AMP\/ATP + Nrf2). Han 2020 meta and others showed additive HbA1c benefit. Keep prescribed metformin under your physician's direction; ALA is an adjunct, not a replacement.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWhat about with \u003ca href=\"\/he\/products\/berberine-hcl-500mg-maximum-strength\"\u003eberberine\u003c\/a\u003e?\u003c\/strong\u003e\u003cbr\u003e\nCommon stack. ALA empty-stomach in the morning, berberine with meals; the schedules don't conflict. Both hit AMPK by different upstream paths. Glucose + lipid + gut layered profile.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWhat about with my \u003ca href=\"\/he\/products\/nmn-1000mg-double-strength-60-capsules-30-day-supply\"\u003eNMN\u003c\/a\u003e stack?\u003c\/strong\u003e\u003cbr\u003e\nExcellent layering. ALA loads PDH and KGDH; those enzymes consume the NAD+ that NMN raises. ALA + NMN are substrate and cofactor for the same Krebs-cycle entry steps.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCan I take it long term?\u003c\/strong\u003e\u003cbr\u003e\nNATHAN 1 ran 600 mg\/day for 4 years with safety equivalent to placebo. Long-term daily use is the use case the trials validated.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCan I take more than 600 mg?\u003c\/strong\u003e\u003cbr\u003e\nYou can — SYDNEY 2 ran 1800 mg\/day for 5 weeks with no efficacy gain over 600 and more nausea. There's no clinical reason to exceed 600 mg\/day for the long-term use case.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWill it interact with my levothyroxine \/ thyroid hormone?\u003c\/strong\u003e\u003cbr\u003e\nPossibly. ALA's chelation can blunt levothyroxine absorption if taken at the same time. Standard practice: take levothyroxine first thing on waking, ALA at least 2-3 hours later. Tell your endocrinologist you're starting ALA.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eI'm B12-deficient or a long-term metformin user. Does that matter?\u003c\/strong\u003e\u003cbr\u003e\nALA does not deplete B12, but adults on long-term metformin should monitor B12 anyway (Aroda 2016). Adequate thiamine (B1) is also important for ALA users in case-report contexts (rare Japanese insulin autoimmune syndrome reports were mostly in thiamine-deficient subjects). A daily B-complex covers this.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWhy do I see \"300 mg\" doses elsewhere when the trials used 600 mg?\u003c\/strong\u003e\u003cbr\u003e\nMost consumer products dose lower because (a) ALA is relatively expensive per gram and (b) the marketing emphasis is general antioxidant support, where lower doses are still meaningful. The 600 mg dose is what the human metabolic and neuropathy evidence base was built on. Splitting one 600 mg capsule into two 300 mg doses across the day is a reasonable variant — same total intake.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDoes ALA help with weight loss?\u003c\/strong\u003e\u003cbr\u003e\nA modest effect — Kucukgoncu 2017 meta showed ~1.27 kg average weight loss vs placebo across 12 RCTs. Don't buy ALA for weight loss alone; do consider it as part of a broader metabolic stack where weight is one of several endpoints.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDoes it help with brain fog or cognition?\u003c\/strong\u003e\u003cbr\u003e\nThe Hager 2007 Alzheimer's pilot and Khalili 2014 MS trial are the strongest signals. The Gosselin 2019 review found a positive effect in MCI\/mild AD and a less clear effect in healthy older adults. Realistic expectation: it's part of a cognitive-aging stack, not a standalone nootropic.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWhy do I see this product compared to \u003ca href=\"\/he\/products\/berberine-hcl-500mg-maximum-strength\"\u003eberberine\u003c\/a\u003e a lot?\u003c\/strong\u003e\u003cbr\u003e\nThey're often discussed in the same metabolic-supplement category, which is why we cross-link them. They're not substitutes — the German clinical literature on ALA is a separate body of evidence from the metformin-comparison literature on berberine. If your goal is comprehensive metabolic support, both belong in the protocol; if you're starting from zero and have to pick one, berberine has the broader profile (lipids + glucose + gut microbiome) and ALA has the more specific neuropathy + antioxidant-recycling profile.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIs ALA the same as omega-3?\u003c\/strong\u003e\u003cbr\u003e\nNo. Omega-3 fish oil delivers EPA and DHA — long-chain polyunsaturated fatty acids that build cell membranes. Alpha-\u003cem\u003elipoic\u003c\/em\u003e acid is a small disulfide cofactor of mitochondrial enzymes — a completely different molecule despite the similar name. Some people also confuse ALA-the-cofactor with ALA-the-omega-3 (alpha-\u003cem\u003elinolenic\u003c\/em\u003e acid, found in flax). Three different molecules.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eStorage?\u003c\/strong\u003e\u003cbr\u003e\nCool, dry, dark. Do not refrigerate (condensation on opening accelerates oxidation). Keep the cap tight; the bottle is amber and nitrogen-flushed for a reason.\u003c\/p\u003e\n\n\u003ch2\u003eWhere this sits in the True Health Protocol catalog\u003c\/h2\u003e\n\u003cp\u003eAlpha-lipoic acid is one of our four pillars of the \u003cstrong\u003eantioxidant-network layer\u003c\/strong\u003e: \u003ca href=\"\/he\/products\/glutathione-500mg-maximum-strength\"\u003eGlutathione\u003c\/a\u003e (the master antioxidant itself), \u003ca href=\"\/he\/products\/n-acetyl-cysteine-600mg-nac-glutathione-precursor-for-antioxidant-longevity-support\"\u003eNAC\u003c\/a\u003e (its precursor), \u003cstrong\u003eALA\u003c\/strong\u003e (the recycler + Nrf2 inducer), and \u003ca href=\"\/he\/products\/liposomal-vitamin-c-1000mg-maximum-absorption-antioxidant-formula\"\u003evitamin C\u003c\/a\u003e (the network's water-phase partner). Most adults building a serious protocol layer all four. The ALA-specific role — the universal-antioxidant + mitochondrial-cofactor + Nrf2-inducer combination — is not duplicated by any other compound in the catalog.\u003c\/p\u003e\n\n\u003cp\u003eIt's also a core member of the \u003cstrong\u003emetabolic foundation layer\u003c\/strong\u003e alongside \u003ca href=\"\/he\/products\/berberine-hcl-500mg-maximum-strength\"\u003eberberine\u003c\/a\u003e, \u003ca href=\"\/he\/products\/calcium-alpha-ketoglutarate-1000mg-caakg-epigenetic-longevity\"\u003eCaAKG\u003c\/a\u003e, and \u003ca href=\"\/he\/products\/omega-3-fish-oil-2000mg-epa-dha\"\u003eomega-3\u003c\/a\u003e. And of the \u003cstrong\u003emitochondrial-energy layer\u003c\/strong\u003e alongside \u003ca href=\"\/he\/products\/coq10-400mg-maximum-strength\"\u003eCoQ10\u003c\/a\u003e, \u003ca href=\"\/he\/products\/pqq-20mg-mitochondrial-biogenesis-activator\"\u003ePQQ\u003c\/a\u003e, and \u003ca href=\"\/he\/products\/urolithin-a-500mg-mitophagy-activator\"\u003eUrolithin A\u003c\/a\u003e. ALA is the connective tissue between three otherwise distinct layers of the protocol — one of the few compounds that earns its place in nearly every adult's longevity stack regardless of starting point.\u003c\/p\u003e\n\n\u003ch2\u003eThe science (selected references)\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003ePacker L, Witt EH, Tritschler HJ. \u003cem\u003eAlpha-Lipoic acid as a biological antioxidant.\u003c\/em\u003e Free Radic Biol Med. 1995;19(2):227-50.\u003c\/li\u003e\n  \u003cli\u003eBustamante J et al. \u003cem\u003eAlpha-lipoic acid in liver metabolism and disease.\u003c\/em\u003e Free Radic Biol Med. 1998;24(6):1023-39.\u003c\/li\u003e\n  \u003cli\u003eHagen TM et al. \u003cem\u003e(R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function.\u003c\/em\u003e FASEB J. 1999;13(2):411-8.\u003c\/li\u003e\n  \u003cli\u003eSuh JH et al. \u003cem\u003e(R)-alpha-lipoic acid restores glutathione homeostasis in old rats.\u003c\/em\u003e Proc Natl Acad Sci USA. 2004;101(10):3381-6.\u003c\/li\u003e\n  \u003cli\u003eZiegler D et al. \u003cem\u003eTreatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid (ALADIN study).\u003c\/em\u003e Diabetologia. 1995;38(12):1425-33.\u003c\/li\u003e\n  \u003cli\u003eReljanovic M et al. \u003cem\u003eTreatment of diabetic polyneuropathy with the antioxidant thioctic acid (ALADIN II).\u003c\/em\u003e Free Radic Res. 1999;31(3):171-9.\u003c\/li\u003e\n  \u003cli\u003eZiegler D et al. \u003cem\u003eTreatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III).\u003c\/em\u003e Diabetes Care. 1999;22(8):1296-301.\u003c\/li\u003e\n  \u003cli\u003eZiegler D et al. \u003cem\u003eEffects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients (DEKAN study).\u003c\/em\u003e Diabetes Care. 1997;20(3):369-73.\u003c\/li\u003e\n  \u003cli\u003eRuhnau KJ et al. \u003cem\u003eEffects of 3-week oral treatment with the antioxidant thioctic acid (ORPIL study).\u003c\/em\u003e Diabet Med. 1999;16(12):1040-3.\u003c\/li\u003e\n  \u003cli\u003eAmetov AS et al. \u003cem\u003eThe sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: SYDNEY trial.\u003c\/em\u003e Diabetes Care. 2003;26(3):770-6.\u003c\/li\u003e\n  \u003cli\u003eZiegler D et al. \u003cem\u003eOral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: SYDNEY 2 trial.\u003c\/em\u003e Diabetes Care. 2006;29(11):2365-70.\u003c\/li\u003e\n  \u003cli\u003eZiegler D et al. \u003cem\u003eEfficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy (NATHAN 1).\u003c\/em\u003e Diabetes Care. 2011;34(9):2054-60.\u003c\/li\u003e\n  \u003cli\u003eMijnhout GS et al. \u003cem\u003eAlpha-lipoic acid for symptomatic peripheral neuropathy: a meta-analysis.\u003c\/em\u003e Int J Endocrinol. 2012;2012:456279.\u003c\/li\u003e\n  \u003cli\u003eZiegler D et al. \u003cem\u003eAntioxidants and diabetic neuropathy.\u003c\/em\u003e Antioxid Redox Signal. 2014;21(8):1291-321.\u003c\/li\u003e\n  \u003cli\u003eKonrad D et al. \u003cem\u003eThe antihyperglycemic drug alpha-lipoic acid stimulates glucose uptake via PI3K and AMPK.\u003c\/em\u003e Diabetes. 2001;50(7):1464-71.\u003c\/li\u003e\n  \u003cli\u003eJacob S et al. \u003cem\u003eOral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with T2DM.\u003c\/em\u003e Free Radic Biol Med. 1999;27(3-4):309-14.\u003c\/li\u003e\n  \u003cli\u003eAkbari M et al. \u003cem\u003eThe effects of alpha-lipoic acid supplementation on glucose control and lipid profiles among patients with metabolic diseases: a systematic review and meta-analysis of RCTs.\u003c\/em\u003e Metabolism. 2018;87:56-69.\u003c\/li\u003e\n  \u003cli\u003eMohammadi V et al. \u003cem\u003eThe effect of alpha-lipoic acid (ALA) supplementation on cardiovascular risk factors in metabolic syndrome.\u003c\/em\u003e Adv Pharm Bull. 2017;7(2):185-194.\u003c\/li\u003e\n  \u003cli\u003eKucukgoncu S et al. \u003cem\u003eAlpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of RCTs.\u003c\/em\u003e Obes Rev. 2017;18(5):594-601.\u003c\/li\u003e\n  \u003cli\u003ede Sousa CV et al. \u003cem\u003eAlpha-lipoic acid in NAFLD: a systematic review.\u003c\/em\u003e 2019.\u003c\/li\u003e\n  \u003cli\u003eGenazzani AD et al. \u003cem\u003eAlpha-lipoic acid as a new treatment option for PCOS.\u003c\/em\u003e Gynecol Endocrinol. 2010.\u003c\/li\u003e\n  \u003cli\u003eKhalili M et al. \u003cem\u003eEffect of lipoic acid consumption on oxidative stress in MS.\u003c\/em\u003e Nutr Neurosci. 2014;17(1):16-20.\u003c\/li\u003e\n  \u003cli\u003eHager K et al. \u003cem\u003eAlpha-lipoic acid as a new treatment option for Alzheimer's disease.\u003c\/em\u003e Arch Gerontol Geriatr. 2007;45(1):S6-S10.\u003c\/li\u003e\n  \u003cli\u003eMaczurek A et al. \u003cem\u003eLipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease.\u003c\/em\u003e Adv Drug Deliv Rev. 2008;60(13-14):1463-70.\u003c\/li\u003e\n  \u003cli\u003eGosselin LE et al. \u003cem\u003eEffect of acute lipoic acid intake on cognitive function: a systematic review.\u003c\/em\u003e Nutr Rev. 2019.\u003c\/li\u003e\n  \u003cli\u003eMagis D et al. \u003cem\u003eA randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis.\u003c\/em\u003e Headache. 2007;47(1):52-7.\u003c\/li\u003e\n  \u003cli\u003eSalehi B et al. \u003cem\u003eInsights on the use of alpha-lipoic acid for therapeutic purposes.\u003c\/em\u003e Biomolecules. 2019;9(8):356.\u003c\/li\u003e\n  \u003cli\u003ePatrick L. \u003cem\u003eMercury toxicity and antioxidants: Part I — role of glutathione and alpha-lipoic acid.\u003c\/em\u003e Altern Med Rev. 2002;7(6):456-71.\u003c\/li\u003e\n  \u003cli\u003eGleiter CH et al. \u003cem\u003eInfluence of food intake on the bioavailability of thioctic acid enantiomers.\u003c\/em\u003e Eur J Clin Pharmacol. 1996;50(6):513-4.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cem\u003eThis product is not intended to diagnose, treat, cure, or prevent any disease. Alpha-lipoic acid is sold in the US as a dietary supplement and is not FDA-approved for any medical condition. These statements have not been evaluated by the FDA. Talk to your doctor before starting any supplement, especially if you are pregnant, breastfeeding, take prescription medication (particularly insulin, sulfonylureas, levothyroxine, or iron), or have any existing medical condition.\u003c\/em\u003e\u003c\/p\u003e\n","brand":"True Health Protocol","offers":[{"title":"Default Title","offer_id":47839563940058,"sku":"THP-ALA-600-60","price":26.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0814\/5158\/1658\/files\/thp_ala.png?v=1778049793"}],"url":"https:\/\/truehealthprotocol.health\/he\/collections\/metabolic.oembed","provider":"True Health Protocol","version":"1.0","type":"link"}